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Abstract 
Idiopathic intracranial hypertension (IIH) is a rare disease that primarily affects 
obese women of reproductive age, characterised by raised intracranial pressure 
(ICP) and papilloedema that drives chronic debilitating headache and visual 
loss. The aetiology of IIH is uncertain, however it is clear that weight loss is 
therapeutic and reduces ICP, headache, and visual morbidity. Novel data has 
highlighted that female IIH patients have an androgen excess phenotype. 
However the role of adipose tissue and androgens in the pathogenesis of IIH 
remains unclear. 
Utilising RNA-sequencing, NMR-based metabolomics and secretomic 
techniques, it has been identified that ex vivo subcutaneous adipose tissue from 
female IIH patients has features of glucocorticoid excess including increased 
lipolysis, ribosomal subunit depletion and a preference for lipid synthesis, driven 
by intra-adipose cortisol accumulation. Moreover, this phenotype is driving 
hyperleptinaemia in IIH patients. Additionally, a novel in vitro Na+/K+ ATPase 
activity assay was developed, which demonstrated that testosterone increases 
Na+/K+ ATPase activity, suggesting capacity to increase ICP. 
Together, these data highlight that adipose tissue in IIH has characteristics of 
glucocorticoid excess, contributing to a specific metabolic phenotype and that 
testosterone could be driving raised intracranial pressure, highlighting routes for 
the development of novel therapeutics and treatments for IIH. 
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1.1 Idiopathic intracranial Hypertension 
Idiopathic intracranial hypertension (IIH) is a neurological condition whose 
diagnostic criteria were formalised in 1937 by Walter Dandy and termed 
pseudotumor cerebri (Dandy, 1937). IIH is a disease of unknown aetiology 
where patients present with raised intracranial pressure (ICP) and 
papilloedema, whereby diagnosis is that of excluding secondary causes for 
raised ICP according to the modified Dandy criteria (see table 1) (Mollan et al., 
2018b). In the general population the incidence of IIH is 4.69 individuals per 
100,000 and is rising in line with the obesity epidemic (Mollan et al., 2018a). 
However in its main patient group, obese women of childbearing age, the 
incidence is raised to 20 per 100,000 (Markey et al., 2016a). Furthermore 82% 
of all IIH patients are female (Mollan et al., 2018a).  
 IIH patients present with chronic debilitating headaches caused by raised ICP 
which is thought to be derived from disrupted cerebrospinal fluid dynamics 
(Mollan et al., 2016). The raised ICP drives papilloedema which causes visual 
defects and in 25% of cases, can lead to permanent visual loss (Corbett et al., 
1982).  
The raised ICP and subsequent papilloedema and headache are symptoms of 
an underlying condition that is of unknown aetiology, as such there is a need to 
understand the pathogenesis of IIH.  
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1.1.1 Idiopathic intracranial hypertension diagnosis 
IIH is primarily a diagnosis of exclusion, where raised ICP secondary to other 
causes is excluded, as based on the modified Dandy criteria (table 1.1) (Mollan 
et al., 2018b). A diagnostic lumbar puncture must have a lumbar puncture 
opening pressure (LP Opp) over 25cmCSF, where cerebrospinal fluid (CSF) is 
essentially acellular, and falls into normal biochemical parameters. 
Papilloedema, swelling of the optic disk, must also be present. Suspected IIH 
patients have neuro-anatomical abnormalities excluded with the exception of an 
empty sella. Furthermore, patients must have a normal cranial nerve 
examination with the exception of a 6th cranial nerve palsy (Mollan et al., 
2018b).  
IIH Diagnostic criteria 
Papilloedema  
Normal neurological exam except 6th cranial nerve palsy 
Evidence of normal neuroanatomy 
Normal CSF composition  
Raised lumbar puncture opening pressure, >25cm CSF 
 
Table 1.1 Diagnostic criteria for IIH 
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1.1.2 Epidemiology of idiopathic intracranial hypertension 
IIH is a rare disease with an incidence in the general population  of 4.69 per 
100,000 in 2016, up from 2.2 per 100,000 individuals in 2002 (Mollan et al., 
2018a). When divided into patient groups IIH has an incidence of 1.6 per 
100,000 in men and affects 7.69 per 100,000 women in the UK where women 
represent 82% of all IIH patients in the UK (Mollan et al., 2018a). The incidence 
of IIH is greatest in obese women of reproductive age, at 20 in 100,000 (Markey 
et al., 2016a). The incidence of IIH is increasing in both men and women in line 
with the obesity epidemic and, as such, is projected to further increase in line 
with obesity (Mollan et al., 2018a). In the UK, IIH is associated with socio-
economic deprivation, a factor also linked with obesity in high income countries  
(McLaren, 2007; Mollan et al., 2018a). 
1.1.3 Idiopathic intracranial pressure and co-morbidities 
 
1.1.3.1 Headache in IIH 
IIH has several co-morbidities that affect the quality of life for the patients. The 
most common co-morbidity is chronic debilitating headache that presents in up 
to 93% of IIH patients at diagnosis that is often migrainous in phenotype 
(Jensen et al., 2016). Although raised ICP is thought to be the primary driver of 
this, IIH headache often persists after resolution of raised ICP and visual 
defects, highlighting long term quality of life issues for IIH patients (Yri et al., 
2014b). Headache was highlighted as the primary determinant of quality of life 
in IIH (Mulla et al., 2015). Importantly, weight loss improves headache morbidity 
in IIH (Sinclair et al., 2010a). 
  
Page | 5 
 
1.1.3.2 Visual loss in IIH 
Perhaps the most concerning co-morbidity in IIH is visual loss linked to 
papilloedema, where the retinal artery is occluded, causing retinal ischaemia. It 
has been demonstrated that visual loss is progressive in IIH, even with 
therapeutic intervention (Hatem et al., 2018). This visual loss is permanent in 
25% IIH patients (Corbett et al., 1982). Due to papilloedema being an obligate 
symptom in IIH, the potential visual loss represents significant morbidity and a 
focus of treatment. 
1.1.3.3 IIH as a metabolic syndrome 
Female IIH patients have an increased incidence of polycystic ovary syndrome 
(PCOS), ranging from 15%-53%, compared to the general population (8.7%), 
dependent on the BMI of the IIH population (Avisar et al., 2012; Glueck et al., 
2005, 2003; March et al., 2010). This increased incidence of PCOS could be 
linked to a novel phenotype of androgen excess elucidated in female IIH 
patients (Appendix 1) (O’Reilly et al., 2019). Conversely, hypoandrogenism is 
associated with IIH in males (Fraser et al., 2010). Furthermore, recent 
unpublished work demonstrates that IIH patients have an increased HOMA2-IR 
score, suggesting insulin resistance. This portfolio of work supports the 
hypothesis that IIH is a distinct metabolic syndrome as well as a neuro-
ophthalmic disease, increasing the need to understand the biochemical and 
metabolic perturbations in IIH to facilitate more effective long term treatment of 
IIH (Hornby et al., 2018b). 
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1.1.3.4 IIH and cognition 
Female IIH patients have diminished cognitive ability, with deficits in reaction 
speed, verbal fluency and executive function. These cognitive deficits persist 
following improvements in headache and reduction of ICP, thus cognitive deficit 
represents serious morbidity in IIH (Yri et al., 2014a). Perhaps linked to the 
chronic headache, IIH patients also present with an increased risk of depression 
and anxiety that contributes to reduced quality of life (Kleinschmidt et al., 2000; 
Mulla et al., 2015).  
1.1.4 Economic burden of IIH 
The comorbidities, particularly the cognitive defects, debilitating chronic 
headache, associated mental health issues and visual loss contribute to IIH 
economic burden: in 2011, it was estimated that IIH costs around $444 million in 
the United States (Friesner et al., 2011). This economic burden of IIH will only 
increase as the incidence and prevalence of IIH increases in line with the 
obesity epidemic (Mollan et al., 2018a). Indeed, IIH is projected to cost English 
health services £462.7 million by 2030, rising from the current hospital cost of 
£49.9 in 2014 (Mollan et al., 2018a). The total economic cost of IIH in the UK 
will be much higher due to lost working days and reduced productivity owing to 
severe headache and depressive episodes. As such there is a need understand 
the pathogenesis and improve the treatment of IIH for both IIH patients and for 
the benefit of society. 
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1.2 Intracranial pressure and cerebrospinal fluid dynamics 
Although the aetiology of IIH is unknown, it is apparent that ICP homeostasis is 
perturbed due to the presence of raised ICP. According to the anatomists 
Monro and Kellie, ICP is determined by three parameters; the volume of the 
brain, cerebral blood volume and CSF volume, where cerebral blood volume 
and CSF are homeostatically controlled and compensate for acute changes in 
ICP (Kim et al., 2012). Indeed, it is clear that changes in cerebral blood volume, 
through changes in cerebral blood vessel calibre alters ICP rather than cerebral 
blood pressure (Dunn, 2002). When any of these three parameters are altered 
outside physiological parameters, intracranial hypotension or hypertension 
occurs. CSF leakages are known to cause intracranial hypotension leading to 
brain slump and significant morbidity. More common are conditions of 
intracranial hypertension, hydrocephalus, brain tumours and intracranial 
haemorrhage. In the case of IIH, gross anatomical alterations are excluded in 
diagnosis, excluding altered brain volume and to a lesser extent alterations in 
cerebral blood volume (Mollan et al., 2018b). Moreover there is little evidence 
for altered cerebral perfusion pressure, cerebral blood pressure and systemic 
blood pressure in IIH, compared to obese controls. Consequently it is likely that 
altered CSF dynamics in IIH are contributing to the raised ICP, whereby the 
contribution of CSF to ICP is a balance between CSF secretion and CSF 
drainage (Mollan et al., 2016). 
1.2.1 Anatomy and physiology of CSF  
The brain and the spinal cord are enclosed within the rigid cranium and 
vertebral column respectively, in an anatomical compartment termed the central 
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nervous system (CNS). Due to being enclosed in this rigid compartment, the 
brain, blood and CSF exert a pressure. Here the brain and spinal cord are 
bathed in CSF, a biofluid that has several functions. CSF provides the brain with 
buoyancy, making the 1.5 kg brain weigh ~45g (Spector et al., 2015). 
Furthermore the CSF acts as a hydraulic cushion, reducing forces that the brain 
may endure.  
Besides its mechanical properties, the CSF also serves to remove waste, such 
as amyloid-β, from the brain (Iliff et al., 2012). Furthermore, CSF facilitates the 
delivery of nutrients, hormones and neurotransmitters such as folate and 
vitamin C to the brain, where the CSF is the sole source of these nutrients for 
the brain (Hammarström, 1966; Spector and Johanson, 2014). Within the brain, 
CSF resides in the cerebral ventricles and parenchymal aqueducts; outside of 
the brain CSF resides in the cisterna magna and the subarachnoid spaces (Fig 
1.1). The subarachnoid spaces are part of the meninges, layers of tissue that 
line the brain, spinal cord and the internal bony surfaces of the CNS. The 
deepest meningeal layer is the pia mater, a thin membrane that lines the brain. 
The arachnoid mater is the intermediate meningeal layer that provides space for 
CSF to flow. The dura mater is the most superficial meningeal layer and lines 
the internal ossified surface of the CNS. Together, the meninges provide the 
brain and spinal cord with structural support. 
1.2.2 CSF flow 
Traditional teaching dictates that CSF produced in the lateral ventricles flows 
through the foramina of Monro (intraventricular foramina) reaching the third 
ventricle where it traverses the aqueduct of Sylvius (cerebral aqueduct) to the 
  
Page | 9 
 
fourth ventricle. From the fourth ventricle, CSF flows through the foramen of 
Magendie  (median aperture) to the cisterna magna, and from the foramina of 
Luschka (lateral aperture) to the subarachnoid space (Cushing, 1925). CSF 
also flows through the central canal of the spinal cord. When in the CSF 
spaces, CSF flows around the brain and spinal cord and is drained through 
several routes (Fig1.1). CSF flow is not simply a feature of a pressure 
differential between the ventricles and the CSF spaces. Instead, it is aided by 
action of motile cilia on the ependymal cells that line the cerebral ventricles and 
the intra-parenchymal aqueducts, whereby the knockout and dysfunction of said 
cilia causes a communicating hydrocephalus (Ibañez-Tallon et al., 2004). In 
humans, CSF flow is pulsatile and displays net movement from the ventricular 
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Figure 1.1 Anatomy of the CSF spaces 
A diagram in the sagittal plane detailing the anatomy of the CSF spaces in the human 
central nervous system. Red arrows represent the net flow of CSF, blue represents 
CSF spaces. Beige circles represent choroid plexus. 
 
1.2.3 CSF production 
Humans produce around 500ml of CSF a day, filling the CSF spaces to a total 
volume of 120-150ml, indicating that the CSF is replaced several times a day 
with an average production rate of around 20 ml per hour  (Nilsson et al., 1992). 
CSF is produced with diurnal variation, where more CSF is produced during 
sleeping hours and less produced in waking hours (Nilsson et al., 1992). A 
portion of CSF is generated from the brain interstitial fluid via the ependymal 
lining of the ventricles and the pia mater, perhaps through hydrostatic forces. 
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However the majority of CSF (80%) is generated via the choroid plexus (Brinker 
et al., 2014). 
1.2.3.1 The choroid plexus 
CSF is primarily produced by choroid plexus, organs that reside in the lateral, 
third and fourth ventricles. Histologically the choroid plexus comprises of villi, 
the functional unit of the choroid plexus. These villi comprise of central, 
fenestrated capillaries that are surrounded by a monolayer of cells residing on a 
basement membrane, the choroid plexus epithelial (CPe) cells. These CPe cells 
are the functional cell of the choroid plexus, whose apical membrane faces the 
ventricular space and are continuous with the ependymal cells that line the 
cerebral ventricles (Fig1.2a). CPe cells have been demonstrated to have apical 
microvilli in non-human primates and rodents (Fig1.2b) (Cornford et al., 1997; 
Keep and Jones, 1990). These provide a brush border and have been proposed 
to increase  the surface area for both the transportation of nutrients and for the 
cardinal role of the choroid plexus: CSF secretion (Brown et al., 2004; Cornford 
et al., 1997).  
 
  




Figure 1.2 Choroid plexus villus 
A) A haematoxylin and eosin stain of a human choroid plexus displaying a 
choroid plexus villus comprising a monolayer of choroid plexus epithelial cells 
(CPEC) surrounding a central blood vessel (BV). B) Electron micrograph of a 
Wistar rat choroid plexus epithelial cell, highlighting stereotypic features such as 
microvilli (Mv), mitochondria (M) and tight junction(Tj).  Lateral ventricle (LV) 
Scale bar=20 microns for A and 1000nm for B. Electron micrograph courtesy 
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The choroid plexus are the primary organs of the blood-cerebrospinal-fluid-
barrier (BCSFB), whereby the CPe cells form a barrier sufficient enough to 
make it impermeable to the diffusion of molecules, through the formation of tight 
junctions (Brown et al., 2004). As such, choroid plexus function dictates the 
molecular composition of the CSF through selective trans-epithelial movement 
of nutrients and macro-molecules. This is exemplified by the hormone leptin, 
where the choroid plexus expresses the OB-Ra slice variant of the leptin 
receptor, which is the transporting splice variant (Fei et al., 1997). Here the 
selective transport of leptin via the OB-Ra splice variant facilitates the 
saturatable transport of leptin from the blood to the CSF (Schwartz et al., 1996; 
Zlokovic et al., 2000). The strength of the BCSFB is further demonstrated by the 
ionic and protein composition of the CSF, if the barrier between the blood and 
CSF were a weak barrier, it stands to reason that the two compartments would 
have a similar composition. However the CSF has a distinct ionic and protein 
composition which further highlights the strength of the BCSFB (Table 1.2). The 
choroid plexus has a putative role in monitoring the composition of the CSF. 
The choroid plexus has been demonstrated to express many receptors at a 
functional level, including glucagon-like 1 receptor, somatostatin receptors, 
serotonin receptors and olfactory receptors, amongst others. (Botfield et al., 
2017; Conn et al., 1986; Gonçalves et al., 2016; Katz et al., 2002). Together 
these suggest the choroid plexus can sense the composition of the CSF, as well 
as alter its function to modulate either the CSF composition or even alter CSF 
secretion to hormonal ques, however more work is required to fully assess the 
properties of these receptors.  
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 CSF Plasma 
Na+ (mM) 151 155 
K+ (mM) 3.0 4.6 
Mg2+ (mM) 1.0 0.7 
Ca2+ (mM) 1.4 2.9 
Cl- (mM) 133 121 
HCO3
- (mM) 25.8 26.2 
Glucose (mM) 4.2 6.3 
pH 7.4 7.4 
Osmolality (mOsm/L) 305 300 
Protein (mg/dL) 25 6500 
 
Table 1.2 Composition of plasma and CSF 
All values taken from dog CSF, except protein which comes from rabbit CSF. 
Table adapted from Brown et al. 2004. 
 
1.2.4 CSF secretion at the choroid plexus 
CSF secretion at the choroid plexus is a complex and energy demanding 
process as exemplified by the rich mitochondrial content of CPe cells and a 
choroid plexus perfusion rate four times that of the brain (Cornford et al., 1997; 
Faraci et al., 1990). CSF secretion at the choroid plexus has been suggested to 
be partially under neuronal control, where sympathetic stimulation decreases 
CSF  secretion by  roughly 20% and parasympathomimetics increase CSF 
secretion (Hayw and Vogh, 1979). However, these experiments were carried 
out in felines, thus replication is required in more standard experimental animals 
to determine whether these are applicable to other species. Moreover, there is 
little understanding of how other physiological ques modulate CSF secretion, 
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perhaps due to the limited range of experimental techniques that are low 
throughput.    
In its simplest terms the choroid plexus has been thought to function like an 
inverted renal tubule cell, whereby the asymmetric localisation of ion 
transporters facilitates the movement of sodium ions from the blood to the 
cerebral ventricles (Botfield et al., 2017). However, the ionic gradients present 
across the choroid plexus, roughly 5mOmol greater in the CSF from the serum, 
are insufficient to generate the volumes of CSF that are produced (MacAulay 
and Zeuthen, 2010). Indeed CSF can be generated against an osmotic gradient 
(Heisey et al., 1962). Furthermore, knockout of the molecular water pore 
aquaporin 1 (AQP1) does not ameliorate CSF secretion, rather it reduces CSF 
secretion by roughly 25%, further suggesting that CSF secretion is not entirely 
dependent on osmosis (Oshio et al., 2004).      
1.2.4.1 Ion transport at the choroid plexus 
Although osmosis does not appear to be the primary driver of CSF secretion, it 
is clear that ionic gradients and transport are fundamental to the secretion of 
CSF (Fig1.3). Inhibition of the carbonic anhydrases, generators of bicarbonate 
ions,  via acetazolamide decreases CSF secretion, perhaps through an indirect 
effect on the Na+/K+ ATPase though reduced activity of the basolateral 
bicarbonate exchangers, namely anion exchanger 2 (AE2), sodium bicarbonate 
cotransporter 1 (NBCn1) and the apical sodium hydrogen exchanger (HNE) or 
altered cellular pH (Damkier et al., 2009; Oshio et al., 2004; Sterling et al., 
2001; Uldall et al., 2017). Indeed Na+/K+ ATPase activity had been proposed to 
contribute to CSF secretion (Vates et al., 1964). Several studies have 
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highlighted that selective inhibition of the Na+/K+ ATPase at the CP by the 
cardiotonic steroid ouabain diminishes production of CSF to up to 80% of basal 
levels, as such the activity of the Na+/K+ ATPase is used as an in vitro surrogate 
measure for CSF secretion (Pollay et al., 1985; Vates et al., 1964). However, 
whether the Na+/K+ ATPase activity directly contributes to CSF secretion or has 
an indirect effect through altering ion transport across CPe cells has yet to be 
elucidated. Regardless of this mechanistic uncertainty, it is clear Na+/K+ 
ATPase activity is linked to CSF secretion.  
More recently it has been demonstrated that the NKCC1 symporter has a 
unique function in the choroid plexus. It is orientated to transport ions out of 
CPe cells rather than into the CPe cells as observed in other cell types, working 
against ionic chloride and sodium gradients to facilitate the production of CSF 
through moving potassium, sodium and chloride ions into the ventricular space, 
driven by a potassium gradient (Haas and Forbush III, 2000; Steffensen et al., 
2018).  
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Figure 1.3 CSF secretion at the choroid plexus 
A simplified schematic of CSF secretion in a choroid plexus epithelial (CPe) cell 
whereby the activity of carbonic anhydrase (CA) generates carbonic acid which 
dissociates to a proton and a bicarbonate ion, these drive the sodium/hydrogen 
exchanger (NHE) and anion exchanger (AE2) respectively, transporting sodium and 
chloride ions into CPe cells. Additionally the basolateral sodium bicarbonate transporter 
(NBCn1) transports bicarbonate and sodium ions into the cell .These provide the ionic 
gradients to drive both the Na+/K+ ATPase and the NKCC1 channel to transport sodium 
into the ventricular spaces, this facilitates the osmosis of water via aquaporin 1 (AQP1). 
Furthermore the action of NKCC1 independently draws water from the cytosol to the 
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1.4.4.2 Water transport at the choroid plexus  
Aquaporin 1 (AQP1) has long been hypothesised to facilitate osmosis in the 
choroid plexus, and thus contribute to CSF secretion. However the choroid 
plexus is relatively impermeable to water. This is perhaps explained by AQP1 
localisation on CPe cells, however, this area is however controversial. Although 
it is clear that the majority of AQP1 is located on the apical membrane of CPe 
cells in both rodents and humans, some studies have also demonstrated diffuse 
basolateral localisation, although these are in the minority (Praetorius, 2007; 
Praetorius and Nielsen, 2006; Speake et al., 2003). However, given that CPe 
cells are relativity impermeable to water, it stands to reason an asymmetrical 
apical localisation of AQP1 is most likely (MacAulay and Zeuthen, 2010). 
Furthermore, as previously stated, AQP1 knockout reduces CSF secretion by 
roughly 25%, indicating that osmosis of water is not the primary method of 
transporting water through CPe cells (Oshio et al., 2004).  
This however leaves the majority of CSF secretion to be carried out by 
unaccounted mechanisms. Interestingly, it was demonstrated that the 
sodium/potassium/chloride (NKCC1) transporter can directly facilitate the 
movement of water through action as a water channel (Hamann et al., 2010). 
This property, combined with the apical orientation of the NKCC1 transporter on 
CPe cells, it has been demonstrated that the NKCC1 transporter directly 
contributes roughly 50% of CSF secretion, driven by a potassium ion motive 
force (Steffensen et al., 2018). The current data does not account for the 
remainder of CSF secretion and more importantly does not account for water 
transport across the basolateral membrane of choroid plexus epithelial cells. It 
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has also been hypothesised that other transporters contribute to water 
transporter at the at the choroid plexus through ion mediated water co-transport 
on both the basolateral and apical membranes, however this requires further 
investigation within the context of the choroid plexus (MacAulay and Zeuthen, 
2010).  
1.2.5 CSF drainage 
The drainage of CSF is vital in maintaining intracranial pressure; indeed, if CSF 
is produced it must also be removed from the CSF spaces at the rate it is 
produced. Considering CSF is produced with diurnal variation, drainage must 
be regulated to match the production rate, otherwise intracranial hypertension 
or hypotension would occur. Of note there is limited understanding of how CSF 
drainage is regulated in humans or rodents, and models do not currently exist to 
assess the molecular components of CSF drainage. Rather only physiological 
assessment CSF drainage via in vivo measurement of CSF drainage 
resistance, this technique has not been utilised to assess modulators of CSF 
drainage (Jones et al., 1987).   
1.2.5.1 Arachnoid granulations 
Classically, the arachnoid granulations that sit in the superior sagittal sinus are 
where CSF is thought to drain directly into the venous system and are the 
classic organ of CSF drainage (Cushing, 1925). The precise mechanism for 
CSF drainage at the arachnoid granulations is unknown and the contribution of 
arachnoid granulations to CSF drainage is unknown. It is hypothesised to be 
facilitated through either paracellular movement of water or the vacuolisation of 
CSF by the capsule cells of the arachnoid granulations (Pollay, 2010).  
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1.2.5.2 Glymphatics 
Recent work has highlighted that cerebral perivascular spaces, Virchow-Robin 
spaces, structures formed by astrocytes, endothelial cells and pericytes within 
the brain parenchyma facilitate the drainage of CSF (Iliff et al., 2012). 
Functionally, subarachnoid CSF was demonstrated to enter the brain 
parenchyma via these perivascular spaces, ‘glymphatics’, where CSF is then 
follows these perivascular spaces where bulk flow occurs. It was demonstrated 
that aquaporin 4 at astrocytes was vital for this, where knock out reduced both 
bulk flow and solute clearance (Iliff et al., 2012) 
1.2.5.3 Lymphatics 
Two distinct branches of the lymphatic system have been demonstrated to drain 
CSF. Historically the lymphatics of the nasal cavity have been demonstrated to 
act as a drain of CSF through the cribriform plate in a variety of mammals 
including human and non-human primates (Johnston et al., 2004; Walter et al., 
2006). More recently in a paradigm shift in CNS biology, lymphatic vessels have 
been shown in the CNS, indicating immune surveillance in the CNS (Aspelund 
et al., 2015; Louveau et al., 2015). Studies demonstrate that these lymphatic 
vessels, which are in intimate contact with the CSF in the dura mater, have the 
capability to drain CSF (Aspelund et al., 2015). More recently, it has been 
demonstrated that damaging these dural lymphatics impairs CSF flow and 
drainage (Da Mesquita et al., 2018).  
1.2.6 CSF dynamics in IIH 
CSF dynamics have been assessed to a limited capacity in IIH patients. 
Perhaps the largest piece of data suggesting altered CSF dynamics in IIH is the 
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fact that ICP is raised in IIH patients. Beyond this, there are limited studies that 
consist of low patient numbers. Several studies utilising a small cohorts of IIH 
patients identified an increased CSF flow rate through the cerebral aqueduct, 
thus increased CSF secretion (Akay et al., 2015; Donaldson, 1979; Gideon et 
al., 1994). Furthermore IIH patients have been identified to have larger ICP 
wave forms compared to headache controls, which could indicate reduced 
parenchymal compliance (Eide and Kerty, 2011). Additionally IIH patients have 
cortical astrogliosis, an inflammatory reactive state in astrocytes, and reduced 
AQP4 at the astrocyte end feet. This could be suggestive of reduced CSF 
clearance via the glymphatics but this has yet to be fully assessed (Eide et al., 
2016). This astrogliosis may be linked to headache persistence, where 
astrocyte dysfunction is linked to headache episodes (Eide et al., 2016; Ricci et 
al., 2009). Additional evidence for IIH patients having reduced CSF drainage 
comes from small studies utilising isotope cisternography, which identify 
increased resistance to CSF drainage, however these findings are not universal 
across IIH patients and could be confounded by increased venous sinus 
pressure (Janny et al., 1981; Malm et al., 1992; Orefice et al., 1992). Of interest, 
IIH patients have a similar CSF osmolality to controls and CSF osmolality does 
not change following resolution of symptoms, suggesting that gross alterations 
in osmotic forces are not associated with disease activity in IIH (Wibroe et al., 
2016), The current literature fails to conclusively elucidate whether IIH patients 
have CSF hypersecretion or reduced CSF drainage, confounded by low patient 
numbers in all studies, furthermore the studies do not address the aetiology of 
the alterations they describe, consequently further studies are required.  
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1.3 IIH pathogenesis 
As its name suggests, the aetiology of IIH is unknown. However, there are 
differing phenotypes between genders and pubertal state, suggesting varied 
aetiologies for IIH. Consequently, the remainder of this thesis will focus on the 
syndrome associated with obese women of child bearing age, the population 
with the highest incidence of IIH. As the diagnostic criterion of IIH alludes to, the 
pathologic drive of IIH is presumed to be biochemical rather than a gross 
anatomical defect. A single genetic study has been carried out to determine any 
polymorphisms in genes associated with IIH, this small study was inconclusive 
and could not exclude or confirm genetic mutations as the pathological basis of 
IIH (Kuehn et al., 2018).  
Several studies have attempted to delineate the potential cause of IIH where 
factors known to cause secondary intracranial hypertension have been 
investigated. Perhaps the longest held hypothesis for the pathogenic drive for 
IIH is altered retinoid metabolism. 
1.3.1 Retinoids 
Retinoids are vitamin A metabolites that have vital roles in the body such as 
acting as a chromophore for rhodopsin in retinal cells (Kiser and Palczewski, 
2016). Retinoids have been known to cause secondary intracranial 
hypertension since the visits of explorers to the Arctic where consumption of 
polar bear liver, a rich source of vitamin A, caused hypervitaminosis A leading 
to IIH like symptoms (Rodahl and Moore, 1943). Furthermore patients receiving 
all-trans retinoic acid (ATRA) to treat malignancies can develop iatrogenic 
intracranial hypertension, which resolves temporally with withdrawal of ATRA, 
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suggesting secondary intracranial hypertension is a toxic effect of 
hypervitaminosis A (Anoop et al., 2014). As such it has been hypothesised that 
IIH is a disease of altered retinoid metabolism, perhaps through as of yet 
unelucidated transcriptomic effects on tissues in the CNS (Libien et al., 2017). 
However, IIH patients only have mildly altered retinoid metabolism compared to 
controls and is most likely clinically irrelevant, suggesting that altered retinoid 
metabolism is unlikely to be pathogenic in IIH (Libien et al., 2017; Warner et al., 
2007).  
1.3.2 Steroid hormones 
Steroid hormones are pleotropic hormones derived from cholesterol and are 
hypothesised to be pathogenic in IIH, predominantly through altering CSF 
dynamics (Mollan et al., 2016). 
1.3.2.1 Steroidogenesis 
Steroid hormones are hormones derived from cholesterol and perform a 
multiplicity of functions and are named according to their function and organ of 
production. Mineralocorticoids such as aldosterone, and glucocorticoids such as 
cortisone fall under the corticosteroids group. Androgens such as testosterone, 
oestrogens such as oestrodiol and pregnanes such as progesterone fall into the 
sex steroid group (Miller and Auchus, 2011). 
Steroid hormones are generated through sequential enzymatic reactions, 
whereby one steroid group acts as a precursor to another steroid species. This 
sequential generation of steroids is underpinned by expression of steroidogenic 
enzymes in a tissue, whereby absence of expression precludes the generation 
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of specific steroid species. The primary organ of steroidogenesis is the adrenal 
cortex, where it is split into discrete layers that produce specific steroid classes 
(Fig1.4). The most superficial layer, zona glomerulosa, generates the 
mineralocorticoid aldosterone from corticosterone via aldosterone synthase. 
The next layer is the zona fasciculata which generates glucocorticoids, where 
humans primarily generate cortisol. The most interior layer of the adrenal cortex 
is the zona reticularis, where androgens are generated. The production of 
steroid hormones is under the regulation of negative feedback loops unique to 
each steroid class. Furthermore, de novo synthesis of steroid hormones occur 
in the gonads, placenta and in the brain. Circulating steroid precursors undergo 
pre-receptor metabolism in target tissues, allowing them to elicit their effect 
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Figure 1.4 Human adrenal steroidogenesis 
Steroid hormones are predominantly generated in the adrenal cortex, cholesterol is 
acted upon by cholesterol side chain cleavage enzyme (P450scc) generating 
pregnenolone. In the zona glomerulosa (blue), pregnenolone is converted to 11-
deoxycorticosterone via sequential 3βHSD and P450c21 reactions. Aldosterone is 
generated via the enzyme aldosterone synthase (CYP11B2). In the zona fasciculate 
(orange), pregnenolone undergoes a P450C17 reaction prior to sequential 3βHSD and 
P450c21, generating 11-deoxycortisol. Cortisol is then generated via CYP11B1. In the 
zona reticularis (red) pregnenolone undergoes sequential generating 
dehydroepiandrostendione (DHEA), where the majority is sulphated via SULT2A1 
generating DHEA-S. A proportion of DHEA undergoes a 3βHSD reaction, forming 
androstenedione (A4). Testosterone (T) is then generated via AKR1C3. Both A4 and T 
are converted to 11 OH-A4 and 11 OH-T via CYP11B1. Mixed colours represent 




Page | 26 
 
1.3.2.2 Steroid receptor signalling 
Steroid hormones predominantly elicit their biological functions through cognate 
steroid receptors, where steroid hormone receptors namely glucocorticoid 
receptor (GR) mineralocorticoid (MR), androgen receptor (AR), progesterone 
receptor (PR) and oestrogen receptors (ERα and ERβ) form part of the class I 
nuclear receptor family. Upon binding of the cognate steroid in the cytoplasm, 
the steroid receptor unbinds from a chaperone proteins, such as heat-shock 90. 
This frees the receptor to form homodimers and heterodimers, where upon 
dimerization the receptors translocate from the cytoplasm to the nucleus via 
microtubules. Within the nucleus, the receptor dimer binds to hormone 
responsive elements (HRE), sequences of DNA specific to each receptor class, 
where co-regulatory proteins then bind to the receptor-HRE complex. These co-
regulatory proteins promote DNA modification, either promoting or repressing 
gene transcription, where transcriptomic effects are the primary output of steroid 
receptor activation (Griekspoor et al., 2007). 
1.3.3 Glucocorticoids 
Glucocorticoids (GCs) are primarily produced in the zona fasciculata of the 
adrenal cortex where cortisol is the primary secreted GC in humans. Adrenal 
synthesis of GC is regulated by the hypothalamic-pituitary-adrenal (HPA) axis 
negative feedback loop. GCs are primarily carried in the circulation by 
transcortin and secondarily by albumin (Miller and Auchus, 2011). 
The action of glucocorticoids in target tissues is gated by 11β-hydroxysteroid 
dehydrogenase (11β-HSD) enzymes within the mitochondria and the 
endoplasmic reticulum. In mineralocorticoid sensitive tissues such as the 
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kidney, circulating cortisol is inactivated to cortisone by 11β-HSD type 2 (11β-
HSD2). This renal inactivation ensures the major circulating GC is cortisone. In 
glucocorticoid sensitive tissues, such as adipose tissue and the liver, 11β-HSD 
type 1 (11β-HSD1) is primarily expressed, which gates at the tissue level, active 
glucocorticoid exposure (Hewitt et al., 2005). This bi-directional enzyme 
preferentially converts the circulating GC cortisone to the active GC cortisol via 
an NADPH dependent oxo-reductase reaction within the endoplasmic reticulum, 
where NADPH  is provided by the activity of the enzyme hexose-6-phosphate 
dehydrogenase (H6PDH) (Fig1.5) (Hewitt et al., 2005). Indeed, knockdown of 
H6PDH reverses the activity of 11β-HSD1, facilitating a dehydrogenase reaction 
(Hewitt et al., 2005). Glucocorticoids are deactivated via 5α or 5β reductase 
reactions followed by a 3α-HSD converting cortisol and cortisone to 
tetrahydrocortisol (THF) or 5αTHF and tetrahydrocortisone (THE) respectively 
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Figure 1.5 Glucocorticoid pre-receptor metabolism 
The enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) gates tissue level 
glucocorticoid exposure through converting the inactive circulating glucocorticoid 
cortisone to the active glucocorticoid cortisol via an NADPH cofactor mediated oxo-
reductase reaction within the endoplasmic reticulum. Availability of NADH is provided 
by the action of hexose-6-phosphae dehydrogenase. 
 
Glucocorticoids primarily act at the glucocorticoid receptor, where cortisol 
binding causes dimerization and nuclear translocation to the glucocorticoid 
response element. Functionally, glucocorticoids are catabolic hormones which 
have a plethora of actions. GCs are immunosuppressive and promote glucose 
sparing metabolic processes and elicit cognitive effects (Baxter and Forsham, 
1972). 
1.3.3.1 Glucocorticoids and IIH 
Iatrogenic intracranial hypertension has been described upon prolonged 
treatment with GC’s (Walker and Adamkiewicz, 1964). Interestingly the 
converse has been described; IIH has been demonstrated as a rare 
complication of Cushing’s disease treatment where one study reported the 
incidence of IIH as 3% in treated Cushing’s patients, a higher incidence of IIH 
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than in the general population (Zada et al., 2010). Together these reports 
highlight a causal relationship between altered GC exposure and IIH. 
A comprehensive study assessing glucocorticoids in IIH patients has yet to be 
completed. However, weight loss in IIH is associated with reduced adrenal GC 
output and reduced systemic 11β-HSD1 activity, which correlates with reduction 
in ICP, linking active glucocorticoids to the disease activity of IIH (Sinclair et al., 
2010b). The physiological rationale for the link between 11β-HSD1 activity and 
ICP is clear. Inhibition of 11β-HSD1 in the eye reduces intraocular pressure, 
most likely through altering sodium transport and reducing aqueous humour 
secretion, in a secretary system analogous to the choroid plexus (Rauz et al., 
2001). With this data, in combination with the expression of functional 11β-
HSD1 and glucocorticoid receptor at the  choroid plexus, it has been 
hypothesised that glucocorticoids could alter ICP through modulating fluid 
secretory processes in a manner analogous to the ocular ciliary epithelium  
(Sinclair et al., 2010b). Indeed, unpublished PhD thesis work has demonstrated 
that glucocorticoids increase CSF secretion in rats (Alimajstorovic, 2016). A 
phase 2 clinical trial has closed that aimed to assess the role of GCs in 
modulating human ICP, results for this are eagerly awaited to shed light on this 
putative pathogenic mechanism in IIH (Markey et al., 2017). The current 
literature does not highlight whether there is an IIH specific GC phenotype. 
Indeed the marker for systemic GC activation, 5αTHF+THF/THE ratio, has not 
been assessed compared to controls, as such this needs to be assessed. 
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1.3.4 Oestrogens and progestogens 
Due to IIH being a disease primarily affecting females of reproductive age, it is 
plausible that alterations in female sex hormones, namely oestrogens and 
progestogens, could be altered and associated with the pathogenesis of IIH 
(Mollan et al., 2016). 
Progestogens are precursor steroid molecules to both androgens and 
corticosteroids and are primarily generated in thecal cells, and the placenta 
during pregnancy. Oestrogens are derived from both androstenedione and 
testosterone following aromatisation via aromatase (CYP19A1), where 
oestrogens are synthesised primarily in the ovarian granulosa cells. Similarly to 
androgens, oestrogens are anabolic hormones (Miller and Auchus, 2011).  
1.3.4.1 Oestrogens, progestogens and IIH 
Case studies have identified a potential causal relationship between oral 
contraceptives and  intracranial hypertension, but no mechanism has been 
elucidated (Finsterer et al., 2006). Of interest, rodent experimentation has 
demonstrated that oestrogens and progesterone reduce Na+/K+ ATPase  
activity at the choroid plexus, thus assumed reduction in CSF secretion and ICP 
(Lindvall-Axelsson and Owman, 1989). Furthermore, a meta-analysis 
demonstrated that in female humans that short term oestrogen treatment 
reduces intraocular pressure (IOP) (Dewundara et al., 2016). This could 
suggest that a refractory increase in ICP following a reduction in systemic levels 
of hormone could contribute to the raised ICP in intracranial hypertension. 
However a recent longitudinal population based study highlights hormonal 
contraceptives do not increase the risk of developing IIH (Kilgore et al., 2018).    
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With relevance to IIH, evidence is mixed as to an oestrogen phenotype in IIH. 
The current studies contain small numbers of patients, are of low quality and 
present conflicting data, demonstrating an uncertain CSF oestrogen phenotype 
but an unaltered serum oestrogen phenotype (Donaldson and Horak, 1982; 
Toscano et al., 1991). Owing to the unique CSF and serum androgen 
phenotype in IIH, it would be prudent to assess IIH CSF and serum oestrogens 
in larger IIH cohorts (O’Reilly et al., 2019). Furthermore there is no apparent link 
between oestrogens and disease activity in IIH. There is no apparent evidence 
for progestogen abnormality in IIH (Klein et al., 2013).  
1.3.5 Androgens 
Androgens are primarily generated in the zona reticularis of the adrenal cortex 
where dehydroepiandrosterone–sulfate (DHEA-s) is the primary secreted 
adrenal androgen. Androgens undergo de novo synthesis in the gonads, where 
ovarian thecal cells and testicular leydig cells generate androgens, under the 
influence of luteinising hormone. Key peripheral androgen metabolising tissues 
include the skin, adipose tissue and the liver (Schiffer et al., 2018).  
Androgens undergo a series of enzymatic reactions as part of their pre-receptor 
metabolism where circulating DHEAs is desulphated via steroid sulfatase (STS) 
to DHEA which is subsequently converted to androstenedione via 3β-HSD 
enzymes. A4 is subsequently converted to testosterone via 17-βHSD enzymes, 
namely 17β-HSD5 (AKR1C3) and 17β-HSD3. Testosterone is further activated 
by 5α-reductase enzymes (SRD5A1, SRD5A2) to dihydrotestosterone (DHT), 
the most potent androgen (Miller and Auchus, 2011). More recently it has been 
identified that 11-oxygenated androgens are potent agonists of the androgen 
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receptor, which are generated via the enzymatic reaction with 11β-hydroxylase 
(CYP11B1), these 11-hydroxy androgens are activated by 11β-HSD2 to form 
the more potent 11-keto androgens (Fig1.6) (Schiffer et al., 2018).  Androgens 
are anabolic hormones, promoting skeletal muscle growth, the initiation of 
puberty, promoting virilisation and secondary sex characteristics and are male 
sex steroids. Androgens also elicit psychological effects, promoting aggression 
and libido. Androgens promote their effects primarily via the androgen receptor 




Figure 1.6 Pre-receptor androgen and oestrogen metabolism  
A schematic describing the peripheral activation of androgens, hormones in bold are 
the most potent agonists of the androgen receptor. Note that CYP11B1 is only 
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1.3.5.1 IIH and androgens  
Recently, novel work has identified that IIH patients have a distinct androgen 
profile, whereby they have raised serum and CSF testosterone but reduced 
serum androstenedione (Appendix 1) (O’Reilly et al., 2019).  Furthermore, 
androgen production is reduced following weight loss in IIH patients (Sinclair et 
al., 2010b). Additionally, IIH presents earlier in those IIH patients who have 
androgen excess (Klein et al., 2013). This androgen excess phenotype perhaps 
explains the raised incidence of PCOS in IIH patients. 
With relevance to disease activity, several case studies exist of female-to-male 
gender reassignment patients receiving therapeutic testosterone developing IIH 
symptoms. These symptoms resolve temporally with the withdrawal of 
testosterone, allowing intracranial hypertension to be defined as a ‘possible’ 
adverse drug reaction to testosterone (Hornby et al., 2017; Kapoor, 2015). 
Functionally, testosterone has been described to increase IOP in both rodents 
and humans, providing further evidence that testosterone has the potential to 
increase ICP (Kass and Sears, 1977; Toker et al., 2003). The current evidence 
surrounding testosterone in IIH highlights it as a putative pathogenic molecule in 
IIH, where testosterone could affect both ICP regulation and perturb metabolic 
function. This warrants further investigation to elucidate whether testosterone 
has the potential to alter ICP. This is especially important to evaluate 
considering other steroids that alter fluid secretory processes at the eye 
demonstrate a similar effect on CSF secretory processes, namely the activity of 
the Na+/K+ ATPase has been demonstrated to be fundamental in the secretion 
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of both CSF and aqueous humour secretion (Riley and Kishida, 1986) (table 
1.3).  
Hormone IOP CSF secretion References 
Progestogens ? 
↓ Na+/K+ ATPase 




Oestrogens ↓ IOP 









HSD1 ↓ IOP 
↑ CSF secretion 
(Alimajstorovic, 
2016; Rauz et al., 
2001) 
Androgens ↑ IOP ? 
(Toker et al., 
2003) 
 
Table 1.3 Effects of steroid hormones on secretory systems 
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1.3.6 Leptin  
Leptin is a 16-kDa peptide hormone that is primarily secreted from adipose 
tissue and secondarily from the gastric mucosa. Leptin was among the first 
identified adipokines, hormones secreted from adipose tissue, whose secretion 
is modulated through dietary and physiological cues. Leptin has several 
functions within the body including immunomodulation, bone metabolism and 
initiation of puberty. However the classic function of leptin is the induction of 
satiety through signalling at the hypothalamus via the OB-Rb splice variant of 
the leptin receptor (Kelesidis et al., 2010). 
1.3.6.1 Leptin and IIH 
Leptin levels in IIH have been investigated due to the association of IIH with 
obesity. It has been demonstrated that IIH patients have raised serum leptin, 
independent of BMI (Ball et al., 2009; Lampl et al., 2002). Furthermore leptin 
has been shown to be raised in the CSF of unfasted IIH patients (Ball et al., 
2009). However these data have not been corroborated by subsequent studies, 
perhaps due to differing methodologies between studies, including differences 
in fasting state, use of appropriate controls subjects and differences in IIH 
phenotypes (Behbehani et al., 2010; Dhungana et al., 2009; Samancl et al., 
2017). Intriguingly, lumbar puncture opening pressure positivity correlates with 
CSF leptin values in control patients, indicating that leptin could be pathogenic 
in IIH through altering CSF dynamics (Ball et al., 2009). This hypothesis is 
plausible: chronic leptin exposure increases Na+/K+ ATPase activity in renal 
tubule cells, cells that function analogously to choroid plexus epithelial cells 
(Bełtowski et al., 2004; Botfield et al., 2017). Being as Na+/K+ ATPase activity is 
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a driver of CSF secretion at the choroid plexus, this highlights leptin as a 
putative pathogenic molecule in IIH. This necessitates in vitro and in vivo 
assessment of leptins capacity to modulate ICP, and Na+/K+ ATPase activity in 
CPe cells. Furthermore there is a need to replicate previous leptin studies in a 
larger homogenous IIH cohort with appropriate controls.   
Although there are several putative pathogenic molecules in IIH, as discussed 
above there has been limited assessment of their capacity to modulate CSF 
secretion, functional surrogates such as Na+/K+ ATPase activity and CSF 
drainage. Indeed there has been limited in vitro assessment on how these 
molecules can alter the molecular processes at key tissues such as the choroid 
plexus, as such more work is required to assess these molecules in a variety of 
tissue and physiological processes.   
1.4 IIH treatment 
Although several hypotheses exist as to the cause of IIH, there is little 
understanding of how these putative factors are pathogenic in IIH. 
Consequently the treatment of IIH primarily focuses on resolving its symptoms, 
namely preserving vison through reducing papilloedema, achieved through 
reducing ICP. These are symptomatic treatments rather than disease modifying 
treatments.  
1.4.1 Surgical interventions 
Treatment for IIH primarily depends on the nature of the symptoms presented. 
Where there is an imminent risk of visual loss, surgical interventions are 
pursued and involve CSF diversion therapies (Mollan et al., 2018b).  
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Although primarily diagnostic, lumbar punctures and more commonly lumbar 
drains are used in IIH to drain excess CSF to reduce ICP and save eyesight 
where vision is at imminent risk. However, IIH patients report poor experience 
with lumbar punctures and often develop exacerbation of headache so these 
procedures are only temporary measures (Mollan et al., 2018b; Scotton et al., 
2018b; Yiangou et al., 2018).  
Subsequent to lumbar drainage, other more permanent CSF diversion 
procedures are utilised. These include optic nerve sheath fenestration and CSF 
shunting procedures. Although surgical interventions work acutely to save 
vision, there are often high revision rates, especially for shunting procedures. 
Furthermore, not every patient requires CSF diversion due to stable vision, as 
such, pharmaceutical and ‘self-help’ options are recommended (Mollan et al., 
2018b). 
1.4.2 Pharmaceutical interventions for IIH  
Non-surgical interventions for IIH are often pharmacological and utilise the 
knowledge that choroid plexus secretes CSF to repurpose other drugs, known 
to modulate secretion at other secretory epithelia, to modulate ICP. The drug of 
choice in IIH is acetazolamide (Mollan et al., 2018b). Acetazolamide is a 
carbonic anhydrase inhibitor and has proven efficacy in both renal and ocular 
secretory epithelia as a diuretic and as an inhibitor of aqueous humour 
formation, through reducing Na+/K+ ATPase activity (Maus et al., 1997). Indeed, 
in rodents acetazolamide decreases both Na+/K+ ATPase activity at the choroid 
plexus and reduces CSF secretion, perhaps through altered bicarbonate 
transport thus altered ionic and pH balance (Oshio et al., 2004; Sterling et al., 
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2001; Uldall et al., 2017) These data have provided the rationale for using 
acetazolamide to reduce ICP in humans. 
The clinical evidence for acetazolamide use in IIH is unconvincing. In a recent 
large scale trial, acetazolamide conferred mild improvements in visual outcome 
compared to a placebo group, although the dose provided in this study is well 
above what most patients in a previous study would tolerate (Ball et al., 2011). 
Furthermore, the study failed to achieve its pre-defined treatment effect for 
clinically relevant change in visual outcomes, suggesting poor clinical efficacy 
for acetazolamide in IIH (Wall et al., 2014).  
Other diuretic compounds such as furosemide, topiramate, amiloride, inhibitors 
of the NKCC1 channel, carbonic anhydrase and NHE channel respectively, and 
the somatostatin analogue octreotide are used to treat IIH on the assumption 
that they reduce CSF secretion in the choroid plexus, however efficacy is limited 
and high quality comparative studies do not exist (Çelebisoy et al., 2007; 
Corbett, 1983; Mollan et al., 2018b; Panagopoulos et al., 2007). Furthermore, 
diuretic drugs have an unfavourable side effect profile. The lack of true efficacy 
with these drugs was highlighted in a recent Cochrane review highlighting the 
need for more high quality randomised clinical trials in IIH (Piper et al., 2015). 
Interestingly, a recent in vivo study demonstrated a single dose of topiramate 
reduces ICP more than any of the other drugs described above in rats (Scotton 
et al., 2018a). 
There is also a need for further preclinical studies and screening of potential 
therapeutic compounds with a reduced side effect profile. An open label trial 
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evaluating the effects of diuretic drugs in treating IIH, utilising ICP as an 
objective measure of treatment effect is currently underway 
(ISRCTN12678718). This trial is also evaluating the ability of glucagon-like 
peptide 1 receptor agonists to decrease ICP, which have shown promise in pre-
clinical studies in reducing ICP in physiological and pathophysiological ranges 
(Botfield et al., 2017). Pharmaceutical interventions for IIH only provide 
symptomatic relief and do not treat the underlying pathology.  
1.4.3 Weight loss and IIH 
The only current intervention with true disease modifying efficacy is weight loss, 
whereby 15% weight loss provides IIH patients with reduced ICP and improved 
visual and headache outcomes (Sinclair et al., 2010a). As such, weight loss is 
the recommended conservative treatment for IIH (Mollan et al., 2018b). The 
effects of weight loss on IIH and its symptoms sheds light on the potential 
pathogenesis of IIH; it is hypothesised that the adipose tissue in IIH is driving 
the pathology of IIH (Hornby et al., 2018b). 
1.5 Adipose tissue 
Adipose tissue is a mesenchyme derived tissue that has three functional 
phenotypes: white adipose tissue which primarily acts as a store for excess 
calories; brown adipose is thermogenic and beige adipose displays an 
intermediate phenotype. Adipose tissue is comprised of adipocytes, the 
functional unit of adipose tissue, and supporting cells such as fibroblasts, 
macrophages, stomovascular preadipocyes and the newly discovered 
adipogenisis-regulatory cells  (Rosen and Spiegelman, 2014; Schwalie et al., 
2018). 
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1.5.1 Adipose distribution 
White adipose tissue is distributed over several depots, where the depots can 
be grouped into either subcutaneous (SC) or visceral adipose depots. SC 
adipose tissue functions as a store of energy and provides thermal insulation, 
whilst visceral adipose, which resides in the body cavities, additionally provides 
mechanical cushioning for organs. The greater and lesser omentum reside in 
the abdominal cavity and comprised of omental (OM) adipose tissue, which are 
the visceral adipose of choice for ex vivo experimentation. 
Two primary adipose distributions exist, this includes the gynaecoid adipose 
distribution whereby SC adipose tissue is found primarily in a gluteo-femeral 
distribution and is associated with the female sex and confers a protective 
metabolic phenotype (Manolopoulos et al., 2010). The second main adipose 
distribution is the android adipose distribution, where SC adipose is primarily 
deposited abdominally with an expansion in visceral adipose depot volume. The 
android adipose distribution is associated with males and an adverse metabolic 
risk (Manolopoulos et al., 2010). Increased visceral adipose mass is strongly 
associated with adverse metabolic risk and contributes to the android adipose 
distribution (Smith et al., 2001; Taksali et al., 2008).  
1.5.2 The adipocyte 
White adipocytes are the functional cell type in white adipose tissue; they are 
post-mitotic and their cell structure is dominated by a large central lipid droplet 
with an acentric cytoplasm and nucleus. The white adipocyte is exquisitely 
adapted for its classical role: the production and storage of triglycerides, and the 
liberation of free fatty acids from triglycerides in a state of fasting.  
  
Page | 41 
 
1.5.3 Lipid storage in adipose tissue  
1.5.3.1 Adipocyte lipogenesis 
Lipogenesis dominates the function of the adipocyte in the post-prandial state, 
where carbohydrates and amino acids contribute to de novo lipogenesis in 
adipocytes (Fig 1.7). The post-prandial insulin increase stimulates the uptake of 
glucose from the blood via the GLUT4 transporter (Huang and Czech, 2007). 
This glucose undergoes glycolysis, where pyruvate is generated. Pyruvate is 
also generated by non-ketogenic amino acid catabolism. Subsequently pyruvate 
is converted to acetyl-CoA, by the mitochondrial pyruvate dehydrogenase 
complex (PDH), which enters the tricarboxylic acid (TCA) cycle forming citrate. 
Amino acids also join the TCA cycle, either as TCA intermediates, or as acetyl-
CoA in the case of ketogenic amino acids. Citric acid then enters the cytoplasm 
due to increased mitochondrial levels facilitated by increased glycolysis and 
TCA intermediate generation. This citrate is cleaved via ATP citrate lyase 
(ACLY), liberating oxaloacetate and acetyl-CoA. Acetyl-CoA is converted to 
malonyl-CoA by acetyl CoA carboxylate (ACACA), which is the precursor for 
fatty acid synthesis. Fatty acid synthesis is performed by the fatty acid synthase 
(FASN) enzyme complex, forming fatty acids from malonyl-CoA (Kersten, 
2001). Interestingly, de novo fatty acid synthesis from BCAA backbones is 
highly efficient in adipocytes, contributing to roughly 25% of acetyl-CoA 
destined for fatty acid synthesis (Crown et al., 2015; Rosenthal et al., 1974).  
Dietary and hepatic derived free fatty acids freely diffuse into an adipocyte 
whereas intestinal derived chylomicrons are acted upon by lipoprotein lipase, 
freeing fatty acids to diffuse into the adipocyte.  Dietary free fatty acids and de 
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novo synthesised fatty acids are conjugated to glycerol-3-phosphate moieties, a 
product of glycolysis, to form triglycerides (Ameer et al., 2014). 
1.5.3.2 Storage of triglycerides 
Triglycerides form the basis of the central lipid droplet in adipocytes, where its 
structural integrity is maintained primarily by perilipin proteins, whose 
conformation prevents lipases from catabolising the lipid droplet (Brasaemle et 
al., 2009). 
1.5.3.3 Lipolysis in adipocytes 
In the fasting state, the adipocyte receives hormonal input, from glucagon and 
adrenaline, which stimulate lipolysis through activation of protein kinase A 
(PKA). PKA phosphorylates  perilipins, facilitating a conformation change, 
allowing PKA phosphorylated lipases to cleave triglycerides, liberating fatty 
acids and glycerol following sequential reaction with  adipocyte triglyceride 
lipase (ATGL), hormones sensitive lipase (HSL) and monacylglycerol lipase 
(MAG) (Fig 1.7) (Brasaemle et al., 2009). Free fatty acids freely diffuse into the 
circulation whereas glycerol diffusion is facilitated by aquaporin 7 (Hibuse et al., 
2006). Free fatty acids are utilised in tissues as a respiratory substrate in β-
oxidation, especially when musculo-heptatic glycogen stores are depleted, 
whereas glycerol is utilised in hepatic gluconeogenesis (Rui, 2014). 
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Figure 1.7 Lipolysis and lipogenesis in adipocytes 
A schematic diagram of lipogenesis and lipolysis in adipocytes. In the post-prandial 
state insulin promotes the influx of glucose into an adipocyte via GLUT4, following 
glycolysis, pyruvate enters the mitochondria where it is converted to Acetyl-CoA via 
pyruvate dehydrogenase (PDH). This subsequently enters the tricarboxylic acid cycle 
forming citrate. Increased mitochondrial citrate enters the cytosol where citrate lyase 
liberates acetyl-CoA. The subsequent action of acetyl-CoA carboxylase forms malonyl-
CoA which is acted upon by the fatty acid synthase complex forming fatty acids. 
Glycerol-3 phosphate and fatty acid are conjugated forming triglycerides. In the fasted 
state, lipolysis facilitated by lipases, liberates fatty acids and glycerol, which enter the 
circulation. Bold words represent processes, TCA= Tricarboxylic acid cycle, AA= amino 
acids, BCAA= branch chained amino acids, ACLY=ATP citrate lyase, ACACA acetyl-
CoA carboxylase, FASN= fatty acid synthase, ATGL= Adipocyte triglyceride lipase, 
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1.6 Adipose tissue as an endocrine organ 
Since the 1990s adipose tissue has been shown to be more than a mere store 
of lipids, it has been shown to be an endocrine organ. The seminal discovery 
that adipose tissue produces the satiety hormone leptin opened up research 
into the hormones that adipose tissue produces. The discovery of a plethora of 
adipose generated hormones, or adipokines, allows adipose tissue to be 
described as an endocrine organ (Coelho et al., 2013).  
1.6.1 Leptin 
The cardinal adipokine is leptin. Identified in 1995, leptin has been 
demonstrated to induce satiety as previously described and is a modulator of 
energy homeostasis (section 1.3.6). Further evidence of leptin as a mediator of 
energy homeostasis and satiety can be demonstrated by patients who 
congenitally lack leptin. These patients develop florid obesity and present with 
hyperphagia which can be reversed following leptin administration (Farooqi et 
al., 1999; Montague et al., 1997). This phenotype was replicated in a classic 
rodent experiment (Pelleymounter et al., 1995). Secretion of leptin from 
adipocytes is tightly modulated in order to facilitate appropriate energy 
homeostasis in an organism. Although the direct molecular mechanism 
facilitating leptin secretion is not entirely clear, both chronic and acute 
modulators of leptin secretion are well characterised. At its highest level, leptin 
secretion follows a circadian rhythm, whereby leptin secretion is minimal in the 
morning and reaches is peak during the hours of sleep, irrespective of BMI 
(Langendonk et al., 1998). 
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1.6.1.1 Positive acute regulation of leptin secretion 
Adipocytes display a basal level of leptin secretion; however other factors 
modulate this secretion. Leptin secretion is regulated acutely to modulate 
satiety in the post-prandial state and following events requiring more dietary 
calories. Acute regulation of leptin secretion is modulated by several factors, 
relating to caloric status. This is demonstrated by a post-prandial increase in 
circulating leptin in lean individuals, highlighting that factors associated with the 
post-prandial state promote leptin secretion (Korek et al., 2013). This post-
prandial increase in leptin is linked to the post-prandial increase in insulin, 
where insulin has been demonstrated to increase leptin secretion both in vitro 
and in vivo settings (Kolaczynski et al., 1996; Malmström et al., 1996). Glucose 
and other molecules that facilitate the production of pyruvate have been 
demonstrated to increase both basal and insulin stimulated leptin secretion in 
rodent adipocytes (Levy et al., 2000). This is likely linked to the ability of 
malonyl-CoA, the precursor molecule to fatty acids, to potentiate leptin secretion 
(Shirai et al., 2004) (Fig1.8).  
1.6.1.2 Negative acute regulation of leptin secretion 
In the fasted state, plasma leptin decreases, due to the reduction in serum 
insulin and glucose following resolution of the post-prandial insulin peak (Boden 
et al., 1996). Catecholamines, affecters of the sympathetic branch of the 
autonomic nervous system, are secreted during times of stress. Adrenoceptor 
activation has been demonstrated to inhibit leptin secretion, mediated  through 
lipolysis, whereby liberated Acyl-CoA moiety’s inhibit ACC preventing malonyl-
CoA synthesis (Gettys et al., 1996; Haystead and Grahame, 1986; Shirai et al., 
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2004). Interestingly,  intracellular free fatty acids have been demonstrated to 
inhibit both basal and insulin stimulated leptin secretion in rodent adipocytes, 
where shorter carbon back bone lipids exhibit stronger inhibition (Cammisotto et 
al., 2003). Lipolysis independent of catecholamines in the fasted state also 
inhibits leptin secretion via the mechanism described (Fig1.8).   
1.6.2.3 Chronic regulation of leptin secretion 
The most substantial contributor to long term leptin secretion is adipocyte 
volume, where increased adipocyte cross-sectional area is positively correlated 
with both leptin mRNA, adipocyte leptin secretion and unsurprisingly BMI 
(Lönnqvist et al., 1997).  Furthermore, chronic glucocorticoid administration  has 
been demonstrated to increase leptin secretion from adipocytes and increase 
serum leptin as demonstrated in Cushingoid and healthy individuals  (Dagogo-
Jack et al., 1997; Masuzaki et al., 1997).  Insulin is also a chronic affector of 
leptin, where adipocytes secrete more leptin after chronic incubation with insulin 
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Figure 1.8 Effectors of leptin secretion 
Adipose tissue secretes leptin at basal levels as determined by adipocyte size. 
However several processes promote leptin secretion. Insulin in the postprandial state 
increases leptin secretion directly and through promoting de novo lipogenesis. 
However lipolysis, mediated through catecholamines and other lipogenic stimulus, 
inhibits lipogenesis. Glucocorticoids also increase leptin secretion.  Flat arrow head= 
inhibits, pointed arrow head = promotes, INSR= insulin receptor, ρ= correlation.   
1.6.2 Adiponectin 
Adiponectin is another peptide hormone secreted from adipose tissue and acts 
as a regulator of metabolism, whereby it stimulates β-oxidation and inhibits 
gluconeogenesis. Adiponectin secretion from adipose tissue and corresponding 
serum adiponectin levels are inversely correlated with BMI in both males and 
females (Kern et al., 2003). This demonstrates that adipose tissue regulates 
whole body metabolism.  
1.6.2 Androgens and adipose tissue 
Adipose tissue is a major organ for peripheral androgen metabolism, where 
adipose tissue expresses androgen activating enzymes (O’Reilly et al., 2014). 
Depot specific androgen metabolism has been demonstrated, where SC 
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adipose preferentially generates testosterone, OM adipose preferentially 
inactivates testosterone to androstenedione, although the precise enzyme 
involved remains controversial (Blouin et al., 2009; Quinkler et al., 2004). 
Consequently SC adipose can be described as a peripheral activator of 
androgens whereas OM adipose can be described as an androgen inactivation 
tissue. Androgens exert several effects on adipose tissue, these include 
increasing lipolysis, reducing lipogenesis and inhibition of pre-adipocyte 
differentiation (O’Reilly et al., 2014). Adipose tissue also expresses aromatase 
and possesses the ability to generate oestrogens (Killinger et al., 1987).  
1.6.3 Glucocorticoids and adipose tissue 
Adipose tissue is a peripheral tissue of GC activation, where depot specific 11β-
HSD1 activity exists, OM adipose has a greater capacity to activate GCs than 
SC adipose (Bujalska et al., 2007). Furthermore, GCs promote depot specific 
effects on adipocyte maturation; CGs promote maturation in SC adipocytes and 
inhibit maturation in OM adipocytes, perhaps explaining why OM adipocytes are 
smaller than SC adipocytes (Bader et al., 2002; Bujalska et al., 2007; Tomlinson 
et al., 2002). Interestingly adipose tissue specific overexpression of 11β-HSD1 
promotes obesity and metabolic syndrome in rodents in a similar manner to 
exogenous GC overdose, where 11β-HSD1 knockout prevents the development 
of metabolic syndrome (Masuzaki et al., 2001; Morgan et al., 2014). As such, 
GCs have been demonstrated to promote both lipolysis and lipogenesis in 
adipose tissue, increasing lipid turnover but favouring triglyceride formation and 
adipocyte hypertrophy (Masuzaki et al., 2001). Furthermore, patients with GC 
excess also develop florid abdominal obesity and metabolic disease, 
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highlighting the obesogenic effects of GCs. GCs also promote androgen 
inactivation in adipose tissue (Blouin et al., 2009).  
1.7 Obesity 
Obesity is a disease on pandemic proportions, affecting 650 million individuals 
as of 2016, where prevalence is highest in the developed world and is 
associated with low socio-economic status (McLaren, 2007). Being defined as 
having a BMI over 30 kg/m2 by  the World Health Organisation, obesity 
increases the chances of an individual developing serious morbidities including 
type 2 diabetes, cancer, musculoskeletal diseases, cardiovascular events, 
hypertension, metabolic syndrome, mental health issues  and premature death 
(Flegal et al., 2013). Obesity is, however, a modifiable disease, where the 
reduction in BMI confers a reduction in comorbid symptoms and even 
amelioration of the comorbid conditions.  
Obesity has a strong genetic component. This was demonstrated by an elegant 
study observing body composition in twins, where monozygotic twins had 
similar body compositions, lean or obese, whereas dizygotic twins often had 
differing body compositions (Börjeson, 1976). Recently, a genome wide 
association study identified that polymorphisms in genes associated with the 
nervous system are strongly associated with the development of raised BMI in 
European men and women (Locke et al., 2015). More recently it was 
demonstrated that polymorphisms associated with a lean phenotype also exist 
(Riveros-McKay et al., 2019). Together, these data highlight that genetics play 
strong role in obesogenisis and the environment is a modifiable component. 
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1.7.1 Obesity and adipose distribution 
Obesity sees expansion of both visceral and subcutaneous adipose depots. The 
volume of the visceral adipose depot, including OM adipose is associated with 
heightened adverse metabolic outcomes including dyslipidaemia, insulin 
resistance and increased risk of metabolic syndrome (Smith et al., 2001; Taksali 
et al., 2008). This highlights that visceral adiposity is particularly damaging to 
health.  
1.7.2 Biochemical phenotype of obesity 
Obese women have a distinct biochemical profile, whereby they exhibit relative 
androgen excess and impaired systemic GC activation mediated via reduced 
hepatic 11β-HSD1 activity (Rask et al., 2002; Stewart et al., 1999; Taponen et 
al., 2003). Obese women also have increased circulating leptin (Lönnqvist et al., 
1997). Obesity can be described as a state of leptin resistance, whereby 
despite increased serum and CSF leptin compared to lean individuals, obese 
patients remain obese (Nam et al., 2001). This is clearly demonstrated in leptin 
receptor knockout mice who develop a similar metabolic phenotype (Cohen et 
al., 2001).  
Furthermore, it is well established that obese patients have increased levels of 
circulating pro-inflammatory cytokines and adipokines such as tumour necrosis 
factor alpha (TNFα) and interleukin (IL) 6 as well as decreased levels of anti-
inflammatory cytokines such as adiponectin (Kern et al., 2003). Consequently 
obesity can be described as a chronic pro-inflammatory disease. Further 
evidence for obesity being a pro-inflammatory state is raised serum C-reactive 
protein (CRP), a protein involved in the acute phase inflammatory response and 
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is a risk factor for hypertension, independently of obesity (Chul Sung et al., 
2003; Visser et al., 1999). 
Furthermore, obesity has a differential biochemical phenotype compared to 
other diseases of chronic inflammation at the hormonal level. Whereas obese 
patients have raised circulating pro-inflammatory cytokines and reduced 
systemic 11β-HSD1 activity, other diseases of chronic inflammation such as 
rheumatoid arthritis and inflammatory bowel diseases display increased 
systemic 11β-HSD1 activity mediated by tissue level pro-inflammatory cytokines 
(Cooper et al., 2011; Hardy et al., 2008). This difference is perhaps mediated, in 
part, by reduced hepatic 11β-HSD1 activity in obesity (Rask et al., 2002). 
Additionally, obese individuals display insulin resistance, hyperinsulinemia and 
are at a heightened risk of developing type 2 diabetes, which comes with its 
own distinct set of side effects (Dandona et al., 2004; Mokdad et al., 2003). 
Obese patients also exhibit dyslipidaemia, contributing to peripheral insulin 
resistance through inhibiting insulin stimulated hepatic and skeletal muscle 
glucose absorption (Huang and Czech, 2007).   
1.7.3 Obesity and adipose tissue 
At the cellular level, obesity sees adipocyte hypertrophy through enlargement of 
the central lipid droplet due to triglyceride accumulation, a direct consequence 
of prolonged positive caloric balance due to an imbalance in caloric intake and 
energy expenditure. 
Adipocyte hypertrophy is not intrinsically pathological and is required for 
physiological energy storage. However, hypertrophy becomes pathological in 
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adipocytes due to reduced oxygen tension causing hypoxia, facilitated by 
insufficient angiogenesis (Sun et al., 2011). This hypoxia accompanied by 
adipocyte hypertrophy and adipocyte death creates an intra-adipose pro-
inflammatory environment that promotes macrophage recruitment to adipose 
tissue depots (Rosen and Spiegelman, 2014; Sun et al., 2011). These recruited 
macrophages promote clearance of dead adipocytes through the formation of 
crown-like structures, forming a differentiation niche for pre-adipocytes. It has 
been hypothesised that these recruited macrophages promote the adverse 
metabolic consequences of obesity (Sun et al., 2011). Functional ablation of 
macrophages in obese mice improves insulin sensitivity and metabolic 
phenotype despite no alteration in adipocyte volume (Patsouris et al., 2008). 
This lends credit to the hypothesis that macrophages, in part, drive the obesity 
related metabolic phenotype. 
One hormone derived from infiltrating macrophages is TNFα, whose secretion 
and expression is increased in obese adipose tissue (Hotamisligil et al., 1995). 
TNFα paracrine signalling contributes to adipocyte insulin resistance through 
inhibiting insulin receptor signal transduction (Hotamisligil et al., 1996, 1995). 
Furthermore, TNFα increases both the expression and activity of 11β-HSD1 in 
pre-adipocyte cultures, likely contributing to increased 11-βHSD1 expression 
and activity in whole SC and OM adipose tissue in obesity (Handoko et al., 
2000; Rask et al., 2002; Tomlinson et al., 2001).  
Increased local 11β-HSD1 activity, coupled with increased adipocyte volume 
contributes to the raised leptin secretion from adipose derived from obese 
individuals (Lönnqvist et al., 1997; Masuzaki et al., 1997). Furthermore 
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glucocorticoid mediated effects such as increased lipogenesis and increased 
pre-adipocyte differentiation contribute to the expansion of the adipose depots, 
exacerbating the remodelling and inflammation, generating the reciprocal 
conditions for further tissue expansion (Masuzaki et al., 2001). The increased 
GC exposure promotes lipolysis, contributing to hyperlipidaemia (Arnaldi et al., 
2010). The increased circulating active androgens in obese women may be 
explained by the increased expression and activity of AKR1C3 in obese women, 
which appears to be regulated by increased circulating insulin acting upon the 
adipose tissue (O’Reilly et al., 2017; Quinkler et al., 2004; Taponen et al., 
2003).  
1.8 Adipose tissue, obesity and IIH  
Adipose tissue is hypothesised to contribute to the pathology of IIH due to a 
striking association between obesity and IIH and the improvement of symptoms 
with weight loss (Sinclair et al., 2010a). Despite this association between 
obesity and IIH, very little is known about the underlying adipose phenotype in 
IIH. However, being as IIH patients are obese, their adipose tissue is by 
definition dysfunctional (Attie and Scherer, 2009). It is clear that IIH patients 
have a similar basal inflammatory response to obese individuals as they 
demonstrate BMI dependent CRP levels and have raised CRP compared to 
lean controls, however CRP has not compared between IIH patients and 
matched obese controls (Hannerz et al., 2011). 
1.8.1 Adipose distribution in IIH 
 The investigation of adipose tissue distribution in IIH has been characterised by 
conflicting results, perhaps exacerbated by inadequate methodologies to 
  
Page | 54 
 
measure adipose distribution. Previous studies have highlighted that IIH 
patients have a more gynaecoid adipose distribution, however these studies 
utilised small patient numbers and used the subjective waist-to-hip ratio 
measurement (Kesler et al., 2010; Klein et al., 2013). More recent unpublished 
work utilising dual x-ray absorptiometry (DEXA), which provides a high 
resolution objective measure of adipose distribution, has highlighted that IIH 
patients have a similar adipose distribution to matched controls (Botfield et al 
unpublished). Furthermore, two studies assessing independent IIH cohorts, one 
of which is currently unpublished, have identified that truncal fat mass positively 
correlates with LP Opp (Hornby et al., 2018a). Congruent with this, a reduction 
in truncal adiposity reduces LP Opp, highlighting truncal adiposity as a putative 
pathogenic determinant in IIH (Hornby et al., 2018a). Although these DEXA 
studies highlight truncal adipose mass as a potential determinate of LP Opp, 
they fail to differentiate between SC and visceral adipose. Additionally it is 
unknown how adipose tissue could contribute to ICP dynamics.  
1.8.2 Endocrinology of IIH adipose tissue 
As previously stated, IIH patients are thought to have raised serum and CSF 
leptin (Ball et al., 2009). This suggests hypothalamic leptin resistance and 
dysfunctional leptin secretion, and it is assumed that this is derived from 
adipocytes but has yet to be demonstrated. Furthermore it is unknown what 
factors in IIH adipose could be facilitating this proposed leptin phenotype. 
 It has been demonstrated that weight loss in IIH patients reduces adrenal GC 
output and peripheral GC activation, suggesting that IIH adipose could be 
contributing to GC activation. However this study did not include a control 
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cohort, consequently an IIH specific GC phenotype has yet to be described 
(Sinclair et al., 2010b). This study also highlights that weight loss in IIH patients 
reduces total androgen output and decreases androgen activation (Sinclair et 
al., 2010b). This however, does not identify whether adipose tissue is the 
source of the unique androgen signature in IIH. Several studies have screened 
serum cytokines in IIH patients in order to determine a serum IIH specific profile 
of cytokines. These demonstrate homology with obese patients with the 
exception of  reduced serum IL-8 (Ball et al., 2009; Samancl et al., 2017).  
These data suggest that IIH adipose tissue will secrete cytokines similarly to 
obese patients, however direct secretion of adipokines from IIH adipose tissue 
has yet to be described.  
As the above detail alludes to, a significant amount of IIH adipose biology is 
currently presumed and therefore undetermined. The transcriptome, the 
expression of RNA, is undetermined. Furthermore the secretome, the hormones 
that IIH adipose secretes is unknown. Similarly the metabolome, the sum total 
of metabolic processes in IIH adipose tissue is unknown. Together investigating 
these factors in both SC and visceral adipose tissue, the two adipose depots 
contributing to truncal adipose, would provide a comprehensive phenotype of 
the proposed pathogenic adipose depots in IIH and facilitate future investigation 
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1.9 Aims and Hypothesises 
1.9.1 Hypothesis 
Given that weight loss reduces the symptoms of IIH and that truncal obesity 
correlates with LP Opp, a marker of disease severity in IIH, it is hypothesised 
that truncal adipose tissue in IIH is phenotypically deranged and that this 
derangement drives the pathogenic phenotype in IIH (Hornby et al., 2018a; 
Sinclair et al., 2010a). 
There is controversy in the leptin phenotype in IIH due to non-standard study 
designs and inappropriate controls. As such, this needs to be addressed in a 
large IIH cohort with appropriate controls. It is hypothesised that leptin dynamics 
are perturbed in IIH. 
Given that IIH patients have an androgen excess phenotype and that 
therapeutic testosterone is thought to cause intracranial hypertension in female-
to-male gender reassignment patients, it is hypothesised that testosterone can 
modulate the Na+/K+ ATPase, thus modulating ICP (Hornby et al., 2017; 
O’Reilly et al., 2019). 
1.9.2 Aims 
1. Comprehensively phenotype adipose tissue in IIH  
2. Investigate leptin biology in IIH 
3. Develop a novel in vitro Na+/K+ ATPase activity assay and validate 
against drugs and in vivo experiments  
4. Evaluate the effects of testosterone on Na+/K+ ATPase activity in choroid 
plexus epithelial cells 
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Chapter 2 General methods 
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Unless otherwise stated, all chemicals and reagents come from Sigma, Poole, 
UK. 
2.1Tissue culture 
All tissue culture was carried out in a microbiological safely cabinet using 
aseptic technique. 
2.1.1 Z310 cells 
Z310 cells, a validated immortalised choroid plexus epithelial cell line derived 
from mixed sex Sprague-Dawley rats, express serval phenotypic markers of 
choroid plexus epithelial cells, such as transthyretin, tight junction markers and 
grow in a cobble-stone-like morphology (Fig2.1) (Zheng and Zhao, 2002).  
 
 
Figure 2.1 Z310 cells express phenotypic markers of choroid plexus 
epithelial cells 
Z310 cells express Na+/K+ ATPase, Transthyretin (TTR) and zona-occluden 1 (ZO-1) 
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2.1.2 Z310 cell culture 
Z310 cells were cultured in high glucose (25 mM) Dulbecco’s modified eagle 
medium (DMEM) with 10% foetal bovine serum, 1% penicillin/streptomycin 
(Thermofisher, Paisley, UK) and 1 ng/ml epidermal growth factor (EGF) 
(PeproTech, London, UK) in T75 flasks and incubated at 37°C in a humidified 
atmosphere at 5% CO2. For maintenance of the cells, Z310 cells were 
passaged at 80% confluence. Cells were washed in warm phosphate buffered 
saline (PBS) and dissociated with TrypLE express (Thermofisher) until cells had 
lifted from the flask and dissociated. Subsequent cell suspensions diluted 2:1 
with DMEM and cell suspension was pelleted at 450 g. Cells were then re-
suspended in culture medium and plated. 
2.2 Plate based Na+/K+ ATPase activity assay 
To determine the Na+/K+ ATPase activity of cultured Z310 cells, Z310 cells were 
cultured in 12 well plates to confluence. When confluent, Z310 cells were 
incubated in artificial cerebrospinal fluid (aCSF) (in mM: 118 NaCl, 22 NaHCO3, 
1.45 K2HPO4, 1 MgSO4, 1 CaCl2 and 10 glucose) at 37°C. Following this, aCSF 
was removed and Z310 cells were incubated in either vehicle (aCSF) or 1 mM 
ouabain (Na+/K+ ATPase inhibitor) in aCSF at 37°C. Subsequently, Z310 cells 
were incubated for 5 minutes with ice cold lysis buffer (in mM: 20 Tris-HCl pH 
7.4, 150 NaCl, 1 EDTA, 0.5 EGTA, 1% NP-40 and 5 μg/ml protease inhibitor 
cocktail) and were centrifuged at 13,000g at 4ºC to remove cellular debris. 
Times of aCSF and ouabain incubation are assessed in chapter 5. Total 
inorganic phosphate was assayed (see section 2.3) and normalised to protein 
(see section 2.4). The difference between inorganic phosphate levels between 
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cells treated with aCSF and ouabain in a particular condition was deemed to be 
the contribution of Na+/K+ ATPase to total cellular phosphate, thus Na+/K+ 
ATPase activity. 
2.3 Inorganic phosphate assay 
Total cell lysate (section 2.2) inorganic phosphate concentration was 
determined via a colorimetric phosphate assay (ab65622, Abcam, Cambridge, 
UK) carried out according to manufacturer’s instructions, where optical density 
(OD) was measured on a Wallac victor3 1420 plate reader (Perkin Elmer, 
London, UK) at 690nm. Samples were ran in triplicate. Sample values were 
interpolated from a standard curve generated from known quantities of 
inorganic phosphate (Fig2.2). 
 
Figure 2.2 Exemplar phosphate assay standard curve  
Following phosphate assay, a standard curve was generated using known 
concentrations of inorganic phosphate, samples were the interpolated using the 
straight line equation y=mx+c. 
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2.4 Protein assay  
A protein assay (DC protein assay, BIO-RAD, Hemel Hempstead, UK) was 
used to quantify lysate protein (2.2) and carried out according to manufacturer’s 
instructions, where samples were ran in triplicate on the Wallac victor3 1420 
plate reader at 690nm. Sample values were interpolated from a standard curve 
generated from known quantities of bovine serum albumin (BSA) (Fig2.3). 
 
Figure 2.3 Exemplar protein assay standard curve 
Following protein assay, a standard curve was generated using known concentrations 
of BSA, samples were the interpolated using the straight line equation y=mx+c. 
 
2.5 Rat tissue collection 
Female Sprague-Dawley rats (Charles-river, UK) weighing between 175-200 g 
were used at the University of Birmingham in accordance with the Animals and 
Scientific Procedures Act 1986, licensed by the UK Home Office and approved 
by the University of Birmingham Ethics Committee. Rats were housed in cages 
  
Page | 62 
 
under a 12 hour light/dark cycle with ad libitum access to food and water. Rats 
were sacrificed via rising CO2 concentration and lateral and 4
th ventricle choroid 
plexus, whole adrenal gland and whole ovary were dissected out and snap 
frozen in liquid nitrogen and transferred to a -80°C prior to RNA extraction.  
2.6 Human choroid plexus 
Human choroid plexus was obtained from the Parkinson Brain bank at Imperial 
Collage London, covered under ethics granted by the Wales research ethical 
committee (REC) (08/MRE09/31+5). Choroid plexus was retrieved within 24 
hours post-mortem, where immediately after dissection tissue was placed into 
RNA later (Thermofisher). Upon arrival to University of Birmingham labs tissue 
in RNA later was placed into a -80°C prior to experimentation.  
2.7 Ribonucleic acid extraction and analysis 
2.7.1 Principle 
Messenger ribose nucleic acid (mRNA) abundance and identity partially 
determines the protein quantity within a cell and determines cellular function 
and phenotype. Consequently assessing mRNA transcript abundance provides 
an assessment of the potential cellular phenotype.  
2.7.2 Gene Elute RNA extraction kit 
Total cell and tissue RNA was extracted in a nuclease free environment.  For 
cultured cells and non-adipose tissue the Gene Elute kit was used according to 
manufacturer’s instructions. Cultured cells were lysed in culture plates using 
lysis reagent supplemented with β-mercaptoethanol prior to going through the 
kits spin columns, whereas tissue was mechanically homogenised utilising a 
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rotational homogeniser in lysis reagent. Lysates were passed though spin 
column washes prior to elution utilising nuclease free H2O. 
2.7.3 Adipose tissue RNA extraction 
The lipid rich nature of adipose tissue necessitates the use of the RNeasy Plus 
Universal kit (Qiagen, Manchester, UK) which separates lipids from polar 
molecules such as RNA. Adipose tissue was mechanically homogenised 
utilising a rotational homogeniser in QIAzol lysis reagent, incubated with a 
genomic DNA eliminator and incubated with molecular grade chloroform prior to 
column washes and elution in nuclease free H2O. 
2.7.4 RNA quantification 
RNA purity and quantity was determined via a Nanodrop ND-1000 
Spectrophotometer (Thermofisher), where 260/230 and 260/280 ratios provided 
information about sample purity and DNA contamination respectively. A ratio of 
around 2 for each represents good purity and DNA free extraction. RNA was 
stored at -80°C. 
2.7.5 RNA reverse transcription 
RNA is an inherently unstable molecule due to being single stranded, as such 
converting to the more stable double stranded DNA provides longevity for the 
transcript. RNA is converted to copy DNA (cDNA) utilising the high-capacity 
cDNA Reverse Transcription Kit (Thermofisher) in a 20μl reaction (See table 2.1 
for components of reaction). A Gene Amp PCR system 2700 (Thermofisher) 
thermal cycler was ran in the following settings, 25°C (10mins), 37°C (120 
mins), 85°C (5 mins) and at 4°C to cool the samples until storage at -20°C. 
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Component Volume (µl) 
10X RT buffer 2.0 
25X dNTP Mix (100mM) 0.8 




RNA diluted in nuclease 
free H2O 
14.2 
Table 2.1 Components of High capacity cDNA kit 
Quantity of each reagent required for one cDNA generation reaction. 
 
2.7.6 Quantitative real-time PCR  
2.7.6.1 Quantitative real-time PCR principle 
Quantitative real time PCR (RT-qPCR) is a sensitive technique that determines 
the quantity of a transcript through the use of fluorescent primers. These 
primers are specific to a particular nucleotide sequence, with primers specific 
for the 3’-prime and 5’-prime ends of the sequence of interest; as such they will 
bind to the cDNA molecule of interest and facilitate its amplification. Taqman 
gene expression assays also contain a probe that binds to a complementary 
portion of DNA between the 3’-prime and 5’-prime primers. The 5-prime end of 
the probe contains a fluorophore that is liberated when DNA-polymerase 
reaches it, this removes the dye from the proximity of a quencher on the 3-
prime end of the probe allowing it to fluoresce and be quantified. Amplification 
runs in heat cycles, each cycle doubles the quantity of the cDNA, as such there 
is an exponential increase in cDNA and therefore fluorescence as cycles 
  
Page | 65 
 
progress. Consequently, 100 times difference in cDNA quantity is represented 
by a 6.64 difference in cycles. Amplification is measured in logarithmic portion 
of the graph, where it provides a cycle threshold value (Ct) (Fig2.4). This Ct 
value is the basis of quantification measurements. 
 
Figure 2.4 Exemplar RT-qPCR plot 
Y-axis represents relative fluorescence compared to baseline. X-axis represents cycle. 
The horizontal lines represent threshold for amplified genes, whereby the threshold fall 
into the linier part of the graph. Coloured lines represent an individual gene’s 
amplification.  
 
2.7.6.2 Quantitative real-time PCR protocol 
RT-qPCR was carried out with single-plex, 10ng cDNA, 10μl assays using an 
ABI 7500 PCR machine (Thermofisher). Assay mix comprises of 0.5 μl of 
primer/probe set, 5 μl of master mix (Thermofisher) and the remainder 
comprised of cDNA diluted in nuclease free H2O. Genes of interest were ran in 
triplicate. Primer probe sets utilised the reporter fluorescein (FAM). VIC is the 
reporter for specific ribosomal subunit 18s, utilised as a reference gene. For a 
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full list of primer probe sets see appendix 2. The thermocycler conditions were 
95°C for 10 minutes followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 
minute.  
Expression was expressed relative to the housekeeper genes 18s or GAPDH 
as ΔCt, where ΔCt = [Ct gene of interest – Ct reference gene]. Arbitrary units 
(AU) were derived as follows:  1000*(2^-ΔCt). Fold change in expression was 
derived as follows 2^-((ΔCt of subject) - (mean ΔCt of control)). 
2.8 Immunocytochemistry 
2.8.1 Principle 
Immunocytochemistry is a semi-quantitative technique that determines the 
presence and localisation of a target protein (epitope) in a cell utilising 
antibodies specific to the epitope (primary antibody). This primary antibody is 
detected by a secondary antibody that is conjugated to a fluorophore that emits 
a known spectrum of light under stimulation of a specific wavelength. 
2.8.2 Method  
Z310 cells were seeded onto 8-well culture slides (VWR, Lutterworth, UK) 
primed with poly-d-lysine (0.1 mg/ml in sterile H20) and coated with laminin (20 
μg/ml) (Thermofisher) for 1 hour each prior to seeding of cells. Following two 
days of culture, Z310 cells were fixed in fixative (2% PFA, 2 % glucose in PBS) 
for 20 minutes at room temperature before a single 3 minute wash in PBS. Z310 
cells were permiabilised with methanol for 6 minutes before washing in PBS. 
Z310 cells were then blocked with blocking solution (10% normal goat serum 
(Vector Laboratories, Peterborough, UK), 2 % BSA in PBS) for 30 minutes and 
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incubated overnight at 4oC with the primary antibody (diluted in 2% BSA in 
PBS) in a humidified chamber. Subsequently, the cells were washed with PBS 
before the addition of the secondary antibody (2% BSA, 1.5% normal goat 
serum in PBS) for 1 hour in the dark. Finally, Z310 cells were washed in PBS 
and a coverslip mounted using mounting media containing 4’,6-diamidino-2-
phenylindole (DAPI) to counterstain nuclei (Vector Laboratories). Slides were 
stored in the dark prior to microscopy. No primary antibody staining was used 
as control. 
2.8.3 Microscopy  
Z310 cell images were taken on a Zeiss Axioplan 2 imaging epifluorescent 
microscope (Carl Zeiss, Jena, Germany) and a AxioCam Hrc (Carl Zeiss) were 
used to view and capture images. 
2.9 Serum, plasma and CSF 
Plasma, serum and CSF were collected from IIH patients in both the IIH drug 
trial (IIH:DT) (NCT02017444) and IIH weight trial (IIH:WT) (NCT02124486) as 
well as controls in IIH:WT according to the published protocols, where CSF 
contained a DPP4 inhibitor (Millipore) and plasma contained both a protease 
inhibitor cocktail and a DPP4 inhibitor (Markey et al., 2017; Ottridge et al., 
2017). Material from IIH:DT was covered under ethics granted by the York-
Humber REC (13/YH/0366) and material from IIH:WT was covered under ethics 
granted by the Black Country REC (14/WM/0011).  
Procedures and sample processing were carried out by staff at the Birmingham 
Wellcome trust clinical research facility (CRF) (IIH:WT and IIH:DT), Department 
of Eye Research Manchester Royal Eye Hospital (IIH:WT), Diabetes and 
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Vascular Research Royal Devon and Exeter Hospital (IIH:WT) and the Walton 
Centre for Neurology and Neurosurgery Liverpool (IIH:DT). 
CSF was collected via a lumbar puncture (LP), were CSF was placed 
immediately on ice and centrifuged to pellet any cellular material. Acellular CSF 
was aliquoted and stored at -80°C. Sites of LPs received local anaesthetic. 
Serum was derived from clotted venous blood that was centrifuged prior to 
storage at -80°C. Plasma was derived from unclotted venous blood in EDTA 
tubes, centrifuged prior to aliqoting and storage at -80°C. 
2.10 Adipose tissue acquisition 
Adipose tissue was derived from two clinical trials, IIH:DT and IIH:WT. Adipose 
tissue collection from the IIH:DT were covered under ethical approval 
(13/YH/0366) and was biopsied, following written informed consent, by clinical 
staff at the CRF. Local anaesthetic applied to biopsy area and subcutaneous 
adipose tissue biopsied, where adipose tissue was placed directly into RNA 
later (Thermofisher) and placed into a -80°C freezer. Paired omental and 
subcutaneous adipose tissue was acquired as part of the IIH:WT (14/WM/0011) 
at Heartlands hospital (Heart of England NHS Foundation Trust Birmingham). 
Control patients, undergoing elective bariatric surgery, provided written 
informed consent and tissue was biopsied by the operating surgeon. Adipose 
tissue from IIH patients was taken from patients who were randomised to the 
surgical arm of the IIH:WT. Patients provided written informed consent for the 
tissue biopsies. Subcutaneous tissue was removed from an area containing 
local anaesthetic and adipose tissue was biopsied by the lead surgeon. Adipose 
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was either immediately placed into RNA later (Thermofisher), placed into phenol 
free DMEM/F12 containing no serum or antibiotics, or placed into 4% 




Figure 2.5 Adipose tissue analysis schematic 
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2.11 Histology 
2.11.1 Tissue processing 
Human subcutaneous adipose and omental adipose were fixed in 4% PFA prior 
to processing. Tissue was dehydrated in serial increasing concentrations of 
industrial methylated spirit for 1 hour at 40%, 70% and twice at 100%. Tissue 
was subsequently cleared in xylene three times for 1 hour each. Tissue then 
incubated in paraffin wax twice for 1 hour each prior to an overnight incubation 
in wax. Tissue was then embedded in paraffin wax.  
2.11.2 Haematoxylin and eosin staining 
Embedded tissue was cut into 5 μm sections. Sections were initially dewaxed 
and rehydrated (immersion in xylene, 3 x 5 minutes, and then in 100% ethanol, 
2 x 5 minutes). Staining was then carried out using Meyer’s haematoxylin for 
approximately 30 seconds. Excess haematoxylin was removed by washing in 
running tap water for 5 minutes and then blued, through immersion in 1% acid 
alcohol for 30 seconds. Counter straining was carried out with eosin and again 
irrigated for 5 minutes in tap water. Sections were dehydrated in 100% ethanol 
(2 x 5 minutes) and cleared in xylene (2 x 5 minutes) prior to mounting with 
VectaMount Permanent Mounting Medium (Vector). 
2.11.3 Histomorphometric analysis  
Images were acquired using Leica DM ILM inverted microscope (Leica 
Microsystems UK Ltd, Milton Keynes, UK) though a Leica DFC290 camera 
(Leica) utilising the Leica application suite (V2.8.1, Leica). The Image J 
(National Institutes of Health, Bethesda, MD) plugin Adiposoft (Galarraga et al., 
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2012), a semi-automated segmentation software, was utilised to segment, count 
and determine the area of adipocytes. Samples were manually segmented 
where adipocytes were not sampled, furthermore erroneous segmentations 
were removed. Where tissue quantity allowed, 3 images from three slides per 
patient were analysed. To determine the frequency of adipocyte areas, 
adipocyte areas for each patient were placed into GraphPad prism (V 7.1, 
GraphPad software, La Jolla, CA) and frequency distribution function was used, 
where the mean frequency for each area bin was calculated. 
2.12 RNA sequencing 
RNA was extracted commercially by AROS (Aarhus, Denmark), Library 
preparation and RNA sequencing was carried out commercially by Eurofins in 
Germany. Bioinformatics were carried out in collaboration with Mark Walsh and 
Daniel Hebenstreit at the University of Warwick and Ildem Akerman at the 
University of Birmingham. 
2.12.1 RNA sequencing method 
RNA was extracted using the RNeasy Lipid tissue mini kit by staff at Aros 
(Copenhagen, Denmark). RNA quality and quantity was analysed using a 
fragment analyser, where there was no difference in RNA quality (7.5±0.82 vs. 
7.7±0.50, P=0.6) between IIH and control patients, indicating acceptable quality 
RNA.  cDNA libraries were prepared using Illumina’s Stranded mRNA kit 
(Illumina Inc. San Diego, CA) and sequencing was ran on the Illumina HiSeq 
2500 platform (Illumina Inc), with 2X100pb paired end reads across two flow 
cells. RNA sequencing data presented as fragments per kilobase million 
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(FPKM), where this is derived as follows, number of mapped gene fragments 
normalised to both the length of the gene and depth of sequencing achieved in 
the sample.  
2.12.2 Bioinformatic analysis 
Quality control on the RNA sequencing was performed with FastQC v0.11.4. 
Read and adapter trimming was carried out using TrimGalore! v0.4.4 with 
Cutadept v1.13 with default settings (Martin, 2011). RNA-seq reads were 
mapped to the human genome (hg19, UCSC annotation) utilising STAR 
software v2.5.3a with default parameters (Dobin et al., 2013). Counts per gene 
were calculated using custom scripts acting in a HTSeqcount compatible mode 
with the following parameters: --format=bam --minaqual=10 --stranded=reverse 
–mode=union (Anders et al., 2015). Differentially expressed genes were 
identified using the DESeq2 (v1.14.1) from Bioconductor release 3.3 (Love et 
al., 2014). Differentially expressed genes were called at a false discovery rate of 
5%. Normalised FPKM values for each gene were calculated using DESeq2 
and GenomicFeatures v1.26.4 package (Lawrence et al., 2013). GSEA analysis 
was utilised to interrogate specific gene sets in the RNA-seq expression data 
(Mootha et al., 2003; Subramanian et al., 2005). GSEA calculates an 
Enrichment Score (ES) through scanning a ranked-ordered list of genes 
(according to significance of differential expression (-log10 p-value x the sign of 
fold enrichment), increasing a running-sum statistic when a gene is in the gene 
set and decreasing it when it is not. The top of this list (red) contains genes 
upregulated in IIH patients while the bottom of the list (blue) represents 
downregulated genes in IIH. Each time a gene from the gene set is found along 
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the list, a vertical black bar is plotted (hit). If the ‘hits’ accumulate at the bottom 
of the list, then this gene set is enriched in upregulated or downregulated 
genes, dependent where it is on the list. If the genes are distributed 
homogenously across the rank ordered list of genes, then that gene set is not 
enriched in any of the gene expression profiles (IIH vs Control subjects).  
2.13 Adipose tissue incubation 
Incubations were carried out in an aseptic manner in a microbiological safety 
cabinet. Tissue was weighed as wet weights prior to incubation. Paired omental 
and subcutaneous adipose tissue had large blood vessels dissected out prior to 
incubation of ~100 mg chunks in phenol free DMEM/F12 (Thermofisher) with no 
serum antibiotics in glass tubes (VWR) covered in cling film for 24 hours in a 
humidified incubator at 5% CO2 at 37
0C without agitation. Media and adipose 
tissue explants were removed and immediately placed in a -80°C freezer. 
Tissue incubation time was optimised through assessing lactate concentrations, 
via NMR (2.14), in explants incubated for either 24 or 48 hours. Although all 
explants generated lactate in the millimolar range the 48 hour incubation 
generated significantly more lactate in both the OM (24h; 2.3±2.0 vs 45h; 
9.7±1.7 ΔmM; P<0.0001) and SC adipose (1.7±0.8 vs 8.0±2.4 ΔmM; P<0.0001) 
indicating major hypoxia and likely cell death at the 48 hour time point. 
Consequently the 24 hour time point was selected (Fig 2.6). 
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Figure 2.6 Adipose tissue time incubation optimisation 
Adipose tissue from control subcutaneous and omental adipose underwent a time 
course experiment where NMR was ran on the conditioned media and lactate was 
assessed. N=5 for each group, data presented as mean±SD, ***=P<0.0001.  
2.14 Nuclear Magnetic resonance spectroscopy  
Thanks to Christian Ludwig who ran the samples on the NMR spectrometer at 
the Henry Wellcome NMR building at University of Birmingham.  
2.14.1 NMR Principle 
Atomic nuclei have a spin, this confers a magnetic property on the nucleus, 
similar to that of a bar magnet. This spin is determined the local nuclear 
environment of the nucleus. This can be manipulated by a magnet to pull all the 
nuclei in the same polarity. The removal of the magnetic force allows atomic 
nuclei to return to their original polarity. This return to polarity causes the nuclei 
to emit electromagnetic radiation which can be detected by a receiver. The 
pattern of the electromagnetic radiation relates to the orientation of molecules 
around the molecule of interest, in the case of this work, it is hydrogen atoms. 
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As such the local nuclear environment of a hydrogen atom will provide a unique 
wave form thus unique spectral footprint (Fig 2.7) 
2.14.2 Sample preparation 
Adipose tissue conditioned media from section 2.13 were thawed and placed 
into NMR buffer with a final concentration of 100 mM sodium phosphate buffer 
containing 500 μM 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS), 2 mM 
imidazole and 10% deuterium (D2O).  
Corresponding adipose tissue explants were homogenised in ice cold HPLC 
grade methanol (500 μl) prior to the addition of HPLC water (500 μl) and 10 
minute sonication followed by 10 minute incubation on ice prior to the addition 
of ice cold HPLC grade chloroform (500 μl) and 10 minute agitation at 4°C. 
Samples were then centrifuged for 15 minutes at 1300 g. The procedure allows 
separation of lipids, protein and polar metabolites into distinct layers. The top 
clear layer containing polar metabolites was aliquoted into new tubes prior to 
evaporation of fluid under a vacuum. Dried samples reconstituted in 60 μl of 100 
mM sodium phosphate buffer containing 100% D2O and 500 µM DSS, where 
samples were sonicated for 10 minutes prior to a brief centrifugation. All 
samples were transferred into 1.7 mm Bruker Sample Jet NMR tubes 
(Cortecnet, Voisins-Le-Bretonneux , France) via an automatic Gilson. 
  




Figure 2.7 NMR peaks and corresponding hydrogen atoms 
Exemplar NMR spectra from conditioned media. Blue dots and adjacent numbers 
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2.14.3 NMR Spectroscopy 
Samples were ran on a Bruker 600 MHz Bruker Avance III spectrometer (Bruker 
Biospin) with a TCl 1.7 mm z-PGF cryogenic probe set at 300K. 1D 1H-NMR 
spectra were obtained, where spectral width was set to 7,812.5. 
2.14.4 Data analysis 
1D-1H-NMR spectra were processed using MetaboLab software (Ludwig and 
Gunther, 2011). All 1D data sets were zero-filled to 131,072 data points prior to 
Fourier Transformation. The chemical shift was calibrated by referencing the 
DSS signal to 0 p.p.m. 1D-spectra were manually phase corrected. Batch 
baseline correction was achieved using a spline function. 1D 1H-NMR spectra 
were exported into Bruker format for metabolite identification and concentration 
determination using Chenomx 7.0 (Chenomx INC, Edmonton, Canada). All 
values obtained were normalised to the mass of the appropriate adipose tissue 




Luminex is an immunoassay based technology that allows the identification of 
multiple analytes, multiplexing, through the use of antibody covered beads. A 
set of beads is coated with antibodies specific to one peptide; furthermore this 
set of beads has a specific colour allowing its identification. Secondary 
antibodies specific for the analyte of interest conjugated to phycoerythrin, a 
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fluorophore, allows for quantification of the analyte. An initial laser identifies the 
bead, thus antibody species and another allows quantification of the analyte. 
2.15.2 Method 
Conditioned media were ran using custom ProcartaPlex luminex kits 
(Thermofisher) used neat and manufacturer’s instructions were followed with 
regards to the protocol. Samples were ran on the Luminex 200 system 
(Luminex Corp.‘s-Hertogenbosch, Netherlands) according to manufacturer’s 
instructions using supplied software. 
2.15.3 Analysis 
Operating software automatically constructs the standard curve and interpolates 
the concentrations of analytes. Data was then exported into Microsoft Excel 
spreadsheets to allow for further analysis. Concentrations were normalised to 
the mass of tissue. Assays ran can be seen in the table 2.2 






Interleukin-8 IL-8 27 9850-2.4 
Leptin LEP 45 49200-12.01 
Monocyte chemotactic 
protein 1 




Interleukin-1β IL-1β 18 825-0.2 
Interleukin 10 IL-10 28 925-0.23 
Interleukin 6 IL-6 25 3780-0.92 
Tumour necrosis factor- 
α 
TNF-α 45 2950-0.72 
Table 2.2  Analytes for Luminex assay 
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2.16 Enzyme-linked immunosorbent assay 
2.16.1 Principle  
Enzyme-linked immunosorbent assay (ELISA) is an immuno-assay that allows 
the quantification of a peptide in a fluid through a chromogenic change. 
Sandwich ELISAs utilise several antibodies to detect and quantify a peptide of 
interest (see figure 2.8). In brief a capture antibody binds the peptide of interest, 
immobilising it. A detection antibody, conjugated to biotin, then binds the 
peptide. The addition of streptavidin-HRP provides the enzyme that develops 
the chromogenic change following the addition of a chromogenic substrate.  
 
Figure 2.8 Sandwich ELISA Principle 
Sandwich ELISAs utilise a capture antibody (1) that coats the well to capture and 
immobilise the antigen (AG). The AG is subsequently bound by a detection antibody (2) 
that has a conjugated biotin moiety. The addition of streptavidin (S) conjugated to the 
horseradish peroxidase (HRP) (3) allows for colour change flowing the addition of a 
chromogen (4). In this situation, the higher the optical density, the higher the 
concentration of the peptide of interest. 
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2.16.2 Protocol 
Human leptin DuoSet ELISA (DY-398,Bio-techne, Abingdon, UK) was utilised, 
used according to manufacturer’s instructions using recommended ancillary kit 
(Bio-techne, DY008). Dilution factor was optimised, where adipose conditioned 
media was diluted 1:50, serum was diluted 1:100, plasma was diluted 1:200 and 
CSF was diluted 1:5. All samples were diluted in supplied regent diluent. A 
standard curve was generated using known concentrations of recombinant 
human leptin, providing a detection range of 2000-31.3 pg/ml. OD was read at 
450 nm, data were exported in Excel spreadsheet (Microsoft, WA) format and 
the standard curve was generated from the log10 OD in Graph-pad Prism using 
the sigmoidal 5PL function, prior to interpolation of samples (Fig2.9).  
 
Figure 2.9 Exemplar leptin ELISA standard curve  
Following an ELISA, a standard curve was generated using known log10 transformed 
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2.17 11β-HSD1 activity assay 
Subcutaneous adipose tissue was cut into roughly 100 mg explants and were 
placed into glass tubes (VWR) in phenol free DMEM/F12 with a 
supraphysiological concentration of cortisone (200 nM) for 24 hours; samples 
were ran in triplicate. A glass tube with phenol free DMEM/F12 and 200 nM of 
cortisone without adipose tissue served as a no conversion control. The 
quantity of cortisol was measured via liquid chromatography-mass spectrometry 
(LCMS) (section 2.17.1). Values were normalised to the mass of the adipose 
tissue explants. Following the 24 hour experiment, samples were aliquoted and 
stored at -20°C prior LCMS. 
2.17.1 LCMS 
Tissue culture media (1ml) had the lipid portion, including steroid hormones, 
extracted via a liquid-liquid extraction with 3 ml of tert-butyl-methyl-ether 
(MTBE) in sylinised glass tubes. 20 µl of internal standard was added to 
facilitate quantitative analysis. Samples were vortexed, and frozen at -20°C for 
a minimum of 1 hour. The subsequent upper clear layer was transferred to a 96-
well plate using glass Pasteur pipettes. Repeated cycles of evaporation at 55°C 
under nitrogen and further liquid transfer were carried out until samples had 
evaporated completely. Following evaporation, samples were reconstituted with 
125 µl of methanol:H2O (50:50) and frozen at -20°C until LCMS analysis. LCMS 
was ran at the University of Birmingham Steroid Metabolome Analysis Core.  
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2.18 Live cell Imaging 
2.18.1 Plating and infection of Z310 cells 
Z310 cells were plated on ethanol cleaned 25 mm diameter glass coverslips 
(VWR, Leighton Buzzard, UK) primed with poly-d-lysine (0.1 mg/ml in sterile 
H20) and sequentially coated with laminin (20 μg/ml in PBS) for 1 hour each. 
Z310 cells were then seeded and allowed to adhere for 30 minutes prior to the 
addition of culture media and an adenovirus containing the biosensor Perceval 
provided as a kind gift from Professor David Hodson (Berg et al., 2009; Hodson 
et al., 2014). Viral titre was sufficient to allow for experimentation 48h after 
infection.   
2.18.2 Imaging protocol 
In brief, ATP/ADP ratio was imaged using a Crest X-Light spinning disk head 
(Crestoptics S.p.A, Rome, Italy) coupled to a Nikon Ti-E automated base (Nikon 
Instruments Europe BV, Amsterdam, Netherlands) and 10x/0.4 NA objective. 
Excitation was delivered by a Lumencor Spectra X Light Engine (Lumencor, 
Beaverton, OR) at 458–482 nm (0.2 Hz), emitted signals were detected with a 
Photometrics Evolve Delta 512 EMCCD (Photometrics, Tucson, AZ) at 500–550 
nm. The ATP/ADP traces were normalised as F/Fmin, where F is the 
fluorescence at a given time point, Fmin is the minimum measured fluorescence. 
A CO2 saturated HEPES-bicarbonate buffer was used, containing in mM: 120 
NaCl, 4.8 KCl, 24 NaHCO3, 0.5 Na2HPO4, 5 HEPES, 2.5 CaCl2, 1.2 MgCl2, 25 
glucose. Cells were imaged to gain a stable 15 minute baseline prior to 
treatment with ouabain (1 mM) to resolve Na+/K+ ATPase activity. 
Concentrations for test reagents can be found in relevant chapters.  
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2.18.3 Analysis of live cell data 
Images were acquired with MetaMorph (Molecular devices, CA). An image 
sequence was initially analysed on ImageJ, where individual random cells are 
selected as a region of interest, motile cells are excluded from the analysis. 
Following this, the multimeasure function was selected with the mean grey 
function to determine the intensity of individual cells at each frame. Subsequent 
to this the F/Fmin is determined for each frame, where F is the intensity for the 
cell in that particular frame and Fmin is the lowest fluorescence intensity in the 
baseline period. This normalises the intensity change to baseline, taking into 
account any quantitative difference in ATP/ADP ratio between cells or 
differences in Perceval protein expression. Ouabain administration was utilised 
to initiate a change ATP/ADP ratio. This change in ratio or ‘Δ’ is the maximum 
value F/Fmin following ouabain administration minus the maximum F/Fmin in the 
pre ouabain administration (baseline). Area under the curve is generated for 
each cell using the area under the curve function in GraphPad prism. Assessor 
was blinded to the treatment of the cells during evaluation of cell fluorescence 
intensity. 
2.19 In vivo intracranial pressure experiments 
2.19.1 Experimental animals 
The study utilised female Sprague-Dawley rats (Taconic, Ejby, Denmark) 
weighing 150-250 g. The rats were housed in cages under an inverted 12 hour 
light/dark cycle with ad libitum access to food and water. All experimental 
procedures were approved by the Danish Animal Experiments Inspectorate 
  
Page | 84 
 
(license number 2014-15-0201-00256). After treatments and surgical 
procedures, the rats were monitored daily for any adverse effects. 
2.19.2 Epidural intracranial pressure probe implantation 
Surgical procedure was carried out as previously described (Uldall et al., 2014). 
In brief rats were anesthetised with a subcutaneous injection (1.25 mg/kg 
midazolam, fluanisone 2.5 mg/kg and 0.079 mg/kg fentanyl citrate made in 
sterile saline) and placed in a stereotaxic frame (David Kopf Instruments, 
Tujunga, CA). Body temperature was maintained via a thermostatic heat pad, 
controlled by a rectal probe. A lidocaine and adrenaline solution was injected 
subcutaneously over the skull to prevent haemorrhage and provide local 
analgesia. Subsequently a 2 cm midline incision was made, tissue retracted 
exposing bregma and lambda. Fascia covering the skull was scraped away, 
including sutural fascia.  A transcranial hole to fit an epidural probe was burred 
utilising a dental drill, keeping the dura intact. Three smaller holes for anchoring 
were made and screws inserted into the holes. Epidural probe (PlasticsOne) fit 
was tested, if the probe balanced on the dura and pulsed, fit was good. Dental 
cement (Clearfil SA Cement, RH Dental, Gentofte, Denmark) was used to affix 
the probe to the skull using the three small screws to anchor the cement (Fig 
2.10a). Intracranial pressure (ICP) probe and transducer (DTX-Plus, Argon 
Medical Devices, Frisco, TX) were then connected via a polyethylene tube filled 
with sterile water and signal tested (Fig 2.10b). Where a good ICP trace is 
observed, the breathing pattern of the animal is apparent on the trace, a jugular 
vein compression confirms correct monitoring of ICP (Fig 2.10c). Skin was then 
sutured together and the wound covered in petroleum jelly. Rats received post-
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operative antibiotics and analgesia. ICP probes were covered with a bite proof 
cap (PlasticsOne). ICP was recorded and visualised using Perisoft v2.5.5 
(Perimed AB, Jarfalla, Sweden). 
 
Figure 2.10 ICP surgery 
Details of surgical procedure and experimental setup. A) Photographs of craniotomy 
with the insertion of anchoring screws, placement of ICP probe and application of 
dental cement. B) A rat attached to the fluid telemetric system. C) Schematic of 
experimental setup with a Perimed ICP trace detailing features of a resting ICP 
waveform.  
 
 2.19.3 Drugs 
Acetazolamide (A6011, Sigma-Aldrich), furosemide (F4381, Sigma-Aldrich) 
powders were reconstituted in NaOH and then the pH lowered to 8.7 and 7.7 
respectively. Furosemide was then diluted to working concentration in 0.9% 
saline. For acetazolamide, the osmolarity was equivalent to 2% NaCl for the 
clinical dose and high dose was equivalent to 4% NaCl. 
Acetazolamide doses were 103.3 mg/kg (clinical) and 413.4 mg/kg (high) and 
Furosemide was used at 4.1 mg/kg (clinical) and 24.8 mg/kg (high), where 
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clinical dose represents a single human dose and high dose represents 1 day 
total dose. Dosage was work out via the following FDA derived equation [Rat 
drug] (mg/kg) = 6.2 X [human] (mg/kg based on 60kg human)(FDA, 2005). See 








Rat high dose 
Acetazolamide 1g 4g 103.3 mg/kg 413.4 mg/kg 
Furosemide 40mg 240mg 4.1mg/kg 24.8 mg/kg 
 
Table 2.3 Drug dosage equivalences 
Drug dose equivalences based on assumed human mass of 60kg. Human dose based 
on the doses in the IIH:TT (Wall et al., 2014). 
 
2.19.4 ICP monitoring and drug administration 
Rats were sedated with 2.5 mg/kg midazolam (subcutaneous injection) and 
placed in an infusion cage (Instech Laboratories, Plymouth meeting, PA), which 
had a levered arm connected to the tube to provide unhindered movement. A 
stable baseline ICP reading was recorded for around 30 minutes, prior to a 
subcutaneous injection of the drug. ICP was recorded for a further 120 minutes 
after which the rat was returned to its normal cage. Animals received treatment 
in a randomised crossover study, where drugs were administered 3 days apart 
allowing for total elimination of the drug from circulation. 
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2.19.5 Power calculation 
Power calculation was carried out based on a previous study (Uldall et al., 
2017), where the minimum effect size was assessed. Where saline reduced ICP 
to 95 %, SD 10, power 0.8, alpha 0.05 for a 18% reduction in pressure yields 
N=5 rats per experimental group, minimising the use of animals. 
2.19.6 Analysis of ICP 
ICP was analysed using the Perisoft software. All ICP traces had the on the day 
atmospheric pressure subtracted to zero the pressure reading. Baseline ICP 
was determined through averaging the ICP 30 minutes prior to the injection of 
solution being investigated. After injection ICP was measured every 15 minutes 
whereby the average ICP 5 minutes prior to the 15 minute mark is averaged, 
this was repeated every 15 minutes for 120 minutes. 
2.19 Statistics 
The statistics package Graph-pad Prism (V7.1) was used to carry out statistical 
analysis and graph data. Normality of data was assessed using a Shapiro-Wilk 
normality test, where data was N<7, data was assumed to be normally 
distributed. Data were reported as mean ± standard deviation (SD) unless 
otherwise stated. Data variance assessed via F-test of equality variances. A P-
value of 0.05 or less was considered significant. Inter-assay variability was 
identified by calculating the coefficient of variation (CV) via the following 
equation %CV = (standard deviation (SD) of plate means/mean of plate means) 
X 100. Intra-assay variability was calculated via the following equation %CV= 
(SD of sample/ mean of sample) X 100.  
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Chapter 3 The Adipose Phenotype 
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3.1 Introduction  
Idiopathic Intracranial Hypertension (IIH) is a condition that primarily affects 
obese women of reproductive age, where weight loss has been demonstrated 
to ameliorate the symptoms of IIH (Sinclair et al., 2010a). This suggests that IIH 
adipose tissue, which will be dysfunctional by definition due to concomitant 
obesity, may be functionally different from adipose tissue from the majority of 
obese women, who do not have IIH (Attie and Scherer, 2009; Sinclair et al., 
2010a). Consequently it is proposed that adipose tissue in IIH is functionally 
distinct to non IIH obesity, such that mechanisms exist in IIH adipose to 
influence ICP, as suggested by the positive association between central 
adipose mass and ICP in IIH (Hornby et al., 2018a). 
Evidence for adipose dysfunction in IIH comes from the observation that IIH 
patients have raised serum and CSF leptin, where this is presumed to come 
from increased adipose leptin secretion (Ball et al., 2009; Lampl et al., 2002). In 
addition, CSF leptin levels positivity correlate with lumbar puncture opening 
pressure (LP Opp)(Ball et al., 2009). Furthermore, it has been demonstrated in 
two independent IIH cohorts, utilising DEXA scans, that truncal adipose mass 
positivity correlates with LP Opp in IIH patients highlighting the potential for 
adipose tissue to contribute to the raised ICP in IIH (Hornby et al. 2018, Botfield 
et al. in preparation). These studies however, do not identify whether 
subcutaneous (SC) or omental (OM) adipose tissue mass is specifically 
associated with LP Opp and thus remains to be determined.  
The association between both CSF leptin, truncal adipose mass and LP Opp 
suggests that factors associated with SC or OM adipose could directly 
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contribute to IIH disease activity and account for some level of differential 
phenotype. However beyond these associations there has been minimal 
assessment of the adipose phenotype in IIH patients. This chapter details the 
phenotyping of IIH adipose tissue. 
3.1.1 Hypothesis 
Given that weight loss improves IIH symptoms and that central adiposity is 
associated with LP Opp, a measure of IIH disease intensity, it is hypothesised 
that adipose tissue from IIH SC and OM adipose tissue is functionally distinct 
from simple obese adipose tissue, and contributes to disease activity in IIH. 
3.1.2 Aims 
1. Complete a histological survey of IIH adipose tissue 
2. Determine the transcriptome of IIH adipose tissue 
3. Investigate the metabolome in IIH adipose tissue 
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3.2 Methods  
 
3.2.1 Adipose tissue collection 
Adipose tissue from the IIH weight (IIH:WT) and IIH drug (IIH:DT) trials were 
utilised in the current study, collected as described in section 2.10,  under the 
following ethics codes: 13/YH/0366 for IIH:DT and 14/WM/0011 for IIH:WT as 
described in section 2.9. Control patients were selected from elective bariatric 
lists on the NHS at Heartlands hospital. Control patients were free from 
endocrinopathies, not on hormonal treatment, and BMI and age was collected 
as anthropomorphic measures. All patients were fasted overnight prior to 
adipose tissue biopsy. In brief adipose tissue was biopsied following written 
consent and was either placed immediately in RNA later, into phenol free 
DMEM/F12 with no antibiotics, or 4% formaldehyde. Tissue analysis was 
carried out according to figure 2.5, where a mixture of untargeted hypothesis 
generating experiments and targeted hypothesis driven experiments were 
carried out. 
 
3.2.2 Histomorphometric analysis 
Adipose tissue was treated as described in section 2.11. In brief, adipose tissue 
was fixed in 4% formaldehyde prior to dehydration and clearing and being 
embedded in paraffin wax. Embedded tissue was cut in 5 µm sections prior to a 
haematoxylin and eosin (H&E) stain. Sections were then imaged and adipocyte 
area assessed via the Image J plugin Adiposoft. Evaluator was blinded to tissue 
type and patient disease state during analysis.  
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3.2.3 RNA sequencing  
Stranded mRNA was sequenced at 2X100 paired end reads on the Illumina 
HiSeq 2500 platform. Control and IIH RNA had comparable RNA integrity 
numbers quality (7.5±0.82 vs. 7.7±0.50, P=0.6), indicating acceptable quality 
RNA. Bioinformatic analysis was carried out according to section 2.12.2. In 
brief, raw RNA sequencing data had adapter sequences cut, mapped to the 
human genome (hg19, UCSC annotation). Gene counts were calculated and 
differentially expressed genes identified using DESeq2. Gene set enrichment 
analysis was carried out. 
3.2.4 Conditioned media protocol 
Adipose tissue had large blood vessels dissected out and was cut into ~100 mg 
chunks prior to a 24 hour incubation in phenol free DMEM/F12 with no 
antibiotics. Following incubation media was aliquoted and corresponding 
explant were stored at -80°C.  
3.2.5 Metabolomics 
NMR metabolomics was carried out according to section 2.14. In brief, 
conditioned media generated in section 3.2.4 was diluted in 1 in 4 in NMR 
buffer, yielding a final concentration of 100 µM sodium phosphate buffer. 
Corresponding OM and SC adipose explants underwent a 
methanol/water/chloroform extraction prior to evaporation of the polar layer. 
Dried metabolites were then reconstituted in NMR buffer containing 100% D2O 
prior to being ran on a 600 MHz spectrometer. Spectra were phase and 
baseline corrected in MetaboLab prior to metabolite identification and 
quantification in Chenomx (Chenomx INC)(Ludwig and Gunther, 2011). Analyte 
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concentration was normalised to explant mass. Full details for this section can 
be found in section 2.14. 
3.2.6 Luminex  
Conditioned media generated in section 3.2.4 underwent a luminex experiment 
according to section 2.15. Total secreted adipokine was normalised to 
corresponding explant mass. 
3.2.7 ELISA 
Leptin was measured in conditioned media generated in section 3.2.4 using the 
human leptin DuoSet ELISA (DY-398,Bio-techne, Abingdon, UK). ELISA was 
carried out according to manufacturer’s instructions using recommended 
ancillary kit (Bio-techne, DY008). Conditioned media was diluted 1:50 in reagent 
diluent. Samples were ran in duplicate. Total secreted leptin was normalised to 
corresponding explant mass. Intra-assay variability CV 7.28 %, inter-assay 
variability CV 8.2%. 
3.2.8 RT-qPCR 
Adipose tissue had RNA extracted via the RNeasy Plus Universal kit (Qiagen). 
RNA quantity was assessed via Nano drop prior to the generation of cDNA via 
the high capacity cDNA kit (Thermofisher). RT-qPCR was carried out according 
to section 2.7, where genes were run in triplicate for each sample where 
GAPDH was utilised as a housekeeper.  QPCR data expressed as fold change, 
fold change= 2-ΔΔCt. Statistics were conducted on ΔCt values. See appendix 2 
for a list of primer/probe sets. Due to 18s being differentially expressed between 
IIH and control adipose tissue (data not shown), GAPDH was selected as the 
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housekeeper where there is no difference in expression is GAPDH between IIH 
and control OM and SC adipose tissue (Fig 3.1). 
 
Figure 3.1 GAPDH expression comparison 
GAPDH expression assessed via QPCR in control and IIH SC and OM adipose tissue, 
t-tests within each tissue. Data presented as mean±SEM.  
 
3.2.9 11β-HSD1 activity assay  
Adipose explants were prepared according to section 3.2.4 and incubated in 
200 nM cortisone for 24 hours in triplicate. Samples underwent liquid/liquid 
extraction prior to liquid-chromatography/mass-spectrometry, according to 
section 2.17. Cortisol generation was normalised to explant mass. 
3.2.10 Statistics 
GraphPad prism (V7.1) was utilised to graph and carryout statistical analysis on 
data, where data is presented as mean±SD unless otherwise stated. 
Appropriate statistical tests utilised following a Shapiro-Wilk normality test. Inter-
assay variability was calculated via the following equation %CV = (SD of plate 
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means /mean of plate means) X 100. Intra-assay variability was calculated via 
the following equation %CV= (SD of sample/ mean of sample) X 100. The data 
generated in multiplex assays, luminex and NMR, was not subjected to multiple 
comparison correction to prevent type II statistical error, due to the exploratory 
nature of the experiments.   
  
  




3.3.1 Sample matching 
Paired OM and SC adipose tissue were taken from IIH and control patients, 
where group matching and experiments were carried out as per tissue 
availability due to the small quantities of biopsy tissue available. See figure 3.2 
for the experimental matching.    
 
Figure 3.2 Sample matching 
A diagram detailing the matching of experiments in the present chapter. Data 
presented as mean±SD. Unpaired T-tests, (N) in brackets.  
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3.3.2 Histomorphometric analysis 
Changes in adipose histomorphometry are a good indicator for adipose 
dysfunction, therefore histomorphometric analysis was carried out on paired OM 
and SC adipose from IIH patients and controls from age, sex and BMI matched 
control cohort (Fig3.2). 
3.3.2.1 Subcutaneous adipose  
H&E staining of SC adipose tissue shows no change in adipocyte cross-
sectional area of adipocytes between control and IIH (5041±488 Vs (5459±440 
μm2; P=0.5) (Fig3.3c).This was coupled with no changes in the distribution of 
















Figure 3.3 Morphology of IIH subcutaneous adipose tissue 
H&E stain of IIH subcutaneous (SC) adipose tissue compared to age, sex and BMI 
matched controls. (A) Representative micrographs of control adipose tissue and (B) IIH 
SC adipose tissue. (C) Mean adipocyte area (D) Adipocyte area frequency. Data 
presented as mean±SEM.  Where tissue quantity allowed, 3 sections per patient were 
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3.3.2.2 Omental adipose  
In contrast to SC adipose, H&E staining of OM adipose tissue shows that IIH 
OM adipocytes have a smaller cross-sectional area than control adipocytes 
(3273±117.1Vs 4056±342.8 μm2; P=0.03) (Fig3.4c). This reduction in adipocyte 
area is due to an increase in the frequency of cells at 1000 μm2 (8.8±1.7% vs 
2.7±1.15%; P=0.01) and at 2000 μm2 (27.9±2.6% vs 17.2±3.9%; P<0.0001). 



















Figure 3.4 IIH omental adipocytes are smaller than controls 
H&E stain of IIH omental (OM) adipose tissue compared to age, sex and BMI matched 
controls. Representative micrographs of (A) control and (B) IIH OM adipose tissue. (C) 
Mean adipocyte area in omental adipose (D) Adipocyte area frequency in omental 
adipose. Unpaired T-test for C, D Two-way ANOVA with Sidaks multiple comparison 
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3.3.2.3 Adipocyte area correlations 
The association between adipocyte cross-sectional area and BMI was assessed 
in OM and SC adipose. In control patients, OM adipocyte area was correlates 
with BMI (P=0.017, R2=0.74) whereas SC adipocyte area does not correlate 
with BMI (P=0.1, R2=0.43), although the graph is comparatively linear (Fig3.5a). 
(Fig3.5b) Conversely in IIH patients, neither OM adipocyte (P=0.9, R2=0.007) or 
SC adipocyte (P=0.7, R2=0.05) correlate with BMI, with little indication of 
linearity.  
 
Figure 3.5 BMI correlations 
Scatter graphs detailing average SC and OM adipocyte cross-sectional area versus 
BMI in (A) control and (B) IIH patients. Pearson’s correlation for A, Spearman’s 
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3.3.3 IIH adipose transcriptome 
Transcriptomic analysis provides a global, unbiased assessment of mRNA 
transcription in a sample of interest, where differences in mRNA expression can 
be indicative of an altered phenotype. Consequently, to gain further insight into 
the IIH adipose phenotype, it was aimed to characterise the transcriptome of IIH 
adipose tissue, comparing IIH SC adipose tissue to a sex, BMI and age 
matched control cohort (fig3.2). SC adipose was selected for RNA sequencing 
due to the hypothesis that SC adipose in IIH could be specifically contributing to 
the pathology of the IIH, similar to SC adipose in PCOS. I.e. generating excess 
androgens and lipogenesis, contributing to systemic metabolic dysfunction 
(O’Reilly et al., 2017). Data highlights that IIH SC adipose tissue has 693 
upregulated and 400 downregulated University of California Santa Crus (UCSC) 
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Figure 3.6 IIH SC adipose has a distinct transcriptome  
Differential gene expression analysis of SC adipose tissue from control vs IIH patients. 
(A) Volcano plots of differential gene expression between adipose tissue from control 
vs IIH subjects. Fold change (Log2, x-axis) of gene expression is plotted against p-
value for differential gene expression (-Log10, y-axis). Coloured dots represent UCSC 
genes that are either upregulated (in orange) or downregulated (in blue) in IIH patients 
at P<0.05. (B) Volcano plot detailing the top most highly expressed genes based on 
FPKM. (C) Bar plot displaying the number of differentially expressed UCSC genes at 
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3.3.3.1 Differentially expressed genes 
Following identification of gene expression levels, the most differentially 
expressed genes in IIH were evaluated within the same RNA sequencing cohort 
(Fig 3.2). This highlights 31 genes that are highly significantly differentially 
expressed. A description of these genes including expression levels can be 
found in appendix 3. 
 
Figure 3.7 Top differentially expressed genes 
Most differentially expressed genes as determined by DESeq2 RNA sequencing output 
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3.3.3.2 Gene set enrichment analysis 
To identify whether genes associated with specific functions are altered in IIH 
adipose, gene set enrichment analysis (GSEA) was carried out. GSEA 
highlights a depletion of ribosomal protein genes in IIH, with a net enrichment 
score (NES) of -3.059 and false discovery rate (FDR) of <0.00001. Conversely 
an enrichment of genes associated with lipid biosynthesis (NES= 1.263, 
FDR=0.01) was demonstrated. There is also an enrichment/depletion pattern in 
gene sets associated with positive caloric intake in IIH patients, in spite of the 
patients being fasted. Gene lists for these gene sets are in appendix 4. 
  
Figure 3.8 IIH adipose is transcriptomic ally primed for lipid production 
Gene set enrichment analysis of four selected gene sets against differential expression 
data from adipose tissue of control vs IIH patients. NES= Net enrichment score, FDR= 
False Discovery Rate. A black line represents a gene, the colour gradient represents 
genes most expressed (red) to genes most lowly expression (blue) compared to 
controls. N=7 Control, N=13 IIH. 
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3.3.4 IIH adipose metabolism 
Metabolomic analysis provides an assessment of the sum total metabolic 
processes in a tissue, where alterations in the metabolism denote altered 
cellular metabolism. Both tissue and conditioned media from ex vivo explants 
were assessed via NMR, providing an unbiased, semi-selective, quantitative 
assessment of metabolites. Analysis of the NMR spectra allowed profiling of 36 
metabolites in the tissue and 34 metabolites in the media, see appendix 5 for 
table of metabolites in extracted tissue and conditioned media. 
3.3.4.1 Glycolysis and energy metabolism 
RNA sequencing data highlighted that IIH SC adipose tissue had an enrichment 
of genes associated with lipogenesis. Consequently glycolytic metabolites were 
assessed as glycolytic processes contribute to de novo lipogenesis. IIH OM 
adipose has unaltered glucose exchange (-1.74±4.7 vs -0.36±1.2 ΔmM/100 mg; 
P=0.84) (Fig3.10a), intracellular glucose (3.61±1.59 vs 4.10±1.13 mM/100 mg; 
P=0.44) (Fig3.10b) and intracellular lactate (1.598±1.98 vs 0.85±0.33 mM/100 
mg; P=0.48) (Fig3.10d) compared to controls. However IIH OM adipose has 
increased intracellular pyruvate compared to controls (23.63±16.77 vs 
4.58±7.18 mM/100 mg, P=0.0039) (Fig3.10c). Similarly to OM adipose, IIH SC 
adipose has no alteration in glucose exchange (-1.67±2.3 vs -0.62±0.37 
ΔmM/100 mg; P=0.15) (Fig3.10e), intracellular glucose (3.55±1.23 vs 3.66±1.63 
mM/100 mg; P=0.87) (Fig3.10f), intracellular lactate (0.66±0.33 vs 0.61±0.41 
mM/100 mg; P=0.48) (Fig3.10h), and additionally unaltered pyruvate 
(21.33±29.47 vs 9.50±8.71 µM/100mg; P=0.48) (Fig3.10g). 
  





Figure 3.9 Glycolysis in adipose tissue 
Glucose exchange (A,E), intracellular glucose (B,F), pyruvate (C,G) and lactase (D,H) 
as measured by NMR in OM (A,B,C,D) and SC (E,F,G,H) adipose tissue from control 
and IIH patients. Unpaired T-test for B and F, Mann-Whitney U-test for A,C,D,E,G and 
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3.3.4.2 Lipogenesis surrogates 
Metabolites known to contribute to de novo fatty acid synthesis, specifically the 
branch chained amino acids (BCAA) leucine and isoleucine, were assessed in 
the NMR data (Crown et al., 2015; Rosenthal et al., 1974). IIH OM adipose 
displays not difference in leucine (-9.85±78.57 vs 3.51±52.72 ΔµM/100 mg; 
P=0.66) (Fig3.11a) or isoleucine (-29.21±71.78 vs -9.73±41.67 ΔµM/100 mg; 
P=0.49) (Fig3.11b) uptake and not difference in intracellular isoleucine 
(124.4±25.00 vs 130.9±30.32 µM/100 mg; P=0.61) (Fig3.11c) and leucine 
(133.3±48.27 vs 139.8±53.75 µM/100 mg; P=0.78) (Fig3.11d). 
Conversely, IIH SC adipose tissue displays preferential uptake of both leucine  
(-38.02±40.76 vs 22.62±54.25 ΔµM/100 mg; P=0.011) (Fig3.11e) and 
isoleucine (-30.22±25.21 vs 25.31±48.26 ΔµM/100 mg; P=0.002) (Fig3.11f) 
without changes in intracellular isoleucine (133.3±48.27 vs 139.8±53.75 µM/100 
mg: P=0.81) (Fig3.11g) and leucine (133.3±48.27 vs 139.8±53.75 µM/100 mg; 
P=0.78) (Fig3.11h). 
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Fig 3.10 Flux of leucine and isoleucine 
Exchange of leucine (A,E) and isoleucine (B,F) and tissue leucine (D,H) and isoleucine 
(C,G) as measured by NMR in OM (A,B,C,D) and SC (E,F,G,H) adipose from control 
and IIH patients. Unpaired t-test for A-E,G-H and Mann-Whitney U-test for F. Data 
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3.3.4.3 IIH adipose tissue displays increased lipolysis 
To determine the function of lipolysis, a major function of adipocytes, glycerol 
secretion and tissue glycerol was assessed on NMR spectra. IIH OM adipose 
tissue secretes more glycerol compared to controls (128.7±45.7 vs 79.4±33.6 
ΔµM/100 mg; P=0.018) (Fig3.12a), without any alteration in intracellular glycerol 
(274.1±87.4 vs 296.1±38.6 µM/100 mg; P=0.16) (Fig3.12b). Furthermore IIH 
OM adipose has an increased secretion-to-intracellular glycerol ratio (0.50±0.18 
vs 0.27±0.11; P=0.0045) (Fig3.12c). Similarly IIH SC adipose tissue secretes 
more glycerol than controls (157.3±62.6 vs 84.5±37.0; P=0.0053) (Fig3.12d), 
with no alteration in intracellular glycerol (305.7±90.8 vs 339.0±97.9 µM/100 
mg; P=0.44) (Fig3.12e), and an increased secretion-to-intracellular glycerol 
ratio (0.58±0.43 vs 0.27±0.16; P=0.0052) (Fig3.12f). These data indicate IIH 
adipose tissue has increased lipolysis compared to controls. Age and BMI does 
not correlate with any of the parameters assessed here so sensitivity analysis is 
not required (see appendix 6).  
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Figure 3.11 Glycerol secretion from adipose tissue 
Glycerol secretion (A,D), tissue glycerol (B,E) and extracellular/tissue ratio (C,F) in OM 
(A,B,C) and SC (D,E,F) adipose tissue derived from IIH (red) and control (blue) 
patients following a 24 hour incubation, as measured via NMR.  Data presented as 
mean±SD, Mann-Whitney-U tests for C and F, unpaired T-tests A,B,D,E. *=P<0.05, 
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To determine whether the increased lipolysis in IIH adipose tissue is associated 
with altered gene expression, genes associated with lipolysis and lipid storage 
were pulled from RNA sequencing data set, thus assessing expression in SC 
adipose only. There is no change in expression of the genes encoding for the 
lipases adipocyte triglyceride lipase (PNPLA2), hormones sensitive lipase 
(LIPE) and monacylglycerol lipase (MGLL) (Fig3.13a). Furthermore there is no 
difference in the expression of perilipin genes (Fig3.13b). 
 
Fig 3.12 Lipolysis and lipid storage genes 
DESeq2 output of RNA sequencing assessing the expression of (A) lipolysis genes and 
(B) perilipins. P-values based of DESeq2 following multiple comparison correction. 








Page | 113 
 
3.3.5 IIH adipose peptide secretion 
Luminex panels were utilised to determine the secretion of a selection of 
peptide hormones from IIH adipose, where adipokines were selected based on 
adipokines previously assessed in IIH serum and CSF, as previously reviewed 
(Markey et al., 2016b). This experiment was utilised as a screening experiment 
to inform future experimentation. 
3.3.5.1 SC adipose peptide secretion 
In the SC adipose depot, no changes in secreted adipokines was demonstrated 
(Fig3.13). The expression of IL-1β (IL1B), IL-10 (IL10), IL-6 (IL6), TNFα (TNF), 
IL-8 (CXCL8), leptin (LEP) and MCP-1 (CCL2) was pulled from SC adipose 
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Figure 3.13 Secretion of adipokines from IIH SC adipose tissue 
Luminex pannels ran on conditioned meida derived from SC adipose tissue from IIH 
patients and age,sex and BMI matched controls (C), where the secretion of  (A) IL-β1, 
(B) IL-10, (C) TNFα , (D) IL-8, (E) IL-6 (F) Leptin and (G) MCP-1 was assessed. 
Unpaired T-tests. N=5. Data presented as mean±SD.  
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Figure 3.14 Evaluation of SC adipokine expression  
The expression of (A) ILB1,(B) IL10,(C) CXCL8 ,(D) TNF,(E) IL6,(F)  LEP and  (G) 
CCL2 were called from DESeq2 output from SC adipose RNA-seq, controls vs IIH. P-
values based on DESeq2 output following multiple comparison correction Data 
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3.3.5.2 OM adipose peptide secretion 
Investigation of OM adipose depot via luminex demonstrated, in similarity to the 
SC depot, general homology between IIH and control adipose tissue. However, 
monocyte chemoattractant protein 1 (MCP-1) had reduced secretion in IIH 
omental adipose tissue compared to controls (259.5±52.0 Vs 391.2±105.5 
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Figure 3.15 Secretion of adipokines from IIH  OM adipose tissue 
Luminex pannels ran on conditioned meida derived from OM adipose tissue 
incubatedfor 24hours,  from IIH patients and age,sex and BMI matched controls (C), 
where the secretion of (A) IL-β1, (B) IL-10, (C) TNFα , (D) IL-8, (E) IL-6 (F) Leptin and 
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3.3.5.3 Leptin secretion in IIH adipose tissue 
IIH is a disease associated with a presumed circulating leptin excess, compared 
to obese individuals (Ball et al., 2009; Lampl et al., 2002). Being as adipose 
tissue is the predominant producer of leptin, leptin secretion from IIH adipose 
explant was compared to sex and BMI matched controls (Fig3.1) in paired SC 
and OM adipose explants in a hypothesis driven experiment. IIH SC adipose 
secretes more leptin compared to control SC adipose (8309±1593 Vs 2366±431 
pg/ml/100mg; P=0.0039) (Fig3.16a), which is independent of gene expression 
as demonstrated in figure 3.14f. Similarly, IIH OM adipose secretes more leptin 
compared to control OM adipose (2994±824 Vs 571.9±102.2 pg/ml/100mg; 
P=0.016) (Fig3.16b). IIH adipose retains the function of SC adipose secreting 
more leptin compared to omental adipose tissue (Control P=0.0016, IIH 
p=0.0097, Fig3.16c and d respectively). No correlations were observed with 
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Figure 3.16 IIH adipose secretes more leptin 
Leptin secretion from ex vivo (A) SC and (B) OM adipose tissue in sex and BMI 
matched control and IIH patients following a 24 hour incubation assessed via ELISA. 
Comparison of paired SC and OM leptin secretion in (C) controls and (D) IIH patients. 
**=P<0.01, *=P<0.05. Unequal variances T-test for A, B, C and D. Data presented as 
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The cohorts analysed for adipose leptin secretion were not matched for age, 
considering leptin secretion decreases with age a sensitivity analysis was 
carried out, matching the control and IIH groups additionally for age (Fig3.1). 
Here, IIH SC adipose retains increased leptin secretion compared to controls 
(8566±1954 vs 2620±1660; P=0.017) (Fig3.17a). Conversely, in OM adipose 
tissue, a trend to increase was demonstrated (2848±1034 vs 517±85; P=0.058) 
(Fig3.17b), indicating that age is a factor altering leptin secretion from OM 
adipose tissue.  
 
Figure 3.17 Leptin secretion sensitivity analysis 
Sensitivity analysis on (A) SC and (B) OM adipose leptin ELISAs on age, sex and BMI 
matched IIH and control cohorts. Unequal variances t-test for A and B. *=P<0.05. Data 
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3.3.6 IIH adipose has increased 11βHSD1 activity 
Glucocorticoids are known to promote lipogenesis, lipolysis, leptin secretion and 
cause depletion of ribosomal subunits in human adipose tissue, all features 
identified in IIH adipose in the previous sections (Hochberg et al., 2015). 
Consequently a targeted assay assessing the activity of the enzyme that gates 
tissue specific GC activity, 11β-HSD1, was carried out on SC adipose from IIH 
and sex, BMI and age matched controls (Fig3.1). It is demonstrated that IIH SC 
adipose tissue produced more cortisol compared to controls (593.8±209.8 vs. 
261.9±75.21 pg/h/100mg; P=0.015), indicating increased potential to produce 
cortisol (Fig3.18a). This increased activity is independent of gene expression: 
RNA sequencing data highlights those genes associated with pre-receptor 
glucocorticoid metabolism (HSD11B1, HSD11B2 and H6PD) and the cognate 
receptors (NR3C1 and NR3C2) have unaltered expression compared to 
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Figure 3.18 11β-HSD1 activity in IIH SC adipose tissue 
Subcutaneous adipose tissue from IIH and control patients incubated with cortisone for 
24 hours. (A) Cortisol generation in subcutaneous adipose explants measured via 
LCMS. (B) DESeq2 gene expression of glucocorticoid pre-receptor metabolism genes 
as measured by RNA sequencing, P-values based on DESeq output following multiple 
comparison correction. A, controls N=4, IIH N=7 where an N represents tissue ran in 
triplicate. B) Controls N=7, IIH N=13. Unpaired T-test for A. *=P<0.05. Data presented 
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3.3.7 IIH SC adipose tissue differentially expresses steroid metabolising 
enzymes  
IIH patients have an androgen excess phenotype (appendix 1) and weight loss 
reduces circulating androgens (O’Reilly et al., 2019; Sinclair et al., 2010b). 
Given that adipose tissue is a well-defined site of peripheral androgens, it is 
hypothesised that IIH adipose tissue has altered expression of steroid 
metabolising enzymes that could increase circulating androgens (O’Reilly et al., 
2014). A targeted RT-qPCR experiment was carried out on both SC and OM 
adipose tissue derived from IIH patients and age, BMI and sex matched 
controls to determine the expression of enzymes associated with sex steroid 
synthesis.  
IIH SC adipose has decreased expression of HSD3B1 (0.20±0.05, P=0.001), 
HSD3B2 (0.49±0.20; P=0.007) and SRD5A1 (0.42±0.08; P=0.007) with no 
alteration in the expression of AKR1C3 (0.88±0.17; P=0.22) (Fig3.19a). 
Conversely IIH OM adipose has no alterations in the expression of HSD3B1 
(3.14±01.59; P=0.0504), HSD3B2 (1.00±0.32; P=0.62), AKR1C3 (1.62±0.27; 













  Subcutaneous Omental 
ΔCt Control IIH Control IIH 
3BHSD1 10.00 11.77  10.01 8.48  
S.E.M 0.31 0.68  0.53  0.33 
3BHSD2 12.33 14.84 11.32 11.71 
S.E.M 0.52 0.59 0.54 0.77 
AKR1C3 5.93 6.55 6.24 5.76 
S.E.M 0.31 0.35 0.83 1.08 
SRD5A1 8.37 10.00 7.82 8.10 
S.E.M 0.51 0.30 0.51 0.48 
 
Figure 3.19 Expression of steroidogenic enzymes in IIH adipose tissue 
Expression of HSD3B1, HSD3B2, AKR1C3 and SRD5A1 in (A) SC and (B) OM 
adipose tissue from IIH patients expressed as fold change relative to sex, age and BMI 
matched controls (dotted line), assessed via RT-qPCR. Table depicts ΔCt values for 
SC and OM adipose in controls and IIH patients, unpaired T-tests performed on ΔCt 
values of control vs IIH. Data presented as mean±SEM, all genes ran in triplicate. 
*=P<0.05, **=P<0.01. Control N=9, IIH N=14. 
 
  




IIH is a disease associated with obesity, where increased truncal mass is 
associated with increased LP Opp and weight loss improves the clinical 
phenotype in IIH patients (Hornby et al., 2018a; Sinclair et al., 2010a). 
Consequently IIH adipose is hypothesised to contribute the disease activity if 
IIH. As such, it was aimed to investigate the phenotype of IIH adipose tissue 
using a mixture of hypothesis free and hypothesis driven approaches.  
3.4.1 IIH SC adipose displays a unique transcriptional and metabolic 
signature 
IIH SC adipose tissue displays a distinct phenotype with transcriptomic 
differences, where ribosomal subunits are depleted and lipid biosynthetic genes 
are enriched. This phenotype is consistent with adipose tissue conserving 
energy, in favour of lipid synthesis (Oie et al., 2014). Furthermore, IIH adipose 
tissue has a transcriptome suggestive of recent caloric intake, despite being 
fasted, which could be interpreted as IIH patients being predisposed to weight 
gain (Franck et al., 2011). This is curious because it is established that IIH 
patients often experience an exacerbation or onset of symptoms following a 
period of rapid weight gain (Giuseffi et al., 1991). 
This lipid synthetic phenotype is corroborated in part by the NMR metabolome; 
IIH SC adipose shows an increased propensity for uptake of branch chain 
amino acids (BCAA) leucine and isoleucine with no alteration in tissue BCAA 
levels. Although it is possible that IIH SC adipose was deficient in these 
essential amino acids in vivo, necessitating uptake from the media, it is also 
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plausible that they are preferentially catabolising leucine and isoleucine to 
promote de novo lipogenesis. Isoleucine and leucine catabolism contributes to a 
quarter of the lipogenic acetyl-CoA pool in rodent adipocytes (Crown et al., 
2015). However this process has yet to be demonstrated in human adipocytes, 
as such this needs to be assessed. Future assessment utilising labelled BCAA 
and mass-spectrometry to facilitate metabolic tracing and an assessment of a 
greater range of metabolites would allow an understanding of the contribution of 
BCAA to de novo lipogenesis in IIH SC adipose. 
This suggestion of increased de novo lipogenesis, with increased lipolysis, 
denoted by increased glycerol secretion, suggests that IIH SC adipose tissue 
has increased overall lipid turnover compared to controls. However, dynamic 
assessment of lipid turnover is required to evaluate this phenotype further.  
The suggestion of increased fatty acid precursors from increased BCAA uptake 
could explain the increased leptin secretion from IIH adipose tissue; lipid 
precursors increase leptin secretion in adipocytes (Crown et al., 2015; 
Rosenthal et al., 1974; Shirai et al., 2004). This increased leptin secretion from 
IIH adipocytes suggests a cause for the presumed hyperleptinaemia in IIH 
patients (Ball et al., 2009; Lampl et al., 2002).  
The depleted ribosomal subunits, increased lipid turnover and increased leptin 
secretion resemble the phenotype of SC adipose tissue from patients with 
Cushing’s disease, thus resembles features of long term glucocorticoid excess 
(Hochberg et al., 2015). Indeed, IIH SC adipose tissue was demonstrated to 
generate more GC compared to controls, independently of genes associated 
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with GC pre-receptor metabolism. This increased cortisol generation might be 
explained by reduced SRD5A1 expression as 5α-reductase is known to 
deactivate GCs (Miller and Auchus, 2011). This suggests that rather than 
generating more cortisol per se, IIH adipose is unable to generate 5α-
dihydrocortisol at the same rate as control adipose tissue, leading to cortisol 
accumulation. Indeed global srd5a1 knockout out leads to reduced 
corticosterone (active rodent GC) clearance in mice (Livingstone et al., 2014). 
The present study, however, does not fully assess the cause of the increased 
adipose cortisol generation. Systemic 5α-reductase activity is increased in IIH 
patients (appendix 1), although this does not contradict the present hypothesis, 
both hepatic and adipose 5 α-reductase activity need to be assessed, due to 
these being the major 5 α-reducing tissues (O’Reilly et al., 2019). As such, this 
hypothesis remains to be tested, with 5α-reductase activity, glucocorticoid 
clearance and intra-adipose 11β-HSD1 activity of IIH adipose tissue needing to 
be assessed. Furthermore other factors associated with 11β-HSD1 activity need 
to be assessed. For example the inability to quantify tissue levels of NADPH 
precluded the analysis of the NADPH/NADP+ ratio, thus potential activity of 
G6PDH activity, a key coenzyme for 11β-HSD1, highlighting this as an 
investigative avenue (Hewitt et al., 2005).  
The reduced expression of androgen metabolising enzymes in IIH SC adipose 
is suggestive of a reduced capacity to activate androgens, contrary to the 
adipose phenotype in polycystic ovary syndrome (O’Reilly et al., 2017). 
However due to the unchanged expression of AKR1C3, it is plausible that IIH 
SC adipose tissue is capable of generating more testosterone compared to 
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control adipose, due to the reduced SRD5A1 expression. 5α-reductase is 
required convert testosterone to dihydrotestosterone, thus the proposed 
catalytic block could cause increased testosterone due to reduced DHT 
generation, contributing to the systemic testosterone excess (Miller and Auchus, 
2011; Schiffer et al., 2018). Indeed, global srd5a1 knockout in female mice 
results in a mild oestrous cycle dependent testosterone excess, suggesting 
reduced metabolic testosterone clearance (Mahendroo et al., 1996). Assessing 
in vivo androgen generation following a DHEA bolus using adipose tissue 
microdialysis would address this hypothesis (O’Reilly et al., 2017). 
Together, the data presented on IIH SC adipose allows the creation of a model 
formed of testable hypothesise. The  proposed model suggests that the reduced 
SRD5A1 expression and therefore reduced 5α-reductase activity is facilitating 
the reduced GC clearance in IIH SC adipose, allowing the development of a 
phenotype of glucocorticoid excess. Furthermore reduced SRD5A1 expression 
is hypothesised to be contributing to the systemic androgen excess through 
reducing DHT generation, increasing testosterone (Fig 3.20). Systemic 
knockout of srd5a1 in mice causes reduced glucocorticoid clearance and a 
moderate oestrus cycle dependent testosterone excess (Livingstone et al., 
2014; Mahendroo et al., 1996). Assessing the phenotype of an adipose specific 
knockdown of 5α-reductase type 1 in female rodents would help to address this 
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Figure 3.20 Model diagram IIH SC adipose tissue 
Schematic diagram of the hypothesis model in IIH adipose tissue. Reduced 5α-
reductase activity reduces the deactivation of cortisol, increasing the intracellular 
cortisol. Increased intra-adipose cortisol promotes classic glucocorticoid (GC) effects 
on adipose tissue such as reducing transcription, increasing lipogenesis and lipolysis 
and increasing leptin secretion. Furthermore, reduced SRD5A1 expression would 
prevent further metabolism of testosterone (T), contributing to the peripheral T excess. 
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3.4.2 IIH OM adipose displays differential features 
IIH OM adipose displays a differential phenotype to control adipose, whereby 
OM adipocytes in IIH have a smaller cross-sectional area compared to matched 
controls, demonstrating relative cellular hypotrophy. This phenotype could be 
explained by the cellular metabolic processes contributing to a net loss in lipid 
mass. IIH OM adipose displays increased glycerol secretion, indicating 
increased lipolysis without any signs of increased de novo lipogenesis, this is 
suggestive of a net loss of lipid volume. The IIH androgen excess phenotype 
could be contributing to the reduced adipocyte cross-sectional area through 
promoting lipolysis (O’Reilly et al., 2014). The reduced cross-sectional area may 
explain the reduced MCP-1 secretion from IIH OM adipose, where smaller 
adipocytes are associated with reduced MCP-1 secretion (Skurk et al., 2007).  
The reduced cross-sectional area of OM adipocytes could be contributing to the 
IIH androgen excess phenotype independently of the unchanged expression of 
androgen metabolising genes. Smaller omental adipocytes are associated with 
a reduced capacity of OM adipose to inactivate androgens (Blouin et al., 2003; 
Quinkler et al., 2004). Given that IIH OM adipose is of a smaller cross-sectional 
area, this allows the formation of the hypothesis that IIH OM adipose possesses 
a diminished ability to deactivate androgens, contributing to the androgen 
excess phenotype. As such, the capacity of IIH OM adipose to deactivate 
androgens should be assessed.  
Other than the above changes, IIH OM adipose displays remarkable similarity 
with control OM adipose, where both the metabolomics and cytokine secretion 
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do not identify any changes. This suggests that IIH OM adipose has a general 
phenotype of obese OM adipose with the exception of the changes mentioned.  
3.4.3 Limitations 
The data in this chapter necessitates recruitment of larger cohorts that are more 
comprehensively phenotyped than the present cohort to confirm these 
preliminary findings. Adipose tissue from obese individuals are inherently 
metabolically deranged compared to lean individuals, consequently the IIH 
adipose features described are assumed to be in addition to obese phenotype 
(Attie and Scherer, 2009). Future studies incorporating adipose tissue from lean 
individuals would allow the comparison to IIH adipose to normal adipose tissue.   
These preliminary data point toward the need to utilise a more integrated 
experimental approach utilising in vivo experimentation on IIH adipose tissue.  
Primarily, utilising microdialysis experiments would facilitate assessment of the 
metabolic phenotype of IIH SC adipose tissue in situ (O’Reilly et al., 2017). 
Moreover, this would facilitate the administration of precursor steroids, such as 
DHEA, facilitating the assessment of steroid activation IIH and control adipose. 
Utilising mass-spectrometry based metabolomics on adipose tissue 
microdialysate would provide a broader assessment of metabolites including 
lipids and allow a greater understanding of potential metabolic differences 
between IIH  adipose and controls compared to NMR, which assessed a limited 
number of metabolites (O’Reilly et al., 2017).  
This study assessed a small fraction of the peptide secretome from adipose 
tissue using a cytokine panel. In future, quantitative proteomics could be 
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deployed to assess a greater range of secreted peptides from adipose tissue 
within the adipose tissue microdialysate, facilitating the discovery of putative 
pathogenic molecules and biomarkers (Wasinger et al., 2013).  
Although this study assessed the cross-sectional area of adipocytes in IIH 
adipose tissue, factors associated with adipocyte stress and inflammation were 
not assessed. Crown-like structures, the remnants of dead adipocytes and 
associated macrophages were not quantified, preventing an assessment of 
adipocyte stress and death, a feature of obese adipose tissue (Cinti et al., 
2005). Furthermore, although a brief survey of the adipose tissue was 
completed, no formal assessment of inflammatory infiltrates was carried out. 
Future assessment of both crown-like structures, via macrophage staining, and 
inflammatory infiltrates would provide a greater insight into adipose tissue 
health in IIH adipose tissue. 
This work presents the first assessment of the cellular phenotype of adipose 
tissue in IIH, where depot specific phenotypes exist. IIH SC adipose displays 
features of glucocorticoid excess and OM adipose displays a comparatively 
hypotrophic phenotype. However both SC and OM adipose tissue display 
general similarity in their metabolome and peptide secretion compared to 
controls. Being as adipose tissue has a strong role in the homeostasis of whole 
body metabolism; it is feasible that the metabolic disturbances in IIH patients 
are contributed to, in part, by the deranged metabolism of IIH adipose tissue. 
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Chapter 4 Leptin Phenotype of 
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4.1 Introduction 
Idiopathic intracranial hypertension (IIH) is strongly associated with obesity. 
Consequently, several studies have evaluated inflammatory cytokines and 
adipokines, which are known to alter in obesity, to determine an IIH specific 
signature in an attempt to understand the pathogenesis of IIH (Markey et al., 
2016b).  
One adipokine that has garnered interest is the cardinal adipokine leptin. 
Studies of leptin in IIH have yielded conflicting results (see table 4.1). The 
original study of leptin in IIH conducted by Lampl et al demonstrated that IIH 
patients have raised serum leptin in a fasted state, compared to a well BMI 
matched control cohort, although there were low patient numbers (N=15 IIH, 
N=16 controls). This study has been corroborated and contradicted by 
subsequent studies. Leptin in cerebrospinal fluid (CSF) has also been 
measured in several studies; Ball et al demonstrated raised CSF leptin 
independent of BMI, however subsequent studies have not corroborated this, 
instead showing unaltered CSF leptin in IIH (Behbehani et al., 2010; Dhungana 
et al., 2009; Samancl et al., 2017). Interestingly it was shown that CSF leptin 
concentration correlates with lumbar puncture opening pressure, suggesting 
leptin could be pathogenic in IIH (Ball et al., 2009). 
This conflicting nature of results can be explained by the varied study designs 
(table 4.1). The primary variable between studies is the fasting state of the 
patients, it is known that serum leptin increases in the post-prandial state (Korek 
et al., 2013). Furthermore the previous studies are often unmatched with 
regards to BMI and age. Control subjects comprised of mixed neurological 
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diseases have been utilised, whereby a disease specific leptin signature is likely 
being highlighted, rather than a true healthy control signature. Previous studies 
also have low numbers of IIH patients, reducing the power of the studies. 
Previous studies have had difficulty obtaining CSF from healthy individuals; 
lumbar punctures are painful procedures that are otherwise avoided unless 
clinically relevant. Consequently the studies utilising CSF have from patients 
with neurological diseases, thus are not true healthy controls. Of those studies 
with appropriate controls with fasted leptin measurements, only serum leptin 
was assessed.  
There has not been an optimal study assessing leptin in IIH patients, namely a 
study assessing both serum and CSF levels in fasted IIH patients compared to 
sex, age and BMI matched controls that are otherwise medically healthy. 
Consequently a study fulfilling the aforementioned criteria is required. 
Furthermore, due to the disparity between fasted and non-fasted leptin 
measurements in IIH, assessing post-prandial leptin in IIH patients would be of 
interest. Previous studies have not assessed the effect of weight loss on leptin 
in IIH. In chapter 3, it was demonstrated that IIH adipose tissue secretes more 
leptin compared to control adipose tissue suggesting that serum leptin should 
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Table 4.1 Previous papers characterising leptin in IIH 
↑=Increased in IIH, - = Not altered in IIH, N/A = not analysed, MND= mixed 
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4.1.2 Hypothesis 
Given that IIH adipose tissue secretes more leptin than control adipose tissue, it 
is hypothesised that leptin levels are altered in IIH patients and contribute to the 
pathogenesis of IIH. 
4.1.3 Aims 
 
1. Assess fasting CSF and serum leptin levels in IIH patients 
2. Assess the post-prandial response to leptin in IIH patients 
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4.2 Methods 
4.2.1 IIH patients  
IIH patients went through a trial visit at baseline in both the IIH:DT and IIH:WT 
and 12 months after baseline in IIH:WT only, according to the published 
protocols (Markey et al., 2017; Ottridge et al., 2017). IIH patients had active IIH 
confirmed and control patients had IIH ruled out via the modified Dandy criteria, 
as assessed by clinicians in the centres described in section 2.9. IIH patients in 
the IIH:WT trial were randomised 1:1 to either a community diet or bariatric 
surgery (gastric band, gastric sleeve or Roux-En-Y gastric bypass),  baseline 
control patients had the same baseline visit as IIH patients. The clinical data 
presented is derived from locked trial data from the IIH:DT and unlocked trial 
data from the IIH:WT.  
4.2.2 Meal stimulation test 
After an overnight fast, control and IIH subjects in the IIH:WT received two 
bottles of Fortisip drinks (Nutricia, Trowbridge, UK). Each bottle contains a total 
of 300kcal, where each bottle comprises of 147kcal carbohydrates, 105 kcal fat 
and 48kcal protein. Plasma was taken prior to and two hours after 
administration of the meal. 
4.2.3 Leptin ELISA 
Human leptin DuoSet ELISA (DY-398,Bio-techne, Abingdon, UK) was utilised, 
used according to manufacturer’s instructions using the recommended ancillary 
kit (Bio-techne, DY008). CSF was diluted 1:5, serum 1:100 and plasma 1:200 in 
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reagent diluent. The intra-assay coefficient of variation was 3.34% and inter-
assay coefficient of variation was 7.9%. 
4.2.4 Body fat assessment 
Body fat percentage was assessed using bioimpedence via a Body 
Composition Analyser TANITA BC-418 MA. A 0.2kg correction was made for 
base layer clothing where a standard female body type pre-set was selected for 
all patients. The machine was used according to manufacturer’s instructions. 
4.2.5 Statistics 
Statistical analysis was carried out using GraphPad prism (V7.1). Data 
normality was assessed using Shapiro-Wilk normality test. Data variance 
assessed via F-test of equality variances. Mann-Whitney U-test and 
Spearman’s correlation were used for non-parametric data. Whereas a two-way 
repeated measured ANOVA, students T-test, unequal variances t-test (Welch’s 
test) and Pearson’s correlation was used for parametric data. P<0.05 was 
considered significant.     
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4.3 Results 
4.3.1 Patient matching 
IIH samples were sourced from the IIH:WT and IIH:DT. No serum samples were 
available from the IIH:DT, consequently serum analysis included only samples 
from the IIH:WT. As expected IIH patients have a higher LP Opp compared to 
control patients (Fig 4.1).   
 
Figure 4.1 Consort diagram 
Allocation of IIH and control patients to each of the analysis groups; CSF leptin 
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4.3.2 IIH patients have raised serum leptin  
Serum and CSF leptin was assessed in fasted IIH and control patients. Serum 
leptin was raised in IIH patients compared to control patients (71.5±29 vs. 
56.3±14 ng/ml, P=0.0033) (Fig4.2a). CSF leptin was unaltered in IIH patients 
(504.8±197 vs. 493.8±152 pg/ml, P=0.99) (Fig4.2b). Serum and CSF correlate 
in both IIH (P<0.0001) and control (P=0.0041) patients where there is a plateau 
in the transport of leptin from the serum to the CSF, demonstrating saturatable 
transport of leptin from the serum to the CSF (Fig4.2c). This process in 
unaltered as demonstrated by the comparable serum/CSF ratio between IIH 
patients and control patients (154.5±56 vs. 137.8±33, P=0.44) (Fig4.2.d). 
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Figure 4.2 Baseline leptin characterisation 
Leptin levels were evaluated in (A) serum, (B) cerebrospinal fluid (CSF) in control and 
IIH patients as measured by ELISA. (C) A correlation between serum and CSF leptin 
and (D) serum/CSF ratio were assessed in IIH patients and a sex and BMI matched 
cohort. Unequal variances t-test for A, Mann-Whitney test for B and C, Spearman 
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The control and IIH cohorts were not matched for age, where age is a known 
determinant for serum leptin levels. Consequently a sensitivity analysis was 
carried out, matching the controls with a subgroup of IIH patients for age 
(control; 38.5±9.4 vs IIH; 34.9±6.9 years, P=0.061) and BMI (43.2±5.5 vs 
44.6±6.6, P=0.6) (Fig4.3d). Serum leptin was raised in IIH (63.66±14.9 vs 
75.57±30.41, P=0.04) (Fig4.3a). Furthermore, no difference in CSF 
(493.8±152.1 vs 516.8±208.4, P=0.96) (Fig4.3b) and serum/CSF ratio 
(137.8±33.1 vs 153.9±60.5, P=0.6) (Fig4.3c) was observed. 
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Figure 4.3 Sensitivity analysis of leptin baseline characterisation 
A sex, BMI and age matched cohort of control and IIH patients were sub analysed for 
(A) serum, (B) CSF leptin and (C) serum/CSF leptin ratio. Unequal variances t-test for 
A, Mann-Whitney test for B and C. N=19 for control, N=43 for IIH. Data presented as 





 Control IIH P-value 
Age 
(Years) 





43.2(5.5) 44.6(6.6) P=0.6 
LP Opp 
(cmCSF) 
23.1(3.5) 34.7(5.5) P<0.0001 
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4.3.3 Association between ICP and leptin  
A previous study assessing CSF leptin levels noted that CSF leptin correlated 
with LP Opp in control patients whereas this was not evident in IIH patients, 
perhaps due to low numbers in the IIH cohort (IIH=22, Control, 52) (Ball et al., 
2009). Consequently, serum and CSF leptin values were correlated against 
lumbar puncture opening pressure (LP Opp) to assess association, in a large 
IIH cohort. In control patients, serum leptin (Fig4.4a) was not found to correlate 
with ICP (P=0.053, R2=0.15), however CSF leptin correlates with LP opening 
pressure (P=0.007, R2=0.33) (Fig4.4b). In IIH patients neither serum (P=0.87, 
R2=0.0001) (Fig4.4c) or CSF (P=0.14, R2=0.01) (Fig4.4d) leptin levels correlate 
with LP Opp. 
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Figure 4.4 Association between leptin and lumbar puncture opening 
pressure 
Scatter graphs detailing LP Opp vs (A,C) Serum and (B,D) CSF leptin in (A,B) control 
and (C,D) IIH patients. Pearson’s correlation for A and B. Spearman’s correlation for C 
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4.3.4 IIH patients have an altered post-prandial leptin response 
The fasting status of subjects in studies assessing leptin in IIH patients has 
been mixed, where non-fasted studies have had a higher chance in finding 
raised serum leptin in IIH patients, suggesting that IIH leptin is altered in the 
post-prandial state (table 4.1). Consequently, the post-prandial leptin response 
was assessed in IIH patients and controls where the groups a well matched 
(Fig4.1). As part of their trial days, IIH patients and controls received a meal 
stimulation test. Here, post-prandial plasma leptin was assessed two hours after 
a meal. Control patients had reduced plasma leptin two hours after a meal 
compared to baseline (65.4±19 vs 58.0±17 ng/ml, P=0.002) (Fig4.5a). In 
contrast, IIH plasma leptin was unaltered (69.2±33 vs 68.4±34 ng/ml, P=0.92) 
(Fig4.5a). Furthermore the control cohort had a greater change in leptin 
compared to controls (89.75±15 vs 100.7±20 % of baseline, P=0.043) (Fig4.5b). 
These data highlight an altered postprandial leptin response in IIH patients 
compared to obese controls. Plasma leptin correlated strongly with paired 
serum leptin measurements (P<0.0001, R2=0.85) (Fig4.5c), indicating that 
dilutions and experiments were carried out correctly. 
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Figure 4.5 Postprandial leptin response in IIH patients 
Fasting and post prandial leptin was assessed in control and IIH patients at their 
baseline visit. (A) Fasted and post prandial plasma leptin. (B) Post-prandial leptin as a 
percentage of fasted leptin. (C) Plasma vs serum leptin in both control and IIH. (A) 
Two-way repeated measures ANOVA with Sidak’s multiple comparison test, (B) Mann-
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4.3.5 Weight loss and leptin in IIH 
Previous studies have not assessed the physiological response of weight loss 
to leptin in IIH patients, as such serum and CSF from IIH patients in the IIH:WT 
were taken from the 12 month visit where patients had been randomised to 
either community weight loss (diet) or bariatric surgery. Although the weight loss 
data from each group is locked clinical trial data, is apparent that patients in the 
surgical arm have a lower BMI compared to those in the diet arm at the 12 
month visit (Fig4.1) .Serum leptin at 12 months was lower in the surgical arm 
compared to the diet arm (29.4±24 vs 75.9±32 ng/ml, P<0.0001) (Fig4.6a). 
Furthermore CSF leptin at 12 months was lower in the surgical arm compared 
to the diet arm (325.7±179.9 vs 504.7±180.1 pg/ml, P=0.001) (Fig4.6b). When 
compared to their respective baseline leptin values, the surgical patients display 
reduced CSF leptin (77.8±26 vs 29.4±24 ng/ml, P<0.0001) (Fig4.6c). 
Conversely the diet arm had no change in CSF leptin (79.2±35 vs 75.8±32 
ng/ml, P=0.77) (Fig4.6c) at 12 months. Similarly, when compared to their 
respective baseline leptin values, the surgical patients have reduced CSF leptin 
(545.2±325.7 vs 325.7±179 pg/ml, P<0.0001) (Fig4.6d). Conversely the diet 
arm had no change in CSF leptin (524.2±175 vs 504.7±180.1 pg/ml, P=0.86) at 
12 months (Fig4.6d). 
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Figure 4.6 Bariatric surgery reduces leptin in IIH patients 
Following a 12 month intervention, IIH patients randomised to diet and surgery had 
(A,C) serum and (B,D) CSF. Direct comparison between groups (A,B) and (C,D) 
comparison to baseline values. Mann-Whitney U-test for A and unpaired T-test for B, 2-
way repeated measures ANOVA with Sidak’s multiple comparison test for C and D. 
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At the baseline visit, CSF leptin was found to be correlated with LP Opp in 
control but not IIH patients. Consequently, at the 12 month visit, the association 
between serum and CSF leptin and LP Opp was assessed. At the 12 month 
visit, serum leptin in both the diet (P=0.62, R2=0.008) and surgical arm (P=0.16, 
R2=0.09) do not correlate with ICP. Conversely, in the surgical group, CSF 
leptin correlates with LP pressure (P=0.0097, R2=0.32), akin to the control 
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Figure 4.7 Association between leptin and lumbar puncture opening 
pressure following bariatric surgery  
Scatter graphs detailing LP Opp vs (A,C) serum and (B,D) CSF leptin in (A,B) diet and 
(C,D) surgically randomised IIH patients at their 12 month visit. Spearman’s 
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4.3.7 Leptin reduction is weight loss dependent in IIH   
Previous studies have identified that weight loss reduces serum and CSF leptin, 
this however has not been assessed in IIH patients. As such, the change in 
both serum and CSF leptin in all patients that completed a 12 month visit was 
assessed against change in BMI and fat mass, factors known to confer changes 
in leptin. Weight loss in IIH patients in the form of BMI reduction is associated 
with a reduction in (Fig4.8a) serum leptin (P<0.0001, R2=0.62) and a reduction 
in (Fig4.8C) CSF leptin (P=0.0002, R2=0.27). Similarly a reduction in fat mass is 
strongly associated with a reduction in serum leptin (P<0.0001, R2=0.45) 
(Fig4.8b), however, fat mass reduction is not associated with a reduction of 
CSF leptin levels (P=0.057, R2=0.021) (Fig4.8d).  
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Figure 4.8 Weight loss reduces circulating leptin in IIH 
Scatter graphs of combined 12 month IIH cohort where change in BMI (A,C) and fat 
mass (B,D) from baseline versus change in serum (A,B) and CSF (C,D) leptin from 
baseline. Following Bonferroni correction P<0.025 was considered significant. 







Page | 155 
 
4.3.8 A reduction in fat mass reduces LP Opp in IIH 
One pathogenesis hypothesis of IIH is that leptin could be driving the raised LP 
Opp. As such the correlation between change in LP Opp and change in leptin 
levels was assessed. At the 12 month time point, a reduction in BMI is strongly 
associated with a reduction in LP Opp (P=0.0001, R2=0.48) (Fig4.9a). Similarly 
a reduction in fat mass is strongly associated with a reduction in LP Opp 
(P=0.0003, R2=0.29) (Fig4.9b). Both reductions in CSF (P=0.003, R2=0.13) 
(Fig4.9c) and serum (P=0.0003, R2=0.342) (Fig4.9d) leptin are associated with 
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Figure 4.9 Association between weight loss and LP Opp reduction 
Scatter graphs of combined 12 month IIH cohort change LP Opp from baseline versus 
change in (A) BMI, (B) fat mass, (C) CSF and (D) serum leptin from baseline. 
Spearman’s correlation’s where following Bonferroni correction, P<0.0125 was 
considered significant.  
  
  




4.4.1 Fasted-leptin in IIH 
IIH in women is strongly associated with obesity, consequently leptin has been 
assessed in IIH patients in several studies (Markey et al., 2016b). However, the 
previous studies do not suggest a definitive leptin phenotype due to conflicting 
study designs and inappropriate controls. Furthermore work in chapter 3 
highlights that IIH adipose secretes more leptin compared to matched controls. 
Consequently, the present study aimed to evaluate the fasting levels of leptin in 
IIH patients compared to a well matched control cohort. 
This study demonstrates that IIH patients have raised serum leptin compared to 
controls, suggesting that increased subcutaneous adipose leptin secretion 
directly contributes to IIH hyperleptinaemia. In contrast, no difference in CSF 
leptin or the serum/CSF leptin ratio was observed, corroborating some studies 
and refuting others. These changes are retained when selecting for a better 
matched cohort. Moreover, the current data replicates previous studies 
demonstrating saturatable transport of leptin from the blood to the CSF, 
indicating that leptin transport into the CSF is not observably perturbed in IIH 
(Schwartz et al., 1996). 
A strength of this study is that the control cohort is the first true healthy cohort to 
provide CSF leptin as a comparator for IIH patients; previous studies assessing 
CSF leptin used mixed neurological controls where a disease specific leptin 
signature could be measured. Furthermore, the current data corroborates a 
previous study highlighting that CSF leptin concentration positively correlated 
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with LP Opp in controls, whereas this is not demonstrated in patients with active 
IIH (Ball et al., 2009).  
4.4.2 IIH patients have an altered post-prandial leptin response 
A further aim of the study was to assess the post-prandial leptin response in IIH 
patients. The study highlights altered post-prandial leptin response in IIH 
patients whereby there is no post-prandial response to leptin, in contrast to 
controls who have reduced plasma leptin in response to a meal, replicating a 
previous study (Korek et al., 2013). Consequently the post-prandial leptin 
phenotype in IIH is intermediate between obese patients, whose leptin 
decreases post-prandialy, and non-obese patients whose leptin increases post-
prandialy (Korek et al., 2013). The present data could suggest that IIH adipose 
is more responsive to insulin, the predominant leptin secretagogue in the post-
prandial state, or to glucose stimulated leptin secretion compared to obese 
controls. These factors have yet to be fully assessed and should be followed up.  
This study has failed to investigate other hormones associated with satiety in 
the post-prandial state, such as ghrelin.  
4.4.3 Weight loss, leptin and LP Opp in IIH patients 
The final aim of the study was to assess the physiological response of leptin to 
weight loss in IIH patients. It is well established in obese patients that reducing 
BMI and fat mass reduces circulating serum and CSF leptin levels, however this 
has never been assessed in IIH patients (Maffei et al., 1995; Nam et al., 2001). 
The present study demonstrates a weight loss dependent serum and CSF leptin 
reduction in IIH patients, highlighting that obesity as a primary determinant of 
raised serum leptin in IIH, rather than inherent high leptin secretion. 
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Furthermore, a reduction in BMI through reduction in fat mass is strongly 
correlated with a reduction in LP Opp, and is coupled with a reduction in serum 
leptin.  
The lack of correlation with CSF leptin and LP Opp at baseline coupled with 
unaltered CSF leptin levels in IIH patients suggests that leptin is not driving the 
raised LP Opp in IIH. Rather, this change in LP Opp is most likely linked to the 
change in fat mass, as such the raised serum leptin is probably a bystander to 
the metabolic perturbations of IIH adipose as discussed in chapter 3. This study 
highlights that adipose may be driving the pathology in IIH. Perhaps of clinical 
significance, the striking association between BMI reduction and reduction in LP 
Opp is almost prescriptive. Based on the current data, where a patient is 
required to reduce their LP Opp by a certain amount to achieve a normal LP 
Opp value, and appropriate method of weight loss could be prescribed. This 
needs further investigation to identify whether this is a true association.   
4.4.4 Limitations 
The present study has several limitations. Primarily the control cohort is not 
large, compared to the largest IIH cohort to have leptin assessed. Furthermore, 
the narrow eligibility criteria for both IIH:DT and IIH:WT limits applicability of the 
current results to the well-defined and characterised cohort of obese women of 
reproductive age with active IIH, excluding applicability to other IIH patient 
groups such as paediatric and male IIH, although these make a minority of IIH 
patients. Assessing serum and CSF leptin in male IIH patients would be a of 
future interest, due to the association of male IIH with obesity (Bruce et al., 
2009). This study also did not directly assess leptins capacity to modulate ICP 
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or CSF secretary processes at the choroid plexus. However it is clear that 
rodent choroid plexus does not express the signalling splice variant of the leptin 
receptor, OB-Rb, and protein expression for this has not been observed in 
humans (Burguera et al., 2000; Couce et al., 1997; Mitchell et al., 2009). Rather 
the choroid plexus expresses the transporting splice variant, OB-Ra, in humans 
and rodents that has minimal signalling capacity and primarily transports leptin 
from the blood to the CSF (Burguera et al., 2000; Couce et al., 1997; Mitchell et 
al., 2009). This does not preclude leptins capacity to alter CSF drainage; 
however leptins effects on CSF drainage have yet to be assessed. Furthermore 
assessing leptins capacity to modulate ICP in an appropriate rodent model is 
nearly impossible. Ideally an obese female rodent will be infused with leptin and 
ICP assessed. However, leptin induces rapid robust weight loss in rodents, thus 
preventing a long term assessment of leptins capacity to alter ICP in obese 
rodents (Halaas et al., 1997).      
The current study fails to assess the mechanisms that could underpin altered 
leptin dynamics in IIH. Although chapter 3 suggests that increased intra-adipose 
glucocorticoid accumulation could be influencing serum leptin levels, other 
factors could be altering leptin. Assessment of leptin secretagogoues such as 
insulin and catecholamine’s in the basal state and post-prandial insulin state 
would inform on the potential causes of the altered leptin dynamics in IIH. 
Perhaps more interesting, the present study fails to investigate other factors that 
regulate energy intake, such as cholecystokinin, glucagon, glucagon-like 
peptide 1 and ghrelin in both the fasting and post-prandial state. Assessing 
these would give a stronger assessment on hormonal control of energy 
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homeostasis in IIH patients. Ghrelin has however been investigated in IIH, 
where no difference in fasting or post-prandial ghrelin was demonstrated, 
however the study had multiple IIH phenotypes and an unmatched cohort 
limiting the utility of the study (Subramanian et al., 2004). Further investigation 
into these factors would allow for an understanding of the role of gut 
neuropeptides in weight and energy homeostasis in IIH. 
The present study highlights that IIH patients have increased fasting serum 
leptin but unaltered CSF leptin levels. Furthermore IIH patients have a distinct 
post-prandial leptin signature. The present data suggests that the leptin 
phenotype is most likely a consequence of other metabolic perturbations rather 
than a pathogenic moiety in IIH due to the strong association between weight 
loss and reduction in LP Opp.   
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Chapter 5 Developing and 
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5.1 Introduction 
Cerebrospinal fluid (CSF) bathes the brain, simultaneously delivering nutrients 
and flushing waste as well as providing buoyancy, allowing the brain to maintain 
its normal functionality and anatomy. CSF volume is a critical determinant of 
intracranial pressure (ICP). This dynamic is tightly regulated: therefore any 
aberration of ICP, as seen in hydrocephalus, idiopathic intracranial hypertension 
(IIH) or following traumatic brain injury can have life-altering consequences. 
Manipulation of CSF volume is used clinically to lower ICP, however, 
pharmacological manipulations of CSF secretion to date low efficacy and are 
poorly tolerated (Mollan et al., 2018b). Consequently there is a need to develop 
and screen for novel therapies that can lower ICP.  
There are currently many methods available to determine ICP, CSF secretion or 
surrogate markers of these (see table 3.1). Current in vivo methods either 
directly measure ICP or measure CSF fluid volume. Such methods provide 
powerful physiological data about molecules that modulate ICP and CSF 
production. Furthermore, they provide temporal data on how ICP or CSF 
production changes following drug administration. Critically, ICP can be 
monitored chronically, providing an understanding of both acute and chronic 
administration drug action (Uldall et al., 2014). However, in vivo methods do not 
allow high-throughput screening of putative modulators of ICP due to the 
requirement of large numbers of animals: consequently animal models are more 
suited to targeted physiological experimentation and pre-clinical evaluation 
rather than high-throughput drug screening. Therefore, in vitro methods provide 
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the optimal method for high-throughput screening of molecules that could alter 
CSF secretion. 
 
Author Method Direct or surrogate 
measure 
(Uldall et al., 2014) In vivo transcranial 
pressure monitor 
Direct long term 
monitoring of ICP 
(Oshio et al., 2004) In vivo CSF 
production 
Direct measure of 
CSF production 
(de Rougemont et 
al., 1960) 
Ex vivo oil covered 
choroid plexus 
Direct measure of 
fluid secretion 
(Klarr et al., 1997) In vitro 86Rb Uptake 
assay 
Direct measure of 
Na+/K+ ATPase  
activity 
(Botfield et al., 2017) In vitro inorganic 
phosphate assay 
Indirect measure of 
Na+/K+ ATPase  
activity 
(Hakvoort et al., 
1998) 
In vitro FITC-dextran 
assay 
Indirect measure of 
In vitro CSF 
production 
 
Table 5.1 Non-exhaustive list of CSF secretion assay methods 
 
One in vitro method involves the measurement of CSF secretion. Due to the 
choroid plexus forming a strong barrier between the blood and the CSF, any in 
vitro CSF secretion assay requires a competent barrier (Hakvoort et al., 1998). 
However, these require large quantities of tissue and are technically difficult to 
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produce. Consequently, using surrogates for CSF secretion is a more 
convenient option, specifically assaying the activity of the ubiquitously 
expressed membrane bound Na+/K+ ATPase. 
The physiological rationale of utilising Na+/K+ ATPase activity as a surrogate for 
CSF secretion is clear. Inhibiting the Na+/K+ ATPase at the choroid plexus 
inhibits CSF secretion up to 80% in vivo, thus Na+/K+ ATPase activity is 
intrinsically linked to CSF secretion, however the exact link between Na+/K+ 
ATPase activity and CSF secretion has yet to be elucidated (Pollay et al., 1985; 
Vates et al., 1964). Furthermore, reducing Na+/K+ ATPase  activity at the 
choroid plexus through indirect means such as inhibiting carbonic anhydrases is 
associated with reduced CSF secretion (Oshio et al., 2004; Uldall et al., 2017). 
Na+/K+ ATPase assays assess either ATP turnover or assess the movement of 
ions. Na+/K+ ATPase activity is elucidated with the cardiotonic steroid ouabain, 
a Na+/K+ ATPase specific inhibitor. Traditional in vitro Na+/K+ ATPase activity 
assays are unphysiological, requiring the lysis of the cells in order to assay ATP 
turnover. This uncouples the underlying biochemistry of the cell from the Na+/K+ 
ATPase and prevents instantaneous changes, such as phosphorylation, from 
being assessed. A further method to investigate Na+/K+ ATPase activity 
includes using a rubidium radio-isotope (86Rb) (Klarr et al., 1997). This assay 
works on the principle that 86Rb is transported through the Na+/K+ ATPase 
similarly to potassium cations. This assay, however useful, requires specialist 
equipment due to use of radioactive isotopes. Furthermore, the previously 
discussed in vitro Na+/K+ ATPase assays measure endpoints, preventing real-
time recordings of activity and understanding of Na+/K+ ATPase dynamics. As 
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such, there is a need for a convenient and reproducible assay to assess 
therapeutic and putative pathogenic molecules that are suspected to alter ICP. 




1. Develop an in vitro surrogate assay for CSF secretion 
2. Compare the developed assay to a validated in vivo model 
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5.2 Methods 
5.2.1 Cell culture  
Z310 cells (section 2.1) were cultured in DMEM supplemented with 10% foetal 
calf serum, 1% Penicillin/streptomycin and 1ng/ml epidermal growth factor 
(PeproTech, London, UK), at 37°C with 5% CO2. For microscopy cells were 
cultured to confluence on 25mm diameter glass coverslips (VWR, Leighton 
Buzzard, UK) seeded with poly-D-lysine and incubated with laminin (20ng/ml).   
5.2.2 Plate based Na+/K+ ATPase activity assay 
Z310 cells were cultured in 12 well plates and phosphate and protein assays 
were ran on the same samples as outlined in sections 2.2, 2.3 and 2.4. 
5.2.3 Live cell microscopy  
Live cell microscopy was carried out as outlined in section 2.18. In brief, Z310 
cells infected with an adenovirus containing the Perceval biosensor for 48h 
were imaged on a confocal microscope in real time. Cells were incubated with 
acetazolamide (100μM), furosemide (100μM) or an appropriate vehicle for two 
days and Na+/K+ ATPase activity elucidated by ouabain octahydrate (1mM). 
Data presented as F/Fmin where F= fluorescence at a given time and Fmin = 
minimum fluorescence during the recording. Assessor was blinded to the 
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5.2.4 Animals 
The study utilised female Sprague-Dawley rats (Taconic, Denmark) weighing 
150-250g. The rats were housed in cages under an inverted 12 hour light/dark 
cycle with ad libitum access to food and water. All experimental procedures 
were approved by the Danish Animal Experiments Inspectorate (license number 
2014-15-0201-00256). Surgical procedures were carried out according to 
section 2.19.2. After treatments and surgical procedures, the rats were 
monitored daily for any adverse effects. 
5.2.5 Drugs  
Acetazolamide and furosemide were administered via subcutaneous injection 
where acetazolamide was used at 103.3 mg/kg and 413.4 mg/kg and 
furosemide was used at 4.1 mg/kg and 24.8 mg/kg. The smaller dose 
represents a clinically relevant dose, the large dose represents a daily maximal 
dose. Dosage was worked out via the following FDA derived equation [Rat drug] 
(mg/kg) = 6.2 X [human] (mg/kg based on 60kg human). Further details can be 
found in section 2.19.3. 
5.2.6 ICP measurements  
Rats were sedated with 2.5 mg/kg midazolam (subcutaneous injection) and 
placed in an infusion cage (Instech Laboratories, Plymouth meeting, PA), which 
had a levered arm to provide unhindered movement. A stable baseline ICP 
reading was recorded for 30 minutes. A subcutaneous injection of drug or 
vehicle was administered at time zero on ICP traces. ICP was recorded for a 
further 120 minutes and then the animal was allowed to recover in its normal 
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cage. ICP was analysed using the Perimed software as outlined in section 
2.19.6. Monitoring period was selected to measure the maximal plasma 
concentration of the administered drugs. 
The animals featured in this work will have had repeated treatments, including 
treatments of drugs otherwise not described here in a randomised fashion. 
However animals had a washout period sufficient to allow for full clearance of 
the drug in question, the equivalent of 5 half-lives of a drug.  
5.2.7 Statistics 
Data was analysed using GraphPad Prism (V7.1) software. Data are presented 
as either median (interquartile range) or mean± standard deviation (SD) unless 
otherwise stated, subject to a Shapiro-Wilk normality test to determine the 
normality of the data. P<0.05 was considered significant. 
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5.3 Results 
5.3.1 Phosphate assay 
The phosphate assay determines inorganic phosphate content of a cell. In the 
context of CSF secretion, the Na+/K+ ATPase liberates inorganic phosphate and 
ADP following the cleavage of ATP to facilitate its function. As such, where a 
cell has higher Na+/K+ ATPase activity there should be increased inorganic 
phosphate when ouabain is added to cells. Although the assay is functional in 
primary choroid plexus cells, the assay requires large quantities of cells that 
cannot be ethically justified in the cost of animal life for drug screening 
experimentation (Botfield et al., 2017). As such, the assay needed to be 
optimised in an immortalised cell line. The particular method used in this assay 
is unique as far as the cells remain complete during the course of the assay and 
only lysed once the assay is completed, keeping the internal biochemistry 
intact. A 1 hour aCSF incubation followed by a 30 minute ouabain incubation 
was selected according to a previous paper that utilised primary choroid plexus 
epithelial cells as a starting point for optimisation (Botfield et al., 2017). 
5.3.2 Ouabain incubation time course  
Initial optimisation involved optimisation of the ouabain incubation time on Z310 
cells. (Fig5.1a) The present data highlights that only a 30 minute incubation with 
ouabain yields a small but significant reduction in inorganic phosphate 
(42.43±1.56) compared to control (52.4±4.56) (P=0.02). Of note, there is high 
variability in the levels of phosphate between the control conditions. (Fig5.1b) 
When comparing the ouabain reductions it is found that 30 minute ouabain 
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incubation (80.98±2.97) is significantly different only to a 60 minute incubation 
of ouabain (100.8±5.56 )(P=0.005). 
 
Figure 5.1  Ouabain incubation time course 
Z310 cells incubated with ouabain for various times. (A) Bar graph of raw normalised 
phosphate values with and without ouabain over various times. (B) Bar graph 
representing the percentage reduction elicited by ouabain relative for control.  Sidak’s 
multiple comparisons test for A, one-way ANOVA with post-hoc Tukey’s test for B. N=5 
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5.3.3 aCSF incubation time course 
Following ouabain time optimisation, the aCSF preincubation time was 
assessed. (Fig5.2a) It was demonstrated that 1 hour aCSF incubation has 
higher levels of phosphate (54.99±9.1) compared to 3 hours (27.9±1.1, P<0.01), 
6 hours (15.74±0.6, P<0.0001) and an overnight incubation of aCSF 
(37.20±1.20, P=0.04). (Fig5.2b) Only 1 hour incubation of aCSF yields a 
significant reduction in inorganic phosphate following ouabain administration 
(54.99±9.2 vs 39.47±2.1, P=0.03). (Fig5.2c) Furthermore 1 hour aCSF 
incubation allowed ouabain to deliver a more robust reduction (71.77±3.7%) 
compared to 3 hour (95.93±5.1%, P=0.03) and 6 hours (113.3±4.8%, P=0.006) 
aCSF incubations. The is no difference in reduction compared to an overnight 
aCSF incubation (90.89±7.9%, P=0.09). 
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Figure 5.2 Artificial cerebrospinal fluid incubation optimisation 
Z310 cells incubated for various times in artificial cerebrospinal fluid (aCSF) prior to 
inorganic phosphate measurement. A) Represents basal normalised phosphate over 
an aCSF timecourse. B) Represents phosphate following subsequent 30 minute 
incubations with ouabain. C) Ouabain reduction as a percentage of baseline. Data 
presented as mean±SEM. A and C one-way ANOVA with post-hoc Dunns test, B Two-
way ANOVA with post-hoc Sidak’s test’s. *=P<0.05, **=P<0.001, ***=P<0.0001 and 
****=P<0.00001. N=5 biological repeats 
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The optimised experimental setup of 1 hour aCSF pre-incubation followed by 30 
minute ouabain administration, generated an intra-assay variability coefficient of 
26.3% and an inter-assay variability coefficient of 39.7%. This indicates that the 
assay produces high variability in Z310 cells, reducing reproducibility. 
Furthermore, the reduction achieved through ouabain was not sufficient due to 
the aforementioned variability, preventing the analysis of drugs. As such, this 
assay was deemed unfit for purpose in Z310 cells. 
5.3.4 Perceval and the ATP:ADP ratio 
The failure of the previous assay facilitated the development of a novel in vitro 
Na+/K+ ATPase activity assay. The utilisation of genetically encoded biosensors 
enables a more physiological method to assess biological parameters. One 
candidate is the Perceval biosensor. Perceval is derived from bacterial GlnK1 
protein and contains a circularly permuted GFP molecule and reports the 
ATP/ADP ratio in real time, where an increased ATP/ADP ratio increases 
emitted fluorescence (Berg et al., 2009). This property presents the possibility of 
Perceval acting as a reporter of Na+/K+ ATPase activity, due to the Na+/K+ 
ATPase deriving its energy from the hydrolysis of ATP to ADP (Fig5.3a). 
Theoretically the addition of ouabain should increase the ATP:ADP ratio 
(Fig5.3b) due to the reduction in ATP hydrolysis. In conditions where the Na+/K+ 
ATPase is less active thus consuming less ATP, it would be expected that there 
would be a smaller increase in ATP compared to basal conditions under 
ouabain addition (Fig5.3c). Conversely, in conditions where the Na+/K+ ATPase 
is more active, thus consuming more ATP, it would be expected that there 
would be a greater increase in ATP compared to basal conditions under 
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ouabain addition (Fig5.3d). These changes in ATP:ADP ratio under the previous 
conditions should be reported by the Perceval biosensor. It was aimed to 
determine whether Perceval is an appropriate biosensor to determine Na+/K+ 
ATPase activity.   
 
Figure 5.3 Perceval assay theory 
(A) The Na+/K+ ATPase transduces energy via ATP lysis, transporting ions, where this 
can be inhibited via ouabain (B). Such an inhibition causes an increase in cellular 
ATP:ADP ratio, a change that could be detected by the Perceval  biosensor though 
changes in fluorescence (B). In situations where Na+/K+ ATPase activity is decreased 
(C) or increase (D), ouabain administration is hypothesised to resolve either a smaller 
(C) or larger (D) change in ATP:ADP ratio compared to normal situations (B), which is 
detectable by the Perceval biosensor as changes in fluorescence. Arrows by Perceval 
represent change in fluorescence. 
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5.3.5 Z310 cells express Perceval 
Following two days of infection with an adenovirus harbouring the Perceval 
biosensor, Z310 cells showed Perceval expression (Fig5.4). Z310 cells retained 
their cobblestone-like morphology. Furthermore there is heterogeneity in 
fluorescence emitted by the Z310 cells, indicating different levels of ATP 
turnover, or heterogeneity in expression of the biosensor.   
 
Figure 5.4 Z310 cells express Perceval 
Confluent Z310 cells express Perceval two days post adenovirus infection, where 
fluorescence is variable between cells. Scale bar = 50 µm. 
 
5.3.6 Heterogeneity in Z310 ATP:ADP ratio 
Due to Z310 cells apparent fluorescence heterogeneity in Perceval infected 
Z310 cells, the size of the variability was assessed. This highlighted a 18.5% 
variability in baseline fluorescence, as shown by Fig5.5a, where the distribution 
of fluorescence is non-parametric. To address this, cellular fluorescence was 
normalised to its minimum fluorescence in the baseline period. This reduced the 
variability to 3.3%, as highlighted in Fig5.5b, where 50% of the cells fall in the 
1.02 bin.  
  




Figure 5.5 Fluorescence heterogeneity in Z310 cells 
A) Traces of raw fluorescence of Z310 cells (B) Histogram representing the distribution 
of mean cell fluorescence in Z310 cells over 15 minutes, where the cell to cell 
variability in fluorescence is 18.5%. (C) Trace of normalised fluorescence of Z310 cells. 
(D) Histogram representing the normalised (F/Fmin) fluorescence of the same cells in A, 
where variability in cellular fluorescence is 3.3%. N=167 cells from 3 pooled coverslips. 
A and C presented as mean±SD. F=fluorescence at a given time, Fmin = minimum 
fluorescence in the trace.  
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5.3.7 Perceval reports changes in the ATP/ADP ratio elicited by ouabain  
Following confirmation of Perceval expression and demonstration of a stable 
ATP:ADP ratio, it was aimed to determine whether ouabain could increase the 
ATP/ADP ratio. Consequently two treatment groups, vehicle (HEPES-
bicarbonate buffer) and ouabain (1 mM) had fluorescence measured prior to 
and after treatment. The raw trace (Fig5.6a) indicates that F/Fmin remains stable 
prior to the administration of the treatment. The addition of treatment creates an 
artefact (0 minutes on trace) perhaps due to disrupted light transit. Vehicle 
treated cells (Fig5.6b) showed a decrease in F/Fmin from 1.043(0.027) to 
1.034(0.03) (P=0.026) indicating that the volume of vehicle alters the 
transmission of light. Conversely, ouabain increases F/Fmin from 1.045(0.23) to 
1.072(0.039) (P<0.0001), indicating that ouabain is increasing the ATP/ADP 
ratio, as predicted.  Following this the change in maximum F/Fmin was assessed 
for both groups (Fig5.6c). It was observed that ouabain changes F/Fmin more 
compared to the vehicle treated group (0.027(0.0269) Vs. -0.005(0.0129),  
P<0.0001). The area under the curve (AUC) of the traces (Fig5.6d), was larger 
in ouabain treated cells versus vehicle treated cells (0.93(0.517) Vs. 
0.55(0.434); P=0.0003).  
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Figure 5.6 Ouabain elicits a change in ATP:ADP ratio in Z310 cells 
 Z310 cells live cell imaged following Perceval infection, with acute vehicle and ouabain 
(1mM) treatment. (A) A trace graph detailing the change in ATP/ADP ratio in vehicle 
treated (red) and ouabain treated (blue) Z310 cells. (B) Represents the F/Fmin of cells 
with and without treatment. (C) Details the change in ATP:ADP ratio elicited by ouabain 
or control. (D) A heat map detailing the F/Fmin in individual cells over the course of the 
experiment. (E) The area under curve (AUC) derived from both traces on A for the 
course of the experiment. A and C are presented as mean±SD. B and E presented as 
median (IQR).  N = 27 for vehicle and ouabain treated cells, derived from 4 pooled 
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coverslips. B Wilcoxon test, C students t-test, E Mann-Whitney U test. ***=P<0.001, 
****=P<0.0001. B presented at median(IQR). 
 
5.3.8 Reversible action of ouabain 
Washout experiments were carried out to determine if the effect of ouabain 
could be reversed. The maximal fluorescence elicited by ouabain peaks around 
15 minutes after administration. It is demonstrated that a washout of media 
containing ouabain reduces F/Fmin (1.16 Vs. 1.10; P=0.03) (Fig5.7b). 
Furthermore, subsequent addition of ouabain increases F/Fmin (1.10 Vs. 1.23; 
P=0.004). Additionally, there is no difference between the changes in F/Fmin 
ouabain elicits prior to or after the washout (Δ9.5±4.4% Vs. Δ11.4±3.8%; P=0.1) 
(Fig 6.7c). These data highlight that the effects of ouabain can be reversed.  
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5.7 Reversible action of ouabain in Z310 cells 
Live cell imaging of Z310 cells following Perceval introduction. (A) Trace detailing the 
F/Fmin, whereby pre-washout is blue, post-washout is red. Break in axis represents 
washout period. (B) Highlights F/Fmin of cells following subsequent treatment of cells. 
(C) Details ouabain mediated change in F/Fmin pre- and post-washout. For B Two way 
repeated measures ANOVA with post-hoc Sidak’s test. For C paired T-test. N=7 cells 
from one coverslip. *=P<0.05, **=P<0.01. 
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5.3.9 Acetazolamide manipulates the ATP/ADP ratio 
Utilising the carbonic anhydrase inhibitor acetazolamide, which has previously 
been shown to reduce Na+/K+ ATPase activity choroid plexus and CSF 
secretion, it was aimed to determine if the current assay can replicate previous 
results (Oshio et al., 2004; Sterling et al., 2001; Uldall et al., 2017). Z310 cells 
were incubated for two days either with vehicle (DMEM) or 100μM 
acetazolamide prior to imaging. Ouabain administration elucidated a smaller 
change in F/Fmin in acetazolamide treated cells compared to vehicle treated 
cells (0.007(0.0103) Vs. 0.024 (0.0318); P=0.029) (Fig5.8b). Furthermore, the 
AUC is smaller for acetazolamide treated Z310’s compared to vehicle treated 
cells (0.0447 (0.3452) Vs. 0.61(0.378); P=0.044) (Fig5.8c). This data indicates 
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Figure 5.8 Acetazolamide decreases Na+/K+ ATPase activity in Z310 cells 
Z310 cells infected with adenovirus harbouring adenovirus and were treated with 
acetazolamide (100μM) or vehicle for two days. (A) Perceval F/Fmin trace of vehicle 
treated cells (blue) and acetazolamide treated cells (red). (B) The change in ATP/ADP 
maximum following ouabain. (C) The AUC of both treatments over the course of the 
recording. (D) Represents individual cell F/Fmin over the course of the recording. Mann-
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5.3.10 Furosemide 
Furosemide, an inhibitor of the NKCC1 and KCC transporters, is utilised as a 
treatment to reduce ICP. However, it is not understood whether its activity is 
independent of the Na+/K+ ATPase, considering its outward facing nature in 
choroid plexus. Z310 cells were incubated with 100μM furosemide for two days 
prior to imaging. There is no difference between the change in F/Fmin between 
vehicle and furosemide treated cells (0.014(0.017) Vs. 0.016(0.017), P=0.76) 
upon acute ouabain administration (Fig5.9b). AUC is indistinguishable between 
vehicle and furosemide treated groups (0.58(0.29) vs 0.54(0.24); P=0.46) 
(Fig5.9c). These data indicate that furosemide does not alter Na+/K+ ATPase 
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Figure 5.9 Furosemide does not alter Na+/K+ ATPase activity in Z310 cells 
Z310 cells infected with adenovirus harbouring Perceval and were treated with 
Furosemide (100μM) or vehicle for two days. (A) Perceval F/Fmin trace of vehicle 
treated cells (blue) or furosemide treated cells (red). (B) Represents change in 
ATP:ADP ratio following ouabain administration. (C) The AUC is indistinguishable 
between the treatment groups. (D) Represents individual cell F/Fmin over the course of 
the recording. Mann-Whitney U test for B, students T-test for C. N=27 cells from 4 
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5.3.11 Perceval can distinguish between drugs  
To assess whether this assay is suitable to compare between drugs the change 
in fluorescence was compared between acetazolamide and furosemide after the 
result was made relative to the appropriate control. We found that 
acetazolamide was more effective at reducing Na+/K+ ATPase activity 
compared to furosemide (41.1(122.6) Vs. 73.74(129.7)%; P=0.03) (Fig5.10). 
This highlights that Perceval in Z301 cells has the dynamic range to distinguish 
between the effectiveness of different drugs. 
 
Figure 5.10 Acetazolamide is a more effective manipulator of Na+/K+ 
ATPase activity than Furosemide 
Comparison of change in F/Fmin between acetazolamide and furosemide treated Z310 
cells relative to respective vehicle. Dotted line at 100% represents control. Mann-
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5.3.12 In vivo comparison  
To determine whether the Na+/K+ ATPase inhibitor activity of the drugs 
assessed corresponds to an effect on ICP, and to assess their capability to 
modulate ICP at clinically relevant doses, acetazolamide and furosemide were 
evaluated in a validated in vivo ICP monitoring model. 
5.3.13 Hypertonic Saline decreases ICP 
Different salinities were required to dissolve the various quantities of 
acetazolamide, generating different vehicles. Consequently the 0.9% saline was 
compared to the 2% and 4% saline in the in vivo ICP monitoring model.  
Compared to their respective baseline measurement, neither 0.9% or 2% saline 
reduced ICP. When comparing overall pressure change between all groups, 4% 
saline differs significantly (P<0.0001) compared to both 2% and 0.9% saline, 
whereas 0.9% and 2% saline have no difference in pressure (P=0.28) 
(Fig5.11a). AUC analysis highlights that 4% saline has a significantly smaller 
AUC (63.8±9.1) compared to 0.9% saline (100±2.4) (P=0.007) whereas 2% 
saline (92.2±8.9) is not different to 0.9% saline (Fig5.11b). However, 4% saline 
decreases ICP relative to baseline at 60 minutes, therefore ICP is significantly 
reduced (-1.1±0.3mmHg, P=0.017)(Fig5.11c). The pressure continues to 
decrease to the end of the recording at 120 minutes (-1.433±0.313mmHg, 
P=0.0005). These data highlight that 4% saline is effective at reducing ICP over 
the time period measured. 
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Figure 5.11 Hypertonic saline decreases ICP in normal pressure rats 
Intracranial pressure measurements (ICP) in rats following subcutaneous (SC) 
injections of 0.9% (blue), 2% (green) and 4% (red) saline. (A) ICP traces over 120 
minute recording, where 0 is time of injection. Dotted line represents no change in ICP. 
(B) AUC for the whole length of the recording in A. (C) graph detailing the pressure 
change in 4% saline relative to baseline. Two–way ANOVA with Tukey’s post-hoc test 
comparing pressure in each group for A. One-way ANOVA with post-hoc Dunnett’s test 
for B. Two-way repeated measures ANOVA with post-hoc Dunnett’s test for C .N=5 for 
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5.3.14 Acute acetazolamide administration does not alter ICP 
Acetazolamide was tested at two doses, a clinically equivalent dose 
(103.3mg/kg) and a high (413.4mg/kg) dose, equivalent to a daily maximal dose 
in humans achieved in the IIH treatment trial (Wall et al, 2014). At the clinically 
equivalent dose, the acetazolamide trace does not alter ICP compared to 2% 
saline, where there is no difference in the AUC with low dose acetazolamide 
relative to 2 % saline (80.8±5.1 vs 100±9.7 %; P=0.1) (Fig5.12b).  
 
However, high dose acetazolamide has a similar ability to reduce ICP compared 
to baseline as 4% saline, where a significant reduction on pressure is observed 
45 minutes after injection (-0.895±0.322 mmHg; P<0.001) (Fig5.13c). The 
decrease in pressure is maintained for the remainder of the recording, where at 
120 minutes pressure is reduced (-1.433±0.392 mmHg; P<0.0001) compared to 
baseline. This is probably a function of the vehicle due to no differences 
between vehicle and acetazolamide existing (see Fig5.11). At high dose, 
acetazolamide does not alter ICP compared to 4% saline, (Fig5.13b) where 
there is no difference in the AUC with high dose acetazolamide relative to 4 % 
saline (80.2±19.18 vs 100±10.03%; P=0.1). These data indicate that high dose 
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Figure 5.12 Clinically equivalent acetazolamide does not alter ICP in 
normal pressure rats 
Intracranial pressure measurements in rats following subcutaneous (SC) injections of 
2% saline (green) and acetazolamide (103.3 mg/kg) (grey). (A) ICP trace of both 
treatment over 120 minutes where 0 is time of injection. Dotted line represents no 
change in ICP. (B) AUC for the whole length of the recording in A. Two way repeated 




Page | 191 
 
 
Figure 5.13 High dose acetazolamide has no pharmacological effect on 
ICP in normal pressure rats 
Intracranial pressure measurements in rats following subcutaneous (SC) injections of 
4% saline (red) and a high dose of acetazolamide (413.4 mg/kg) (grey). (A) ICP trace 
of both treatment over 120 minutes where 0 is time of injection. Dotted line represents 
no change in ICP. (B) AUC for the whole length of the recording in A. (C) 
Acetazolamide compared to baseline. Two-way repeated measures ANOVA with post-
hoc Sidak’s test for A. Students T-test for B. Two-way repeated measures ANOVA with 
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5.3.15 Furosemide does not acutely alter ICP 
The acute effects of the NKCC1 cotransporter inhibitor furosemide on ICP were 
assessed. The appropriate vehicle (0.9% saline) was compared to a clinically 
equivalent dose (4.1mg/kg) and high dose (24.8mg/kg) furosemide. ICP trace 
highlights that furosemide does not alter ICP when compared to the vehicle 
(Fig5.14a). AUC does not differ between saline (100±5.4) and high dose 
furosemide (86.8±17.6%; P=0.27) or clinically equivalent furosemide 
(101.2±16.68%; P=0.99) (Fig5.14b). Data highlights that furosemide does not 
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Figure 5.14 Furosemide does not alter ICP in normal pressure rats 
Intracranial pressure measurements in rats following SC injections of vehicle (0.9% 
saline) (blue), high dose furosemide (24.8mg/kg) (pink) and low dose furosemide 
(4.1mg/kg) (grey). (A) ICP traces detailing no difference in pressure between saline 
and high dose furosemide and low dose furosemide. (B) AUC for the course of the 
recording in A. Two-way repeated measures ANOVA with post-hoc Dunnett’s test for A. 
One-way ANOVA with post-hoc Dunnett’s test for B. N=5 for all groups. 
  
  




5.4.1 Development of an in vitro Na+/K+ ATPase activity 
In this work, a novel in vitro Na+/K+ ATPase activity was developed utilising the 
biosensor Perceval. It was successfully demonstrated that ouabain can elicit an 
increase in the ATP:ADP ratio, indicating that the ATP production relating to 
Na+/K+ ATPase ATP utilisation can be detected by the Perceval biosensor. 
This novel assay has several advantages over previous assays. Primarily, the 
Perceval assay allows the underlying cellular biochemistry to be maintained 
with continuous recording, this facilitates temporal analysis pharmacological 
agents on Na+/K+ ATPase activity. Moreover, temporal analysis allows for an 
individual cell’s baseline to be taken into account, removing cell-to-cell 
variability at baseline as a confounding factor in analysis.  
The reversibility of ouabain mediated Na+/K+ ATPase inhibition demonstrates 
specific reversible inhibition that allows for complex experimental designs where 
multiple pharmacological agents could be assessed, including experiments 
assessing rapid changes in Na+/K+ ATPase activity. The fluorescent modality of 
the assay predisposes its use in high-throughput plate based assays, a 
potential route for future assay development. 
There are however limitations with the current assay. Primarily, Perceval was 
introduced into Z310 cells via a functionally active adenovirus, consequently 
cellular metabolism is likely perturbed by intracellular virion assembly, meaning 
that the current results should be interpreted with caution. Furthermore the use 
  
Page | 195 
 
of the virus reduces the practicality of the assay due to the need to maintain 
viral stocks and infect cells for every assay. In the future, stable transfection of 
the Perceval biosensor into Z310 cells would allow for a more practical assay 
that enables Z310 cells to maintain a more physiological phenotype, in 
particular metabolism, unperturbed by viral load. Additionally, the current assay 
assumes that the Na+/K+ ATPase activity is the primary facilitator of CSF 
secretion at the choroid plexus, whereas other factors have been identified that 
contribute to CSF secretion. The present assay presents with a small change in 
fluorescence upon ouabain addition, roughly 4-5% in untreated conditions, this 
represents a small change relative to baseline. However the variant of Perceval 
utilised has a relatively small dynamic range and saturates at low ATP:ADP 
ratio, around 10, with low fluorescent resolution, whereas mammalian cells can 
have much larger ATP:ADP ratios, up to 100 (Berg et al., 2009; Tantama et al., 
2013). Consequently the Perceval variant utilised is perhaps suboptimal for use 
in the present assay as the addition of ouabain is likely saturating the biosensor. 
Development of this assay with a higher range variant, PercevalHR, would 
facilitate experiments with better resolution and perhaps allow greater changes 
in the ATP:ADP ratio to be observed following ouabain administration (Tantama 
et al., 2013).  Carrying out this assay in primary choroid plexus epithelial cells 
would facilitate further validation as other Na+/K+ ATPase activity assays could 
be utilised to confirm results (Botfield et al., 2017; Uldall et al., 2017).  
Assessment of the infection efficacy though assessing plaque forming units and 
Perceval expression via PCR would provide important information for 
experimental replication. 
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5.4.2 Pharmacological manipulation of in vitro Na+/K+ ATPase activity 
Following establishment of the Na+/K+ ATPase activity assay, functional studies 
were carried out to validate the function of the assay. It was demonstrated that 
acetazolamide decreases Na+/K+ ATPase activity following a two day 
incubation, matching previous data using a different Na+/K+ ATPase  activity 
assay in primary choroid plexus epithelial cells, thus validating the activity of the 
assay (Uldall et al., 2017). This highlights that carbonic anhydrase activity is 
fundamental in driving Na+/K+ ATPase activity and confirming the utility of the 
assay. However these data do not assess who acetazolamide elicits its action 
on the Na+/K+ ATPase, assessing bicarbonate transport and changes in 
intracellular pH will help elucidate this mechanism further (Sterling et al., 2001).    
Conversely, it was demonstrated that furosemide does to supress Na+/K+ 
ATPase activity in Z310 cells, in contrast to the renal proximal tubule, where 
furosemide indirectly inhibits the Na+/K+ ATPase through a reduction in 
available sodium ions (Grossman and Hebert, 1988). This is perhaps 
unsurprising considering recent work has identified that the NKCC1 channel, 
the target for furosemide, functions as an efflux pump on the apical membrane 
of the choroid plexus. This functions to efflux sodium, potassium and chloride 
ions, rather than facilitating the influx the aforementioned ions as previously 
thought (Steffensen et al., 2018). In the context of Na+/K+ ATPase activity at the 
choroid plexus, this would suggest that the NKCC1 channel is not contributing 
to the ion gradient  that the Na+/K+ ATPase requires for function. It has also 
been demonstrated that NKCC1 activity corresponds with CSF secretion in vivo: 
consequently experimental approaches combining both Na+/K+ ATPase activity 
  
Page | 197 
 
and NKCC1 activity assays would further elucidate the effect of drugs on CSF 
secretion (Steffensen et al., 2018). This highlights that the present assay can 
only assay drugs that either modulate the Na+/K+ ATPase or alter processes 
contributing to the ionic gradient facilitating Na+/K+ ATPase activity.  
5.4.3 In vivo assessment of drugs on ICP 
To determine the physiological relevance and validate the novel Na+/K+ ATPase 
activity assay, in vitro experiments were validated in a rodent ICP model. Prior 
to assessment of pharmacological agents, the vehicles were assessed due 
differing osmolalities. The current data highlights that hypertonic saline 
decreases ICP, which is in keeping with current clinical practice, most likely due 
to a reduced osmotic gradient in the CP blood vessels (Mortazavi et al., 2012). 
The current data also demonstrates that at clinically relevant doses, 
acetazolamide has no pharmacological effect on ICP in rats: this is not 
congruent with previous data which suggests that acetazolamide reduces ICP in 
rats (Uldall et al., 2017). However, the previous study does not use a clinically 
relevant dose of acetazolamide, but instead uses a large dose of 769-869 
mg/kg, double the current dose of this study. Furthermore, the previous study 
uses 0.9% saline as a control, which the current study identifies as an 
inappropriate vehicle for acetazolamide. Consequently, the current study 
provides physiologically relevant data on acetazolamide in rats, highlighting it 
has no pharmacological effect at the concentrations used. 
The current study demonstrates that a subcutaneous dose of furosemide does 
not alter ICP. This could be due to the apical membrane position of the NKCC1 
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on choroid plexus epithelial cells (Steffensen et al., 2018). Previous studies 
indicate that furosemide and loop diuretics in its class only inhibit the NKCC1 
channel when applied to the ventricular surface of the choroid plexus. This 
demonstrates that furosemide cannot penetrate the blood cerebrospinal fluid 
barrier at sufficient concentrations to elicit an acute response (Karimy et al., 
2017; Vogh and Langham, 1981). Although furosemide can inhibit CSF 
secretion at supra-clinical doses (50mg/kg), this is most likely through weak 
carbonic anhydrase inhibition, rather than through directly inhibiting the NKCC1 
channel (Vogh and Langham, 1981). These previous data and the current study 
highlight that acute furosemide administration does not reduce ICP through 
clinically relevant doses and delivery methods. 
5.4.4 Disparity between Na+/K+ ATPase assay and in vivo ICP   
measurements 
The in vitro acetazolamide data is not congruent with the in vivo data. It is 
possible that the acetazolamide concentration utilised in the in vitro assay 
exceeds the concentration that the clinically relevant dose of acetazolamide 
could achieve at the choroid plexus in vivo. Indeed, when administered 
intravenously, brain acetazolamide concentrations reach 30% of the plasma 
max, indicating relative lipophobicity (Ichikawa et al., 1998). Consequently, this 
indicates that acetazolamide may not exit the subcutaneous depot 
appropriately, suggesting that subcutaneous administration of acetazolamide is 
unsuitable for acetazolamide. However, when acetazolamide is administered 
orally, a clinically relevant route, it does not lower ICP when given at clinically 
relevant doses in rats (Scotton et al., 2018a). Together these suggest that 
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clinically relevant delivery routes are not suitable for acetazolamide at clinically 
relevant doses.  
Furthermore, the effects of these drugs on other aspects of CSF dynamics are 
not fully understood; although drugs have the potential to reduce Na+/K+ 
ATPase activity in normal physiology, ICP is strongly regulated, through 
changes in cerebral blood flow or alterations in drainage. Furthermore, 
acetazolamide might not be effective at modulating ICP in healthy ranges. In a 
situation where ICP is pathologically raised, drugs observed to decrease Na+/K+ 
ATPase activity may decrease ICP. As such, further in vivo experimentation to 
investigate the role of drugs in a model of raised ICP, such as kaolin induced 
hydrocephalus, which has been used successfully to identify novel ICP reducing 
agents, could identify the role of acetazolamide and furosemide in modulating 
raised ICP (Botfield et al., 2017). Consequently, the current study is only 
applicable to normal pressure rats. Additionally, these studies are based on a 
single dose; future studies with chronic, multiple dosing of these drugs would be 
informative on their role in regulating ICP. 
In summary, the Perceval assay is a novel in vitro assay that determines Na+/K+ 
ATPase activity in immortalised choroid plexus epithelial cells. However, this 
data cannot currently be generalised to ICP modulation because the drugs 
tested do not elicit an effect due to their pharmacological availability. This 
Perceval assay has the potential for drug screening studies to identify novel 
modulators of Na+/K+ ATPase activity.  
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Chapter 6 Evaluating the Role of 
Testosterone in CSF Secretion 
  
  
Page | 201 
 
6.1 Introduction 
The pathogenesis of IIH remains unclear. The primary symptom of the 
pathogenesis is raised ICP which drives the common symptoms of IIH, 
headache and papilloedema. Consequently, studies investigating IIH attempt to 
understand the cause of the raised ICP. Several molecules have been 
hypothesised to be causative in the raised ICP in IIH, but there have been 
limited in vitro studies assessing these putative pathogenic molecules. 
One putative pathogenic molecule in IIH is testosterone. Recent data highlights 
a distinct androgen profile in IIH patients, of reduced serum androstenedione, 
and raised serum testosterone, indicative of increased systemic 17β-
hydroxysteroid dehydrogenase (17β-HSD) activity. Moreover, IIH patients have 
raised cerebrospinal fluid (CSF) testosterone and androstenedione (Appendix 
1) (O’Reilly et al., 2019). Furthermore, several case reports highlight that 
female-to-male gender reassignment patients receiving therapeutic testosterone 
can develop IIH, where the IIH resolves temporally with testosterone withdrawal 
(Hornby et al., 2017). In line with this, androgen excess is associated with 
earlier onset of IIH (Klein et al., 2013). These data together highlight 
testosterone as a potential pathogenic molecule in IIH. 
There is, however, no literature describing the effects of testosterone on CSF 
secretion or intracranial pressure. Interestingly, it has been demonstrated that 
testosterone increases intraocular pressure, whose fluid secretion system is 
analogous to secretion at choroid plexus epithelial cells (Kass and Sears, 1977; 
Toker et al., 2003). Similarly, oestrogen has been demonstrated to decrease 
intraocular pressure and  Na+/K+ ATPase  activity, a surrogate for CSF 
  
Page | 202 
 
secretion, suggesting that the effects of sex steroids on intraocular pressure is 
mirrored by proposed changes CSF secretion (Dewundara et al., 2016; Kass 
and Sears, 1977; Lindvall-Axelsson and Owman, 1989).  
Furthermore, there is limited evidence describing the expression of the 
enzymes and receptors that metabolise and respond to sex hormones in the 
choroid plexus (CP). The presence of aromatase has been described in human 
CP  but its activity has not been assessed (Ishunina et al., 2005). As such, the 
expression of sex steroid metabolising enzymes in CP needs to be evaluated 
prior to assessing whether testosterone could alter CSF secretion. This chapter 
details the characterisation of androgen metabolising enzymes in both human 
and rodent CP and an assessment of the effects of testosterone on Na+/K+ 
ATPase activity as a basis for future studies. 
6.1.2 Hypothesis 
Given that IIH patients have a unique androgen excess phenotype and that 
testosterone is potentially causative in intracranial hypertension in female-to-
male gender reassignment patients, it is hypothesised that the choroid plexus 
expresses the enzymatic pathway capable of producing testosterone as a 
mechanism to modulate Na+/K+ ATPase activity. 
6.1.3 Aims 
1. Characterise the mRNA expression of sex steroid metabolising enzymes 
in the choroid plexus 
2. Assess effects of testosterone on Na+/K+ ATPase activity 
  
  




6.2.1 Z310 cell culture 
Z310 cells (see section 2.1) were cultured in DMEM supplemented with 10% 
foetal calf serum, 1% Penicillin/streptomycin and 1ng/ml epidermal growth 
factor at 37ºC with 5% CO2. For microscopy, Z310 cells were cultured to 
confluence on either 8-well culture slides or 25 mm diameter glass coverslips 
(VWR, Leighton Buzzard, UK) seeded with poly-D-lysine and incubated with 
laminin as described in section 2.8 and 2.19. 
6.2.2 Human tissue and RNA 
Human choroid plexus derived from the Parkinson’s UK Brain Bank (Imperial 
Collage London) arrived in RNA later and stored immediately in -80ºC(section 
2.6 for more detail). See table 6.1 for donor characteristics. Commercial human 
RNA, derived from non-diseased tissue were utilised as control tissue from both 
Agilent (Agilent biotechnologies, Craven Arms, UK) and AMS (AMS 












Table 6.1 Characteristics of donor derived choroid plexus 
 Age in years, M=male, F=female. 
 
Sample Sex Age 
Liver 1 P 43 
Liver 2 F 43 
Liver 3  F 33 
Adrenal 1 P 25 
Adrenal 2 M 60 
Adrenal 3 M 49 
Ovary 1 F 47 
Ovary 2 F 20 
Ovary 3 F 37 
 
Table 6.2 Characteristics of control tissue donors 
Age in years, mix represents pooled donors, P=mixed pooled sample, M=male and 
F=female. 
 
6.2.3 Rat tissue 
Female Sprague-Dawley rats (Charles-river) weighing between 175g-200g  
were sacrificed via rising CO2 concentration and the choroid plexus from the 
lateral and fourth ventricles as well as whole adrenal and ovary were dissected 
out. Tissue was snap frozen in liquid nitrogen and transferred to a -80ºC freezer 
prior to RNA extraction. Rats were housed in the Biomedical Service Unit 
(University of Birmingham) in accordance with the Animals and Scientific 
Patient ID Disease Sex Age 
CO87 No disease F 84 
CO88 No disease M 94 
MS620 Multiple sclerosis F 88 
PD847 Parkinson’s disease F 82 
PD858 Parkinson’s disease M 90 
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Procedures Act 1986, licensed by the UK Home Office and approved by the 
University of Birmingham Ethics Committee in a 12 hour light/dark cycle with ad 
libitum access to food and water. 
6.2.4 RNA extraction  
RNA was extracted from human and rat choroid plexus using the Genelute total 
RNA kit, where tissue was mechanically homogenised prior to the column 
steps. Z310 cells had RNA extracted via five minute incubation in lysis buffer 
prior to column steps. RNA was then converted to cDNA using the high-capacity 
cDNA kit as described in section 2.7.5. 
6.2.5 RT-qPCR 
RT-qPCR was carried out as previously described in section 2.7.6 Details of 
primer/probe sets can be found in appendix 2.  
6.2.6 Immunocytochemistry 
Z310 cells were cultured and processed as described in section 2.8. In brief, 
Z310 cells were cultured on 8 well culture slides for two days. Z310 cells were 
sequentially fixed, permiabilised, blocked and incubated with primary and 
secondary antibody prior to mounting with media containing DAPI as a 
counterstain.  Z310 cell images were taken on a Zeiss Axioplan 2 imaging 
epifluorescent microscope (Carl Zeiss) and a AxioCam Hrc (Carl Zeiss) was 
used to view and capture images. Antibody information including dilutions can 




















mouse Ig  
(Alexa 
594) 




Table 6.3 Antibody concentration table 
Antibody reactivity, m=mouse, r=rat and h =human. 
 
6.2.7 Live cell microscopy  
Live cell microscopy was carried out according to the method in section 2.19. In 
brief Z310 cells infected with an adenovirus containing the biosensor Perceval 
were grown to confluence prior to imaging on a confocal microscope. Z310 cells 
were incubated with testosterone (100 nM) or vehicle for 48 hours prior to 
treatment with ouabain (1 mM) to resolve Na+/K+ ATPase activity. Assessor was 
blinded to the treatment of the cells during evaluation of cell fluorescence 
intensity. 
6.2.8 ATP production rate 
To determine the arbitrary cellular ATP production rate in Z310 cells, the slope 
on the trace was measured as the following for each cell ((F/Fmin value at end of 
recording – F/Fmin value at addition of ouabain) / length of time ouabain 
present), where F= fluorescence at a specific time point and Fmin= minimal 
fluorescence in the trace. 
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6.2.9 Statistics 
GraphPad prism (V7.1) was utilised for statistical analysis where P<0.05 was 
considered significant. Students T-test or Mann-Whitney U-Test subject so 
Shapiro-Wilk normality test. Data presented as mean±SEM unless otherwise 








6.3.1 Human choroid plexus expresses steroidogenic enzymes 
To determine whether human CP has the capacity metabolise androgens, CP 
from aged, mixed sex and diseased post-mortem donors were probed via RT-
qPCR to determine the presence of sex steroidogenic enzymes (Fig6.1). 
Human CP expresses 3BHSD2 (Fig6.1a) at low levels compared to the other 
tissues assessed. Human CP expresses the 17βHSD enzymes 17β-HSD5 
(AKR1C3) and 17BHSD3 (Fig6.1b and c) at levels comparable to the liver, 
suggesting the CP is an androgen activating tissue. Furthermore human CP 
expresses 5α-reductase (SRD5A1, SRD5A2) (Fig6.1d and e), suggesting the 
ability to generate the more potent androgen dihydrotestosterone. Aromatase 
(CYP19A1) (Fig6.1f) expression is negligible in human CP. The CP does not 
express CYP11B1 (Fig6.1g) or AKR1D1 (Fig6.1h) suggesting an inability to 
generate 11-oxygenated androgens or 5-β reduced steroid metabolites. 
 
  
Page | 209 
 
 
Figure 6.1 Human choroid plexus expresses androgen metabolising 
enzymes 
RT-qPCR on human tissue to determine the expression of sex steroid metabolising 
enzymes in the choroid plexus (CP), (A) 3BHSD2, (B) AKR1C3, (C) 17BHSD3, (D) 
SRD5A1, (E) SRD5A2, (F) CYP19A1, (G) CYP11B1 and (H) AKR1D1. Data presented 
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6.3.2 Human choroid plexus expresses androgen receptor  
To determine whether human CP has the potential to respond to sex steroids, 
the mRNA expression of cognate receptors for sex steroids was assessed. 
Human CP expresses androgen receptor (AR) (Fig6.2a) and oestrogen 
receptors ESR1 and ESR2 (Fig6.2b and c). 
 
Figure 6.2 Human choroid plexus expresses cognate sex steroid 
receptors 
RT-qPCR on human tissues to determine the expression of (A) AR, (B) ESR1 and (C) 
ESR2 in human CP. Data presented as arbitrary units (AU) Mean+SEM, N=5 for 
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6.3.3 Rat choroid plexus expresses steroidogenic enzymes 
For comparative purposes, CP from female rats were probed via RT-qPCR for 
the expression of sex steroidogenic enzymes. Rat CP expresses 17βHSD 
enzymes Akr1c3 and 17bhsd3, Z310 cells also demonstrate amplification of the 
17β-HSD genes (Fig6.3a and c). Rat CP and Z310 cells expresses both 5α-
reductase (Srd5a1) and aromatase (Cyp19a1) (Fig6.3 b and c). 
 
Figure 6.3 Rat choroid plexus expresses androgen metabolising enzymes 
RT-qPCR on whole female rat tissues and Z310 cells to determine the expression of 
(A) Akr1c3, (B) Srd5a1, (C) 17bhsd3 and (D) Cyp19a1 in CP and Z310 cells. Data 
presented as arbitrary units (AU) mean+SEM N=3 animals or 3 independent passages. 
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6.3.4 Rat choroid plexus expresses cognate sex steroid receptors 
The expression of cognate sex steroid receptors was assessed in rat CP. 
Female rat CP expresses Ar and Esr1 at comparable levels, with Esr2 being the 
lowest expressed (Fig6.4 a-c). Z310 cells display minimal expression of sex 
steroid receptors, however, immunofluorescence highlights immune reactive 
androgen receptor present in discrete cytoplasmic loci (Fig6.4d). No IgG control 
can be found in appendix 7. 
 
Figure 6.4 Rat choroid plexus expresses cognate sex steroid receptors 
RT-qPCR on whole female rat tissues and Z310 cells to determine the expression of 
(A) Ar, (B) Esr1 and (C) Esr2 in CP and Z310 cells. (D) Immunofluorescence staining 
for androgen receptor (AR) where DAPI represents nuclei. Insert represents a single 
cell. Scale bars represent 50 μm and 10 μm in insert images. Data presented as 
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6.3.5 Testosterone increases Na/K ATPase activity 
The effect of testosterone on Na+/K+ ATPase activity was assessed in Z310 
cells (Fig6.5a). Following two days of testosterone (100 nM) incubation, there 
was an increase in the ATP/ADP ratio change compared to control 
(Δ0.042(0.07) Vs. Δ0.01(0.022); P<0.0001), following acute ouabain 
administration (Fig6.5b). Furthermore, area under the curve (AUC) analysis 
highlights that testosterone treated Z310 cells have a higher AUC compared to 
controls (0.81(0.53) Vs 0.58(0.27); P<0.01) (Fig6.5c). These data indicate that 
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Figure 6.5 Testosterone increases Na+/K+ ATPase activity 
Z310 cells infected with adenovirus harbouring adenovirus and were treated with 
testosterone (100 nM) or vehicle for two days. (A) Perceval F/Fmin trace of vehicle 
treated cells (blue) or testosterone treated cells (red). (B) The change in ATP/ADP 
maximum following ouabain. (C) The area under the curve of both treatments over the 
course of the recording (20 minutes). (D) Individual cell F/Fmin over the course of the 
recording. Mann-Whitney U-test for B and C. **=P<0.01, ****=P<0.0001. N=30-39 cells 
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6.3.6 Testosterone increases ATP production in Z310 cells 
The ATP production rate was assessed in Z310 cells with and without 
testosterone treatment. Testosterone treated Z310 cells had a greater slope 
gradient compared to vehicle treated cells (0.24(0.41) vs. 0.12(0.19); P<0.001), 
indicating an increased rate of ATP production (Fig6.6).  
 
Figure 6.6 Testosterone increases ATP production in Z310 cells 
Slope gradient of the ouabain incubation period on live cell trace. Mann-Whitney U-test. 
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6.3.7 Testosterone increases carbonic anhydrase expression 
Proteins known to modulate Na+/K+ ATPase activity, Atp1a1, Car2 and Car3, 
had gene expression assessed after a 48 hour incubation with testosterone, the 
time point that Na+/K+ ATPase activity was assessed. Expressed as fold 
change, no change in expression was observed for Atp1a1 (1.6±0.2; P=0.06), 
whereas both Car2 (2.36±0.32; P<0.025) and Car3 (2.8±0.39; P<0.015) 
displayed increased expression (Fig6.7). 
 
ΔCt Control Testosterone 
Atp1a1 12.7 12.1 
S.E.M 1.82 1.82 
Car2 19.23 17.99 
S.E.M 1.39 1.47 
Car3 18.79 17.28 
S.E.M 1.64 1.55 
Figure 6.7 Testosterone increases carbonic anhydrase expression 
RT-qPCR on Z310 cell treated with 100nM testosterone for 48 hours, where Atp1a1, 
Car2 and Car3 expression was interrogated. Dotted line represents vehicle. Data 
expressed as fold change±S.E.M, T-tests ran on ΔCt values. Table details ΔCt values.  
.N=3 biological replicates. *=P<0.05.   
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6.4 Discussion  
 
6.4.1 The choroid plexus as peripheral organ of steroid activation 
An aim of the present study was to characterise the expression of steroid 
metabolising enzymes within the CP. This work demonstrates both rodent and 
human CP expresses, at the mRNA level, the genes responsible for the 
peripheral activation of classical androgens. However, the lack of expression of 
CYP11B1 and 11β-HSD2 suggests the inability to generate and activate 11-
oxygenated androgens (Sinclair et al., 2010b). Although the present data 
demonstrates negligible expression of aromatase in human CP, a previous 
study identified protein expression (Ishunina et al., 2005). Furthermore the 
presence of cognate sex steroid receptors suggests that the choroid plexus has 
the capacity to respond to androgens and oestrogens. However, this work fails 
to confirm the expression of the steroidogenic genes at both the protein level 
and at the enzyme activity level, as such these experiments need to be carried 
out. The exception is with androgen receptor in Z310 cells, where the 
demonstration of androgen receptor corroborates previous work (Costa et al., 
2016). These data together, with the previous demonstration of active 11β-
HSD1 in both human and rabbit choroid plexus, suggests that the choroid 
plexus is a peripheral organ of steroid hormone metabolism (Sinclair et al., 
2010b, 2007).  
The expression of 5α-reductase enzymes has further implications for the steroid 
environment of the central nervous system. 5α-reductase enzymes are able to 
metabolise not only testosterone to the more potent androgen 
dihydrotestosterone but also modify other steroid classes to their 5α-metabolites 
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(Reddy, 2010). It has been demonstrated that within the brain, 5α-reduced 
cortisone and progesterone undergo a subsequent 3α-reduction, generating 
potent modulators of GABAergic and glutamatergic receptors, which potentiate 
and inhibit receptors depending on the steroid species (Reddy, 2010). As such, 
it could be suggested that the choroid plexus has a role in modulating the 
excitability of neurons through supplying precursor 5α-reduced steroids, through 
the CSF to neocortical and circumventricular regions, where 3α-reductase 
expression has been demonstrated (Stoffel-Wagner et al., 2003). Further work 
to identify whether the choroid plexus generates 5α-reduced steroids and 
assess the choroid plexus’ contribution to steroid mediated neuro-modulation 
would be worthwhile.  
The human CP RT-qPCR data should be interpreted with caution, due to the 
tissue originating from post-mortem samples from elderly donors with a mixture 
of disease states and mixed sex. Obtaining fresh tissue from younger and 
healthier individuals would provide a more comprehensive understanding of the 
expression of these genes in normal physiology. Furthermore, expression of 
steroidogenic enzymes was not directly assessed in choroid plexus epithelial 
cells, highlighting a requirement to assess this in future experimentation, 
particularly because of the differences seen in gene expression between Z310 
cells and whole choroid plexus.  
6.4.2 Androgens and Na+/K+ ATPase activity  
A further objective of the present study was to assess the effects of 
testosterone on Na+/K+ ATPase activity in Z310 cells. The novel Na+/K+ ATPase 
activity assay determined that testosterone increases Na+/K+ ATPase activity in 
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Z310 cells, suggesting that testosterone could increase CSF secretion and ICP, 
thus be pathogenic in IIH as previously proposed (Hornby et al., 2017). Gene 
expression analysis suggests that testosterone treatment increases carbonic 
anhydrase expression, providing a potential mechanism for a testosterone 
mediated increase in Na+/K+ ATPase activity: increased carbonic anhydrase 
expression generates a higher proton gradient, allowing for greater movement 
of sodium across the CP epithelial cell driving osmosis and CSF secretion. This 
corroborates previous work suggesting expression of carbonic anhydrases is 
under control of androgens (Jeffery et al., 1984). Assessing carbonic anhydrase 
activity in Z310 cells following testosterone incubation utilising an oxeograph to 
measure extracellular acidification rate would confirm this mechanism, through 
indirectly assessing extracellular carbonic acid accumulation and confirm the 
ATP production rate through assessing oxygen consumption.  
Increased ATP production, facilitated by the anabolic action of testosterone, 
could also be potentiating the increased Na+/K+ ATPase activity independently 
of gene expression changes, through providing more substrate for the Na+/K+ 
ATPase. The current data does not assess the ability of testosterone to 
modulate ICP in rodents or the effects of testosterone on Na+/K+ ATPase 
activity in both human or in the more physiologically relevant primary rodent 
choroid plexus epithelial cells, highlighting avenues for future study. 
6.4.3 Testosterone and ICP in IIH patients 
The choroid plexus lies at the interface of both the blood and the CSF 
compartments. In IIH where there is raised serum and CSF testosterone, it is 
plausible that testosterone is acting to increase CSF secretion. Furthermore, the 
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increased CSF androstenedione (Appendix 1) in IIH patients and the presence 
of AKR1C3 in human choroid plexus suggests that androstenedione could be 
activated in to testosterone, further increasing CSF secretion (Fig6.8). This 
data, however, presents a paradox: if high levels of testosterone increase ICP, 
males should have pathologically raised ICP. However, studies suggest males 
that develop IIH have hypoandrogenism rather than hyperandrogenism (Fraser 
et al., 2010). Indeed, it has been hypothesised that androgen concentrations 
that constitute male hypoandrogenism and female hyperandrogenism pose 
heightened metabolic risk, where IIH and raised ICP could fall within this 
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Figure 6.8 Suggested action of testosterone at the choroid plexus in IIH 
In IIH patients, where there is raised serum testosterone, it is hypothesised that the 
testosterone (T) diffuses into the CP, acting to increase the expression of carbonic 
anhydrases 2 and 3 (CAII and CAIII) where the increase in ionic gradients drives the 
activity of the Na+/K+ ATPase, increasing CSF secretion. Furthermore, it is 
hypothesised that the raised CSF androstenedione (A4) in converted to T in CP 
epithelial cells, increasing T exposure, further increasing CSF secretion. 
 
This data does not exclude other effects of testosterone on ICP dynamics or 
claim that testosterone is the only pathogenic molecule in IIH. It was recently 
demonstrated that IIH patients have astrogliosis, suggesting a reactive 
inflammatory state within their cerebral parenchyma (Eide et al., 2016). 
Interestingly, increased astrogliosis was negatively correlated with aquaporin 4 
expression at astrocyte end feet, suggesting that glymphatic drainage could be 
impaired in IIH patients. Furthermore, it was demonstrated in female rats that 
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testosterone excess can induce astrocyte expansion (Chowen et al., 1995). 
This data suggests that raised testosterone could play a role in the astrogliosis 
in IIH patients. This has the potential to alter CSF dynamics due to astrocytes 
being a principle component in forming perivascular spaces (Iliff et al., 2013).  
This highlights the need to research the effects of testosterone on glymphatic 
drainage of CSF and the modulation of cerebral compliance.  
These data highlight that the CP expresses, at mRNA level, genes that can 
metabolise and activate androgens. Furthermore, these data indicate that 
testosterone can increase Na+/K+ ATPase activity in Z310 cells. Consequently, 
these data are the first in vitro demonstration that a putative pathogenic 
biomarker in IIH, testosterone, has the potential to raise ICP. This highlights the 
need for further in vivo research to ascertain the role of testosterone in ICP 
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Chapter 7 General Discussion 
  
  
Page | 224 
 
7.1 General conclusions 
IIH is a rare disease primarily affecting obese women of reproductive age, 
where patients present with debilitating headache and papilloedema causing 
significant morbidity. However, the pathogenic mechanism underlying IIH is 
poorly understood. Reducing abdominal obesity confers improvements in 
disease morbidity in IIH, allowing the formation of the hypothesis that adipose 
tissue in IIH is pathogenic (Hornby et al., 2018b; Sinclair et al., 2010a). 
Consequently, this thesis explored the adipose phenotype of IIH patients and 
evaluated putative pathogenic mechanisms hypothesised to be derived from the 
adipose tissue. 
The adipose phenotype in IIH was assessed utilising targeted and non-targeted 
approaches which demonstrate that IIH adipose tissue presents with a 
distinctive phenotype. This IIH SC adipose phenotype presents with features of 
glucocorticoid excess which appear to be driven by reduced intra-adipose 
glucocorticoid (GC) clearance, potentially mediated by reduced SRD5A1 
expression. This phenotype of adipose glucocorticoid excess appears to be 
driving the raised serum leptin. Reduced SRD5A1 expression could also be 
driving the increased serum testosterone through reducing the generation of 
dihydrotestosterone, this would highlight that AKR1C3 inhibitors could be a 
potential therapeutic intervention in IIH to reduce circulating testosterone levels. 
These data highlight that IIH adipose tissue is metabolically deranged.  
Furthermore, it was demonstrated that although IIH patients have raised fasting 
and post-prandial leptin, it is likely that this raised leptin is not pathogenic in IIH 
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and is merely a bystander of the metabolic consequences of SC adipose 
glucocorticoid excess, causing hypersecretion of leptin from adipocytes.      
It was also aimed to develop and evaluate a novel in vitro Na+/K+ ATPase 
activity assay to assess a CSF secretion surrogate in a more physiological 
setting for high-throughput assessment. Here it is demonstrated that the 
Perceval biosensor can detect specific reversible inhibition of the Na+/K+ 
ATPase by ouabain. Furthermore pharmacological manipulation of Na+/K+ 
ATPase activity can be assessed, where the reduction in Na+/K+ ATPase 
activity observed with acetazolamide is congruent with previous data (Uldall et 
al., 2017). This assay was utilised to demonstrate that testosterone can 
modulate Na+/K+ ATPase activity in Z310 cells. Given this modulation, it is 
possible that the raised serum and CSF testosterone in IIH could drive the 
raised ICP in IIH. This demonstrates the need to assess androgen receptor 
modulation therapy as potential treatment for IIH in the future, as this could 
target both the ICP and the generic androgen excess phenotype. The novel 
demonstration that the choroid plexus has the potential to be a peripheral organ 
of androgen activation is of interest due to its implications on cerebral 
homeostasis, highlighting the need for this property to be further explored in the 
future. 
The data in this thesis allows the formation of the following testable hypothesis: 
reduced SC adipose SRD5A1 expression is, in part, driving the pathogenic 
phenotype of IIH (Figure 7.1). It can be hypothesised that this is driving the 
increased serum testosterone though reducing intra-adipose androgen 
clearance, where this raised serum testosterone is increasing ICP (chapter 6). 
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Similarly the reduced SRD5A1 expression is hypothesised to cause 
glucocorticoid accumulation in SC adipose, through reducing GC clearance, 
(chapter 3). This adipose dysfunction is hypothesised to be driving the 
phenotype of raised serum leptin (chapter 4), suggesting that raised serum 
leptin is a biomarker adipose dysfunction in IIH. This hypothesis is however not 
fully encompassing as it does not address the cause of the reduced SC 
SRD5A1 expression, and neither does it address other organ systems that 
could be contributing to the disease state such as the adrenal glands and the 
liver. 
Of note, IIH patients within this thesis display high levels of variance while 
following a Gaussian distribution, compared to control groups, despite the tight 
inclusion criteria intended to make the IIH patients as homogenous as possible. 
This is indicative that the IIH syndrome associated with obese women of 
reproductive age could be a disease of several biochemical phenotypes 
presenting with a similar clinical phenotype. This heterogeneity in IIH patients 
should be subject to further investigation. 
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Figure 7.1 IIH pathogenesis model diagram 
A schematic model for proposed pathogenesis in IIH. Reduced SRD5A1 expression in 
IIH SC adipose serves as a molecular road block, reducing the deactivation of both 
testosterone (T) and cortisol. The increased intra-adipose F facilitates the generation of 
a glucocorticoid excess phenotype that is contributing to increased serum leptin. 
Reduced T deactivation promotes increased serum testosterone in IIH, driving the 
increased ICP in IIH. CAII= carbonic anhydrase 2, CAIII= carbonic anhydrase3,       
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7.2 Future experimentation 
Future experimentation is required to further elucidate the phenotype and 
pathogenesis of IIH. On the basis of the work presented in this thesis, future 
work should be focused on the following areas.  
7.2.1 In vivo assessment of the IIH adipose phenotype  
The current adipose data represents the first molecular phenotyping of IIH 
adipose tissue, it is limited by the ex vivo nature of the metabolomic and 
secretomic experimentation due to being in an artificial environment which will 
alter the properties of the tissue. Utilising the microdialysate method in adipose 
tissue, the comparative metabolome could be assessed in vivo via mass 
spectrometry, assessing whether the changes observed ex vivo are congruent 
with the in vivo phenotype in IIH patients (O’Reilly et al., 2017). Moreover, the 
microdialysate method would facilitate the assessment of the in vivo adipose 
steroid metabolism, where further data could be garnered through providing test 
subjects with a DHEA bolus, assessing the capability of IIH adipose tissue to 
activate androgens (O’Reilly et al., 2017). Furthermore, explicit assessment of 
factors associated with intra-adipose glucocorticoid metabolism, specifically 
G6PDH activity, adipose tissue NADPH/NADP+ ratio, 5 α-cortisol/cortisol ratio is 
required, especially in lieu of IIH patients having increased systemic 5 α-
reductase activity (O’Reilly et al., 2019). 
7.2.2 In vivo assessment of testosterone on intracranial pressure 
The current data suggests that testosterone can increase Na+/K+ ATPase 
activity, they however do not identify whether this alters ICP in vivo, or even if 
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testosterone increases Na+/K+ ATPase activity in primary choroid plexus cells. 
Assessment of the effects of testosterone on whole rodent and human choroid 
plexus Na+/K+ ATPase activity would be prudent to validate the current data. 
Furthermore, assessing the effects of chronic testosterone exposure on ICP in 
obese female rodents is vital in order to ascertain whether testosterone could 
be truly pathogenic in IIH.  
7.2.3 In vivo adipose specific knockdown of 5α-reductase type 1  
The model presented in figure 7.1 is underpinned by the reduced expression of 
SRD5A1 in IIH SC adipose tissue and the proposed metabolic consequences. 
Although a global knockout of srd5a1 in mice causes reduced glucocorticoid 
clearance and a moderate oestrus cycle dependent testosterone excess, the 
global knockout does not assess adipose tissue specific contributions to the 
steroid phenotype (Livingstone et al., 2014; Mahendroo et al., 1996). 
Consequently knocking down 5α-reductase specifically in adipose tissue, either 
through genetic knockdown or pharmacologically in female rodents, would be 
required in order test if the proposed mechanism could modulate ICP.   
7.2.4 Developing a high through-put Na+/K+ ATPase screening assay 
The novel in vitro Na+/K+ ATPase activity assay has utility, however, the inability 
to simultaneously assay multiple pharmaceuticals is the rate limiting factor in 
the acquisition of data. Furthermore, the necessity to infect cells with viruses will 
cause metabolic disturbances that could confound any results. Several steps 
could be utilised in order improve the assay. Firstly, developing a stable line of 
Z310 cells with the Perceval biosensor present would negate viral transcription 
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mediated metabolic disturbances. Developing a plate based assay to generate 
a high throughput assay would increase the rate of data acquisition, through 
facilitating the assessment of multiple pharmaceuticals at once in a fraction of 
the time it takes to complete one experiment on a microscope, allowing the 
rapid identification of potential therapeutics that could modulate ICP. 
Furthermore the present assay is limited through the use of a low resolution 
Perceval biosensor that may be saturated in the experiments, limiting its current 
utility (Berg et al., 2009). Utilisation of a higher resolution variant, PercevalHR, 
could allow experiments to observe changes in ATP:ADP ratio over a much 
larger dynamic range (Berg et al., 2009; Tantama et al., 2013) 
7.3 Closing remarks 
The field of IIH research is currently maturing, where old hypotheses of IIH 
pathogenesis are being addressed and novel pathogenic hypothesise are being 
developed, although the pathogenic mechanism for IIH remains undiscovered 
(Hornby et al., 2018b; Libien et al., 2017). Furthermore, recent work has moved 
IIH away from being neuro-ophthalmic disease to being a disease with unique 
metabolic derangement where neuro-ophthalmic symptoms form part of a 
greater disease. The work in this thesis demonstrates that adipose tissue, a 
fundamental tissue in determining whole body metabolism, has a deranged 
phenotype that has the potential to influence the deranged whole body 
metabolism in IIH. Furthermore, the demonstration of an androgen excess 
phenotype with data highlighting the potential for testosterone to increase ICP 
highlights a novel hypothesis for the pathogenesis of IIH.    
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Chapter 8 Appendices   
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Appendix 1 – Steroid profile of IIH patients 
The following table present the androgen phenotype in IIH patients, the data is 
for reference purposes only as I had no participation in the analysis of the data. 
I however extracted the CSF prior samples to LCMS.  
 
Table 8.1 Serum and urine androgen characterization of IIH patients 
Baseline characteristics and biochemical data in healthy controls, women with PCOS 
and women with IIH as measured by LCMS for serum data and GCMS for 24 hour 
urine data. Data are presented as median and interquartile range. Statistical 
comparison was carried out by analysis of variance with post hoc Tukey testing. 
Significance levels were indicated as follows: a, p<0.05, b, p<0.01, c, p<0.001 for the 
comparison of PCOS or IIH v healthy controls; d, p<0.05; e, p<0.01; f, p<0.001 for the 
comparison PCOS v IIH. Abbreviations: 5-THF, 5alpha-tetrahydrocortisol; 11OHA4, 
11-hydroxyandrostenedione; 11KA4, 11-ketoandrostenedione; 11OHT, 11-
hydroxytestosterone; 11KT, 11-ketotestosterone; A4, androstenedione; An, urinary 
androsterone; BMI, body mass index; DHEA, dehydroepiandrosterone; DHEAS, 
dehydroepiandrosterone sulfate; Et, urinary etiocholanolone; T, testosterone; THF, 
tetrahydrocortisol.  
 Controls (n=40) PCOS (n=60) IIH (n=70) 
Age (years) 34 (28-38) 30 (27-35) 34 (28-38) 
BMI (kg/m2) 37.3 (35.0-41.1) 38.5 (35.5-43.1) 37.9 (34.9-42.3) 
Serum androgen concentrations (nmol/L) 
T 1.0 (0.5-1.4) 1.2 (0.5-1.5) 1.7 (1.0-2.4) c, f 
A4 3.6 (2.7-7.5) 5.7 (4.3-9.1) b 2.4 (1.4-4.4) a, f 
DHEA 17.9 (9.7-25.1) 13.3 (8.5-22.6) 9.5 (4.9-18.9) d 
DHEAS(mol/L) 4.1 (3.0-6.4) 6.2 (4.3-8.5) 4.5 (2.5-8.4) 
11OHA4 3.4 (2.1-7.4) 30.0 (10.6-42.1) c 2.5 (1.6-3.4) f 
11KA4 0.7 (0.3-1.0) 12.1 (6.6-21.2) c 0.4 (0.2-0.7) f 
11OHT 0.3 (0.1-0.5) 0.3 (0.2-0.5) 0.2 (0.1-0.45) 
11KT 1.7 (0.8-2.2) 2.3 (1.5-3.6) a 2.3 (1.9-3.1) 
24-h urine androgen metabolite profiling 
5-THF/THF 0.9 (0.5-1.3) 0.9 (0.7-1.3) 1.2 (0.8-1.80) 
a, d 




2575 (1864-4436) 4341 (2508-5497) 3332 (1914-5847) 
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Age (years) 46 (38-57)a 37 (32-46) 30 (27-35) 
BMI (kg/m2) 27 (22.7-32.3)a 44.8 (39.7-47.3)a 37.9 (34.9-42.3) 
LP pressure  
(cm H20) 
16.5 (13.5-20.8)a 23.5 (21-25.5)a 36.0 (29.5-40.0) 
CSF androgen concentration (nmol/l) 
T 0 (0-0) 0 (0-0) 0.10 (0.06-0.13)c,e 
A4 0.28 (0-1.83) 0.70 (0.21-0.98) 8.25 (3.43-12.19)b,e 
DHEA 2.23 (0.14-8.49) 0.81 (0.54-1.44)c 1.09 (0.33-2.59) 
DHEAS (µmol/l) 0.16 (0.15-0.18) 0.70 (0.29-0.93)d 0.07 (0.05-0.17) b,e 
 
Table 8.2 Androgen characterisation of CSF in IIH patients 
Baseline characteristics of CSF study patients. Data are presented as median and 
interquartile range. Statistical comparison was carried out by analysis of variance with 
post hoc Tukey testing. Significance levels were indicated as follows: a, p<0.001, b, 
p<0.0001 for the comparison of lean controls v IIH; c, p<0.05, d, p<0.0001 for 
comparison between lean vs obese controls; e, p<0.0001 for obese controls vs IIH. 
Abbreviations: BMI, body mass index; IIH, idiopathic intracranial hypertension; LP, 
lumbar puncture; DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone 
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Appendix 2 – Primer probe sets 





Manufacturer codes Reporter 
18s Mammalian Thermofisher 431941E VIC 
Esr1 Rattus norvegicus Thermofisher Rn01640372_m1 FAM 
Esr2 Rattus norvegicus Thermofisher Rn00562610_m1 FAM 
Cyp19a1 Rattus norvegicus Thermofisher Rn00567222_m1 FAM 
Hsd17b3 Rattus norvegicus Thermofisher Rn00588942_m1 FAM 
Srd5a1 Rattus norvegicus Thermofisher Rn00567064_m1 FAM 
Akr1c3 Rattus norvegicus Thermofisher Rn00684527_m1 FAM 
Ar Rattus norvegicus Thermofisher Rn00560747_m1 FAM 
Car2 Rattus norvegicus Thermofisher Rn01462065_M1 FAM 
Car3 Rattus norvegicus Thermofisher Rn01461970_M1 FAM 
AR Homo sapien Thermofisher Hs00171172_m1 FAM 
AKR1C3 Homo sapien Thermofisher Hs00366267_m1 FAM 
CYP19A1 Homo sapien Thermofisher Hs00903411_m1 FAM 
GAPDH Homo sapien Thermofisher Hs99999005_m1 FAM 
HSD3B1 Homo sapien Thermofisher Hs04194787_g1 FAM 
HSD3B2 Homo sapien Thermofisher Hs00605123_m1 FAM 
SDR5A1 Homo sapien Thermofisher Hs00602694_m1 FAM 
17BHSD3 Homo sapien Thermofisher Hs00970004_m1 FAM 
CYP11B1 Homo sapien Thermofisher Hs01596404_m1 FAM 
ESR1 Homo sapien Thermofisher Hs01100353_m1 FAM 
ESR2 Homo sapien Thermofisher Hs01046816_m1 FAM 
SRD5A2 Homo sapien Thermofisher Hs00165843_m1 FAM 
AKR1D1 Homo sapien Thermofisher Hs00818881_m1 FAM 
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Appendix 3 – Most differentially expressed genes 
This appendix highlights the most differentially expressed genes in IIH, DESeq2 
output as referred to in section 3.3.3.1 
Gene Expression Fold Change Padj name 
HSPA1A 816 -1.15 7.94E-05 Heat shock protein family A (Hsp70) member 1A 
HSPA1B 448 -1.04 0.000619 Heat shock protein family A (Hsp70) member 1B 
HNRNPU-AS1 809 0.80 0.000768 NA 
FADS2 649 1.01 0.001117 Fatty acid desaturase 2 
HSPA6 121 -0.96 0.002605 Heat shock protein family A (Hsp70) member 6 
NFYC-AS1 37 0.85 0.002667 NFYC antisense RNA 1 
STAG3L2 219 0.66 0.003288 Stromal antigen 3-like 2 (pseudogene) 
SRPX 1163 -0.55 0.011518 Sushi repeat containing protein, X-linked 
LMOD1 1417 -0.57 0.020383 Leiomodin 1 
DNM3OS 474 0.71 0.021029 DNM3 opposite strand/antisense RNA 
FMO3 320 -0.76 0.021029 Flavin containing monooxygenase 3 
HCG27 42 0.83 0.021029 HLA complex group 27 (non-protein coding) 
VIM 48131 -0.35 0.021029 Vimentin 
FKBP4 509 -0.58 0.025744 FK506 binding protein 4 
MIR143HG 162 0.75 0.025744 NA 
MAFF 373 -0.82 0.027337 MAF bZIP transcription factor F 
IGLL5 77 -0.80 0.028142 Immunoglobulin lambda like polypeptide 5 
TCOF1 342 -0.28 0.028142 Treacle ribosome biogenesis factor 1 
LINC01355 155 0.77 0.031745 Long intergenic non-protein coding RNA 1355 
RPS12 6522 -0.50 0.031931 Ribosomal protein S12 
RPLP1 7347 -0.47 0.040782 Ribosomal protein lateral stalk subunit P1 
MAGOH2P 23 0.75 0.046975 Mago homolog 2, pseudogene 
PDZD3 25 0.76 0.046975 PDZ domain containing 3 
RBM33 1176 0.41 0.046975 RNA binding motif protein 33 
SREBF1 800 0.73 0.046975 Sterol regulatory element binding transcription 
factor 1 
NRXN1 9 0.73 0.047343 Neurexin 1 
LINC00472 137 0.64 0.04767 Long intergenic non-protein coding RNA 472 
RPS5 2975 -0.38 0.04767 Ribosomal protein S5 
SFPQ 1595 -0.59 0.04767 Splicing factor proline and glutamine rich 
CD151 5624 -0.51 0.049961 CD151 molecule (Raph blood group) 
DDAH2 1498 -0.39 0.049961 Dimethylarginine dimethylaminohydrolase 2 
 
Table 8.4 List of differentially expressed genes in IIH SC adipose 
List of most differentially expressed UCSC genes in IIH SC adipose tissue compared to 
age, sex and BMI matched controls based on DESeq2 output following multiple 
comparison correction. Expression = Mean combined expression of both groups. Fold 
change = Log2 fold change in expression from control. Padj= adjusted P-value.  
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Appendix 4 – Gene set enrichment analysis gene lists 
Gene set enrichment analysis gene lists as referred to in section 3.3.3.2 
 
Ribosomal Proteins Caloric Intake UP Caloric Intake DOWN 
RPSA RPL7 AACS FLJ10357 ACSM5 MATN2 
RPS2 RPL7A ABCC6 GCSH ANGPTL4 NAP1L1 
RPS3 RPL8 ABCC6P2 GLYAT C1NH NFE2L1 
RPS3A RPL9 ACACA GPX1 C6 PCK2 
RPS4X RPL10 ACLY HSPA12A CCNI PRDX6 
RPS4Y RPL10A ACSL1 INSIG1 CDKN1C RPL13 
RPS5 RPL12 AGTRL1 LAMB3 CIDEA RPL13A 
RPS6 RPL13A ALDH9A1 LOC55908 CLIPR-59 RPL14 
RPS7 RPL14 ALDOC LOX CPT1B TD26 
RPS8 RPL15 AQP1 LOXL2 EIF3E RPL30 
RPS9 RPL17 ATP2B4 MGC4172 EIF3F RPL36AL 
RPS10 RPL18 ATR MGLL EIF4B RPL37 
RPS11 RPL18A C1orf54 MME EIF4EBP1 RPL5 
RPS12 RPL19 COL3A1 MXRA5 EIF4EBP2 RPL9 
RPS13 RPL21 COL5A1 NMB FAU RPLP1 
RPS14 RPL22 COL5A2 PEDF FXYD1 RPS15A 
RPS15 RPL23 COL5A3 PRDX2 GPD1L RPS16 
RPS15A RPL23A CYP46A1 PTPLB GPR153 RPS24 
RPS16 RPL24 DBI SCD GPX3 RPS25 
RPS17 RPL26 DLAT SEMA3C GSDML RPS4X 
RPS18 RPL27 DOCK6 SPARC HNRPA1 RANGNRF 
RPS19 RPL27A ECHDC1 TCTA IGBP1 SEMA3G 
RPS20 RPL30 ELOVL5 TF IMPA2 SIK2 
RPS21 RPL31 FADS1 THBS4 ITSN1 SRPX 
RPS23 RPL32 FADS2 TP53I3 MAOB TINP1 
RPS24 RPL34 FASN TSPO 
  RPS25 RPL35 
    RPS26 RPL36 
    RPS27 RPL36A 
    RPS27A RPL37 
    RPS28 RPL39 
    RPS29 RPL40 
    RPS30 RPL41 
    RPL3 RPP0 
    RPL4 RPP1 
    RPL5 RPP2 
    RPL6  
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Lipid Biosynthesis 
A4GALT ALDH1A2 CDS2 CYP46A1 FAM57B GBGT1 IDI2 
ABCB11 ALDH1A3 CECR5 CYP51A1 FAR1 GGPS1 IMPA1 
ABCD3 ALDH3A2 CEPT1 CYP7A1 FASN GGT1 INPP4A 
ABHD3 ALDH3B1 CERS1 CYP7B1 FCER1A GGT2 INPP4B 
ABHD5 ALDH3B2 CERS2 CYP8B1 FDFT1 GGT3P INPP5D 
ACAA2 ALDH8A1 CERS3 DDHD1 FDPS GGT5 INPP5E 
ACACA ALG1 CERS4 DDHD2 FDX1 GGT6 INPP5F 
ACACB ALG5 CERS5 DECR2 FDX1L GGT7 INPP5J 
ACBD3 ALOX12 CERS6 DEGS1 FDXR GGTA1P INPP5K 
ACER1 ALOX12B CFTR DEGS2 FGF1 GGTLC1 INPPL1 
ACER2 ALOX15 CH25H DGAT1 FGF10 GGTLC2 INSIG1 
ACER3 ALOX15B CHAT DGAT2 FGF16 GGTLC3 INSIG2 
ACHE ALOX5 CHKA DGKE FGF17 GK IRS1 
ACLY ALOX5AP CHKB DHCR24 FGF18 GNPAT IRS2 
ACOT7 ALOXE3 CHPT1 DHCR7 FGF19 GPAA1 ISPD 
ACOT8 AMACR CLN8 DHDDS FGF2 GPAM ISYNA1 
ACOX2 ANG CNBP DHRS9 FGF20 GPAT2 JUB 
ACSF3 APOA1 COL4A3BP DOLK FGF22 GPD1 KDSR 
ACSL1 APOA2 COQ2 DOLPP1 FGF23 GPD1L KL 
ACSL3 APOA4 CPNE1 DPAGT1 FGF3 GRB2 KLB 
ACSL4 APOA5 CPNE3 DPM1 FGF4 HEXB LARGE 
ACSM1 ARF1 CPNE6 DPM2 FGF5 HINT2 LBR 
ACSM3 ARF3 CPNE7 DPM3 FGF6 HMGCR LCAT 
ACSS1 ARV1 CRH EBP FGF7 HMGCS1 LCLAT1 
ACSS2 ATM CRLS1 EDN1 FGF8 HMGCS2 LHB 
ADM B3GNT5 CSNK1G2 EDN2 FGF9 HPGDS LIAS 
AGK B4GALNT1 CWH43 ELOVL1 FGFR1 HSD11B1 LIPC 
AGMO BAAT CYB5R1 ELOVL2 FGFR2 HSD11B2 LIPT2 
AGPAT1 BCMO1 CYB5R2 ELOVL3 FGFR3 HSD17B1 LOC100288072 
AGPAT2 BRCA1 CYB5R3 ELOVL4 FGFR4 HSD17B11 LOC643181 
AGPAT3 C14orf1 CYP11A1 ELOVL5 FIG4 HSD17B12 LPCAT1 
AGPAT4 C1orf93 CYP11B1 ELOVL6 FITM1 HSD17B14 LPCAT2 
AGPAT5 C20orf173 CYP11B2 ELOVL7 FITM2 HSD17B2 LPCAT3 
AGPAT6 C20orf79 CYP17A1 EPT1 FRS2 HSD17B3 LPCAT4 
AGPAT9 C5orf4 CYP19A1 ETNK1 FSHB HSD17B4 LPGAT1 
AGPS C9orf3 CYP1A1 ETNK2 G6PD HSD17B6 LPIN1 
AGXT2L1 CACNA1H CYP21A2 FA2H GAB1 HSD17B7 LPIN2 
AKR1B1 CBR1 CYP27A1 FABP5 GAL3ST1 HSD17B8 LPIN3 
AKR1B15 CBR4 CYP27B1 FADS1 GAL3ST2 HSD3B1 LPL 
AKR1C3 CD74 CYP2R1 FADS2 GAL3ST3 HSD3B2 LSS 
AKR1C4 CDIPT CYP39A1 FADS3 GAL3ST4 HSD3B7 LTA4H 
AKR1D1 CDS1 CYP3A4 FADS6 GBA IDI1 LTC4S 
 
 
Gene list continued on next page.  
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Lipid biosynthesis (continued) 
MBOAT1 PDSS1 PIK3CG PPAP2C SCP2 ST6GALNAC2 
MBOAT2 PDSS2 PIK3R1 PPARD SDR42E1 ST6GALNAC3 
MBOAT7 PECR PIK3R2 PPM1L SERAC1 ST6GALNAC4 
MCAT PEMT PIK3R3 PRG3 SERINC1 ST6GALNAC5 
MECR PEX7 PIK3R4 PRKAA1 SERINC4 ST6GALNAC6 
MED1 PGAP1 PIK3R5 PRKAA2 SERINC5 ST8SIA1 
MGLL PGAP2 PIK3R6 PRKAB1 SGMS1 ST8SIA2 
MGST2 PGAP3 PIKFYVE PRKAB2 SGMS2 ST8SIA3 
MIF PGS1 PIP4K2A PRKAG1 SGPL1 ST8SIA4 
MLYCD PHOSPHO1 PIP4K2B PRKAG2 SGPP1 ST8SIA5 
MOGAT1 PI4K2A PIP4K2C PRKAG3 SGPP2 ST8SIA6 
MOGAT2 PI4K2B PIP5K1A PRKD1 SH3YL1 STAR 
MOGAT3 PI4KA PIP5K1B PRLR SLC27A1 STARD3 
MPPE1 PI4KB PIP5K1C PRPF19 SLC27A2 STARD5 
MSMO1 PIGA PISD PTDSS1 SLC27A5 SYK 
MTM1 PIGB PLA2G10 PTDSS2 SLC44A1 SYNJ1 
MTMR1 PIGC PLA2G12A PTEN SLC44A2 SYNJ2 
MTMR14 PIGF PLA2G16 PTGDS SLC44A3 TAMM41 
MTMR2 PIGG PLA2G1B PTGES SLC44A4 TAZ 
MTMR3 PIGH PLA2G2A PTGES2 SLC44A5 TBXAS1 
MTMR4 PIGK PLA2G2D PTGES3 SMPD1 TECR 
MTMR6 PIGL PLA2G2E PTGIS SMPD2 TFCP2L1 
MTMR7 PIGM PLA2G2F PTGS1 SMPD4 THNSL2 
MVD PIGN PLA2G4A PTGS2 SPHK1 TLR9 
MVK PIGO PLA2G4B PTPLA SPHK2 TM7SF2 
MYO5A PIGP PLA2G4D PTPLAD1 SPTLC1 TPTE2 
NANS PIGQ PLA2G4F PTPLAD2 SPTLC2 TRERF1 
NDUFAB1 PIGS PLA2G5 PTPLB SPTLC3 TSPO 
NPC1L1 PIGT PLA2G6 PTPMT1 SPTSSA UGCG 
NR0B1 PIGU PLAUR PTPN11 SPTSSB UGT8 
NSDHL PIGV PLCE1 QKI SQLE VAC14 
NUS1 PIGW PLCG2 RBP1 SRD5A1 VAPA 
OCRL PIGX PLD1 RDH10 SRD5A2 VAPB 
OLAH PIGY PLD2 RDH8 SRD5A3 WNT4 
OXSM PIGZ PLD6 RNPEP SREBF1 XBP1 
P2RX1 PIK3C2A PLP1 RNPEPL1 ST3GAL1 
 P2RX7 PIK3C2B PLSCR1 SACM1L ST3GAL2 
 PBX1 PIK3C2G PMVK SAMD8 ST3GAL3 
 PCK1 PIK3C3 PNPLA3 SC5DL ST3GAL4 
 PCYT1A PIK3CA PNPLA8 SCARB1 ST3GAL5 
 PCYT1B PIK3CB PPAP2A SCD ST3GAL6 
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μM/100mg Control IIH P Control IIH P 
Acetate 232.7(176.8) 215.4(145.5) 0.81 286.8 (64.8) 166.5 (75.2) 0.0012 
Alanine 51.1 (20.8) 82.1 (43.0) 0.06 62.6 (28.7) 109.0 (73.4) 0.052
$
 
Arginine 202.8 (62.4) 215.8(117.7) 0.76 246.9 (72.2) 238.3 (88.4) 0.81 
Formate 57.6 (47.9) 72.5 (52.9) 0.35
$
 56.1 (28.5) 53.9 (34.7) 0.73
$
 
Glucose (mM) 3.7 (1.6) 3.6 (1.2) 0.86 4.1 (1.1) 3.6 (1.5) 0.43 
Glutamate N/A 146.5 (63.0) 150.6 (69.0) 0.79
$
 
Glutamine 551.5(287.2) 509.7(253.5) 0.73 679.6(241.7) 719.6(233.7) 0.71 
Glutathione 13.2 (6.6) 22.9 (17.6) 0.12
$
 20.9 (13.3) 16.7 (5.6) 0.57
$
 
Glycerol 339.0 (97.9) 305.7 (90.8) 0.44 296.1 (38.5) 274.1 (87.4) 0.16
$
 
Glycine 105.5 (44.6) 117.3 (47.7) 0.57 132.8 (36.3) 148.5 (68.2) 0.53 
Histidine 41.9 (21.3) 36.4 (13.1) 0.49 38.9 (10.3) 43.5 (10.0) 0.32 
Isoleucine 121.0 (46.6) 116.1 (42.8) 0.81 130.9 (30.3) 124.4 (25.0) 0.6 
Lactate (mM) 616.2(409.3) 660.5(330.1) 0.48
$
 0.85 (0.33) 1.59 (1.97) 0.48
$
 
Leucine 139.8 (53.8) 133.3 (48.3) 0.78 144.3 (35.6) 138.3 (26.9) 0.67 
Lysine 134.1 (60.4) 151.1 (55.8) 0.52 162.1 (51.10 172.1 (43.0) 0.64 
Methionine 34.1 (17.5) 29.7 (17.6) 0.58 34.1 (9.4) 41.3 (11.2) 0.13 
Methylsuccinate 5.1 (3.7) 4.3 (2.4) 0.85
$
 4.9 (2.8) 7.1 (5.1) 0.49
$
 
NAD+ 5.3 (2.4) 5.4 (2.5) 0.96 6.2 (2.9) 8.1 (4.7) 0.31 
NADH N/A 8.2 (4.0) 13.1 (9.1) 0.16
$
 
HAD+NADH N/A 14.4 (6.0) 21.2 (12.9) 0.1
$
 
NADP+ 1.4 (0.7) 2.1 (0.9) 0.07
$
 2.7 (0.8) 2.7 (1.1) 0.93 
NADPH N/A 11.5 (7.9) 18.5 (12.2) 0.14 
NADP+NADPH N/A 14.3 (8.6) 21.3 (12.9) 0.16
$
 
Niacinamide 6.8 (1.3) 6.4 (3.2) 0.77 5.8 (2.2) 6.2 (1.7) 0.36
$
 
Phenylalanine 60.0 (27.4) 58.5 (19.7) 0.89 65.1 (18.7) 72.5 (15.7) 0.34 
Proline 56.1 (38.2) 60.1 (30.7) 0.39 74.5 (24.9) 83.1 (23.4) 0.43 
Pyroglutamate 191.6 (89.3) 184.2(132.1) 0.88 190.0 (84.4) 181.9 (86.3) 0.83 
Pyruvate 9.5 (8.7) 21.3 (29.4) 0.79
$
 4.5 (7.1) 23.6 (16.7) 0.003
$
 
Sarcosine 6.7 (2.6) 6.4 (2.9) 0.81 5.4 (1.4) 6.7 (2.6) 0.22 
Succinate N/A 13.5 (4.6) 18.2 (8.4) 0.14 
Threonine 149.4 (57.7) 166.9 (70.0) 0.48
$
 188.3 (44.5) 196.1 (60.4) 0.74 
Tryptophan 10.6 (4.6) 11.3 (2.9) 0.66 12.3 (3.5) 13.8 (3.4) 0.34 
Tyrosine 71.4 (30.4) 75.9 (28.7) 0.74 87.4 (23.4) 95.0 (21.4) 0.46 
Valine 144.6 (52.5) 142.3 (50.9) 0.92 159.3 (38.3) 157.1 (31.1) 0.89 
myo-Inositol 162.0 (74.1) 171.4 (86.7) 0.79 130.7 (59.0) 147.2 (86.7) 0.91
$
 
Sn-glycero-3-PC 94.0 (26.9) 95.9 (54.8) 0.79 83.9 (27.5) 77.3 (22.6) 0.56 
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Ratios Control IIH P Control IIH P 
NADP/NADPH N/A 0.87 (0.41) 0.73 (0.41) 0.47 
NAD/NADH N/A 0.32 (0.18) 0.14 (0.07) 0.02 
Lactate/Pyruvate 140.6(154.9) 155.2(160.3) 0.85
$




Table 8.5 Adipose tissue metabolite concentration 
Concentration of tissue explant metabolite concentration in adipose explants from 
paired OM and SC adipose tissue from IIH and control patients as determined by NMR. 

























(250.5) 0.63 800.9(414.6) 335.4(176.4) 0.004 
Adenosine -2.8 (0.4) -1.9 (0.8) 0.012 N/A 
Alanine 87.1 (84.8) 141.6 (84.3) 0.16 67.9 (43.9) 102.8(53.4) 0.14 
Arabinose -32.2 (5.2) -23.1 (22.9) 0.23
$
 N/A 







Asparagine 2.8 (18.3) -1.5 (19.0) 0.60 0.1 (6.3) 8.3 (10.8) 0.31
$ 
Aspartate -23.9 (15.7) -29.2 (15.6) 0.45 -23.6 (14.0) -24.7 (5.3) 0.82 
Choline -5.2 (13.4) -7.4 (14.3) 0.27
$
 -6.5 (17.0) 0.3 (3.4) 0.76 
Cysteine 19.6 (27.3) 30.1 (52.9) 0.58 12.9 (23.6) 10.0 (21.1) 0.18 
Cystine 0.9 (37.5) 5.2 (61.7) 0.78 -42.6 (31.9) -2.8 (21.5) 0.005 
Formate 34.6 (21.1) 53.5 (41.0) 0.31
$






(0.840) 0.22 -0.35 (1.2) -0.27 (0.91) 0.85 
Glutamate 1.7 (72.6) -2.4 (35.5) 0.54 1.3 (64.0) -10.2 (45.8) 0.85
$
 
Glutamine -8.1 (467.9) 34.9 (28.6) 0.94 
-86.8 
(380.4) 105.3 (203) 0.18 
Glycerol 84.5 (37.0) 157.3 (62.6) 0.005 79.4 (33.5) 128.7 (45.6) 0.016 
Glycine 56.2 (40.3) 41.7 (52.5) 0.19
$
 39.6 (34.1) 47.2 (28.5) 0.6 
Histidine 39.8 (16.1) 33.8 (10.1) 0.33 28.9 (9.9) 33.9 (14.9) 0.40 
Hypoxanthine 0.3 (10.4) 3.8 (9.6) 0.45 3.5 (7.2) -2.9 (6.5) 0.055 
Inosine 1.1 (2.8) -0.2 (1.1) 0.59
$
 N/A 
Isoleucine 25.3 (48.3) -30.5 (25.2) 0.002
$
 -9.7 (41.6) -29.2 (71.8) 0.48 
Lactate (ΔmM) 1.4 (0.6) 1.5 (0.5) 0.35 1.8 (1.5) 1.8 (0.9) 0.29
$ 
Leucine 22.6 (54.3) -38.0 (40.8) 0.011 3.8 (55.9) -9.8 (78.6) 0.66 
Lysine 29.4 (139.1) -8.4 (64.5) 0.97 17.6(159.7) 9.7 (50.5) 0.24
$ 
Methionine -0.5 (15.1) -8.9 (8.3) 0.16
$
 -3.2 (12.4) -1.7 (10.2) 0.54
$ 
Niacinamide 15.8 (4.1) 12.9 (3.5) 0.12 16.3 (6.9) 11.9 (2.4) 0.08 
Phenylalanine 26.5 (19.6) 21.5 (17.9) 0.56 22.8 (10.6) 19.7 (13.5) 0.57 
Proline -11.2 (44.1) 38.8 (178.2) 0.73
$
















 -344.0 (107) -226.1 (100) 0.02 
Serine -129.8 (42.0) -102.4 (79.5) 0.34 
-120.7 
(82.5) -90.5 (91.5) 0.46 
Threonine 119.6 (56.3) 77.6 (58.6) 0.19
$
 106.1(82.2) 69.1 (51.6) 0.25 
Tryptophan 0.5 (4.0) -1.5 (2.8) 0.63
$
 -4.5 (4.6) -1.4 (1.9) 0.07 
Tyrosine 54.9 (34.3) 39.0 (23.7) 0.43
$
 48.2 (17.5) 52.0 (10.9) 0.18
$ 
Valine 103.2 (63.9) 52.8 (49.3) 0.04
$ 
83.6 (52.8) 66.0 (43.7) 0.43 
 
Table 8.6 Conditioned media metabolite flux 
Conditioned media metabolites as assessed by NMR In paired omental and 
subcutaneous adipose tissue explants from IIH and control patients.$= Mann-Whitney 
U-test, unmarked = unpaired T-test. Data presented as mean±SD.  
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Age 0.00 0.29 0.77 0.69 0.49 0.70 0.01 0.70 0.87 0.65 








0.69 0.23 0.82 0.00 0.88 0.59 0.76 0.44 0.89 0.53 
[G]i 
OM 
0.49 0.61 0.20 0.88 0.00 0.20 0.53 0.68 0.53 0.20 
[G]i 
SC 
0.70 0.49 0.14 0.59 0.20 0.00 0.75 0.70 0.16 0.00 
[Pyr]i 
OM 
0.01 0.39 0.24 0.76 0.53 0.75 0.00 0.31 0.52 0.84 
[Pyr]i 
SC 
0.70 0.39 0.11 0.44 0.68 0.70 0.31 0.00 0.77 0.49 
[Lac]i 
OM 
0.87 0.75 0.68 0.89 0.53 0.16 0.52 0.77 0.00 0.07 
[Lac]i 
SC 
0.65 0.20 0.49 0.53 0.20 0.00 0.84 0.49 0.07 0.00 
 
Table 8.7 Glycolysis correlation matrix 
P-values for correlation matrix for glycolysis metabolites compared to BMI and age. 
Spearman’s correlation. Abbreviations: G=glucose, Pyr =pyruvate, Lac=lactate, 
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Branch chain amino acids 





















Age 0.00 0.71 0.41 0.15 0.35 0.06 0.56 0.88 0.63 0.82 
BMI 0.71 0.00 0.74 0.95 0.49 0.67 0.52 0.84 0.43 0.71 
Leu 
Flux 
OM 0.41 0.74 0.00 0.37 0.00 0.96 0.57 0.54 0.51 0.49 
Leu 
Flux 
SC 0.15 0.95 0.37 0.00 0.76 0.00 0.56 0.54 0.69 0.80 
Iso 
Flux 
OM 0.35 0.49 0.00 0.76 0.00 0.96 0.93 0.38 0.92 0.34 
Iso 
Flux 
SC 0.06 0.67 0.96 0.00 0.96 0.00 0.87 0.85 0.92 0.61 
[Leu]i 
OM 0.56 0.52 0.57 0.56 0.93 0.87 0.00 0.03 0.00 0.03 
[Leu]i 
SC 0.88 0.84 0.54 0.54 0.38 0.85 0.03 0.00 0.04 0.00 
[Iso]i 
OM 0.63 0.43 0.51 0.69 0.92 0.92 0.00 0.04 0.00 0.04 
[Iso]i 
SC 0.82 0.71 0.49 0.80 0.34 0.61 0.03 0.00 0.04 0.00 
 
Table 8.8 Branch chain amino acids correlation matrix  
P-values for correlation matrix for branch chain amino acid metabolites compared to 
BMI and age. Spearman’s correlation. Abbreviations: Leu=leucine, Iso =isoleucine, 
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Lipolysis 
 Age BMI [OM]Ex [SC]Ex [OM]i [SC]i OM R SC R 
Age  0.386 0.009 0.250 0.461 0.970 0.023 0.347 
BMI 0.288  0.551 0.386 0.003 0.975 0.086 0.262 
[OM]Ex 0.009 0.551  0.367 0.495 0.808 <0.001 0.758 
[SC]Ex 0.25 0.386 0.367  0.184 0.531 0.079 <0.001 
[OM]i 0.461 0.184 0.495 0.184  0.920 0.016 0.112 
[SC]i 0.347 0.975 0.808 0.531 0.920  0.994 0.014 
OM R 0.023 0.086 <0.001 0.079 0.016 0.994  0.235 
SC R 0.347 0.262 0.748 <0.001 0.112 0.014 0.235  
 
Table 8.9 Glycerol correlation matrix 
P-values for correlation matrix for glycerol secretion in subcutaneous (SC) and omental 
(OM) adipose for secreted (Ex), intracellular (i) and ratio (R) tissue compared to BMI 














Page | 245 
 
Appendix 7 – No IgG control AR staining 
 
Figure 8.1 No IgG control for androgen receptor  
No IgG staining control for androgen receptor staining in figure 6.4 on Z310 cells 
containg both blue and red channels. Note some non-specific staining. Scale bar = 50 
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